


REVIEW

Open Access



# Multidisciplinary management of elderly patients with rectal cancer: recommendations from the SICG (Italian Society of Geriatric Surgery), SIFIPAC (Italian Society of Surgical Pathophysiology), SICE (Italian Society of Endoscopic Surgery and new technologies), and the WSES (World Society of Emergency Surgery) International Consensus Project

Mauro Podda<sup>1\*</sup> , Patricia Sylla<sup>2</sup>, Gianluca Baiocchi<sup>3</sup>, Michel Adamina<sup>4</sup>, Vanni Agnoletti<sup>5</sup>, Ferdinando Agresta<sup>6</sup>, Luca Ansaloni<sup>7</sup>, Alberto Arezzo<sup>8</sup>, Nicola Avenia<sup>9</sup>, Walter Biffi<sup>10</sup>, Antonio Biondi<sup>11</sup>, Simona Bui<sup>12</sup>, Fabio C. Campanile<sup>13</sup>, Paolo Carcoforo<sup>14</sup>, Claudia Commisso<sup>15</sup>, Antonio Crucitti<sup>16</sup>, Nicola De'Angelis<sup>17</sup>, Gian Luigi De'Angelis<sup>18</sup>, Massimo De Filippo<sup>15</sup>, Belinda De Simone<sup>19</sup>, Salomone Di Saverio<sup>20</sup>, Giorgio Ercolani<sup>21</sup>, Gustavo P. Fraga<sup>22</sup>, Francesco Gabrielli<sup>23</sup>, Federica Gaiani<sup>18</sup>, Mario Guerrieri<sup>24</sup>, Angelo Guttadauro<sup>23</sup>, Yoram Kluger<sup>25</sup>, Ari K. Leppaniemi<sup>26</sup>, Andrea Loffredo<sup>27</sup>, Tiziana Meschi<sup>28</sup>, Ernest E. Moore<sup>29</sup>, Monica Ortenzi<sup>24</sup>, Francesco Pata<sup>30</sup>, Dario Parini<sup>31</sup>, Adolfo Pisanu<sup>1</sup>, Gilberto Poggioli<sup>32</sup>, Andrea Polistena<sup>33</sup>, Alessandro Puzziello<sup>27</sup>, Fabio Rondelli<sup>9</sup>, Massimo Sartelli<sup>34</sup>, Neil Smart<sup>35</sup>, Michael E. Sugrue<sup>36</sup>, Patricia Tejedor<sup>37</sup>, Marco Vacante<sup>11</sup>, Federico Coccolini<sup>38</sup>, Justin Davies<sup>39</sup> and Fausto Catena<sup>40</sup>

## Abstract

**Background and aims:** Although rectal cancer is predominantly a disease of older patients, current guidelines do not incorporate optimal treatment recommendations for the elderly and address only partially the associated specific challenges encountered in this population. This results in a wide variation and disparity in delivering a standard of care to this subset of patients. As the burden of rectal cancer in the elderly population continues to

\* Correspondence: [mauropodda@gmail.com](mailto:mauropodda@gmail.com)

<sup>1</sup>Department of Emergency Surgery, Cagliari University Hospital "D. Casula", Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

increase, it is crucial to assess whether current recommendations on treatment strategies for the general population can be adopted for the older adults, with the same beneficial oncological and functional outcomes. This multidisciplinary experts' consensus aims to refine current rectal cancer-specific guidelines for the elderly population in order to help to maximize rectal cancer therapeutic strategies while minimizing adverse impacts on functional outcomes and quality of life for these patients.

**Methods:** The discussion among the steering group of clinical experts and methodologists from the societies' expert panel involved clinicians practicing in general surgery, colorectal surgery, surgical oncology, geriatric oncology, geriatrics, gastroenterologists, radiologists, oncologists, radiation oncologists, and endoscopists. Research topics and questions were formulated, revised, and unanimously approved by all experts in two subsequent modified Delphi rounds in December 2020–January 2021. The steering committee was divided into nine teams following the main research field of members. Each conducted their literature search and drafted statements and recommendations on their research question.

Literature search has been updated up to 2020 and statements and recommendations have been developed according to the GRADE methodology. A modified Delphi methodology was implemented to reach agreement among the experts on all statements and recommendations.

**Conclusions:** The 2021 SICG-SIFIPAC-SICE-WSES consensus for the multidisciplinary management of elderly patients with rectal cancer aims to provide updated evidence-based statements and recommendations on each of the following topics: epidemiology, pre-intervention strategies, diagnosis and staging, neoadjuvant chemoradiation, surgery, watch and wait strategy, adjuvant chemotherapy, synchronous liver metastases, and emergency presentation of rectal cancer.

**Keywords:** Rectal cancer, Elderly, Frailty, Multidisciplinary management, Consensus

## Introduction

According to the World Health Organization, colorectal cancer is the third most commonly diagnosed cancer in males and the second in females. Although rectal cancer, with a mean age at the time of diagnosis of 68 years for men and 72 years for women, is predominantly a disease of older patients, [1], current guidelines do not incorporate optimal treatment recommendations for the elderly and address only partially the associated specific challenges encountered in this population. This results in a wide variation and disparity in delivering a standard of care to this subset of patients [2]. With the aging population, the number of elderly rectal cancer patients is expected to increase further. These patients often have more comorbidities, increased complication rates, and a poorer prognosis [3].

There is a paucity of clinical trial evidence explicitly addressing the risks and benefits of all aspects of rectal cancer in the elderly, which is mainly attributable to the fact that older adults comprise a heterogeneous population covering a spectrum from very frail to fit patients. Moreover, although surgeons are usually accustomed to operating on elderly patients, both in emergency and elective settings [4], recent data indicate that older adults affected by rectal cancer are more likely to be offered a suboptimal range of care for their disease.

The EURECCA international study on the treatment and survival of rectal cancer patients over the age of 80 years in Belgium, Denmark, the Netherlands, Norway,

and Sweden found a substantial variation in the 5-year relative survival between European countries, next to a wide variation in treatment modalities, especially in the use of preoperative radiotherapy in stage II–III patients and the rate of stage IV patients undergoing surgery. Overall, among over 19,500 rectal cancer patients included, 5-year relative survival varied from 61.7% in Belgium to 72.3% in Sweden for stage I–III patients. The proportion receiving preoperative radiotherapy ranged between 7.9% in Norway and 28.9% in Sweden, whereas the rate of patients undergoing surgery varied from 22.2% in Denmark to 40.8% in Norway. An explanation for the lower use of preoperative radiotherapy in elderly patients with rectal cancer might be that a higher risk of recurrence may be considered acceptable in these patients, as in this group maintaining function and quality of life is of great importance [5, 6].

Treatment regimens for rectal cancer patients are more challenging to tolerate than colon cancer, especially for old frail patients. The current standard of care for stage II and III rectal cancer requires multimodality treatments that include three phases: neoadjuvant chemo-radiotherapy (nCRT), surgery with rectal resection, and postoperative adjuvant chemotherapy. In the study by Thiels et al., a total of 160 elderly patients (median age 80 years) with stage II and stage III rectal cancer underwent surgical resection. However, only 30% and 33.8% received neoadjuvant or adjuvant therapy, respectively. Among patients with stage II rectal cancer,

there was no significant difference in 60-month survival between patients who received any additional therapy and those who had surgery alone. Conversely, additional therapy (neoadjuvant chemotherapy or chemoradiotherapy or adjuvant chemotherapy) improved survival in patients with stage III tumors (58% vs. 30%) [7].

As the older rectal cancer patients' prognosis and treatment decisions are primarily influenced by comorbidity and frailty, there is a growing awareness of the need for geriatric assessment as an essential component in the preoperative workup.

Many oncology and surgical societies agree that frail and vulnerable patients could access standard treatments after being adequately pre-habilitated. For this reason, they have established specific task forces to include in their guidelines recommendations that provide an in-depth analysis of all domains of functioning (functional, physical, mental, emotional, pharmacological, and socio-economic) that can help in determining potential compliance of intensive anti-cancer treatments in the elderly [8]. The interest is justified, as it has been recently pointed out that for the fitter elderly, the multimodal treatment including nCRT, resectional surgery, and adjuvant chemotherapy leads to cancer-specific survival rates comparable to those found in the younger population [9]. On the other hand, for patients at higher risk of toxicity or those who refuse surgery, response to neoadjuvant treatment is emerging as a new prognostic factor.

Areas of major debate in the treatment of elderly patients with rectal cancer also remain about the watch and wait strategies after neoadjuvant therapy [10], local excision [11], fractionation and duration of radiotherapy (short course vs. long course), the optimal time to surgery [12], and the benefit of adjuvant chemotherapy.

Cancer treatment in the elderly is also different from the general population in terms of outcomes prioritization and goals of the whole therapeutic strategy. Tailored therapies, including surgical interventions, should focus on the patients' quality of life and functional recovery rather than simple conventional 5-year disease-free survival while maintaining, as far as possible, oncological standards.

The surgical population has increased not only in volume, but also in comorbidity profile and age, requiring an improved preoperative selection and definition of classes of risk for surgery and antineoplastic therapies.

The questions arising from the debates on the management of cancer in the older population problem are multiple: Is the patient going to die with cancer or of cancer? Is the patient able to tolerate the stress of chemotherapy? Is the treatment producing more benefits than harm?

A multidimensional geriatric assessment can identify three different categories of patients based on their life

expectancy and functional status: "fit patients" (people who are functionally independent and without comorbidity) who are candidates for any form of standard cancer treatment and can receive the same treatments as younger patients; "vulnerable patients" who require tailored treatment strategies with some special pharmacological schemes, such as reduction in the initial dose of chemotherapy with subsequent dose escalations, or surgical strategy; and "frail patients" (dependence in one or more activities of daily living, three or more comorbid conditions, one or more geriatric syndromes) who are only candidates for palliative treatment [13, 14].

Since elderly patients older than 70 have been excluded from randomized controlled trials (RCT), very little evidence exists in this population, most of it not being of high level [15]. The project of this experts' consensus arises from the acknowledgment of the lack of evidence about the subgroup of elderly patients with rectal cancer. As the burden of rectal cancer in the elderly population continues to increase, it is crucial to assess whether current recommendations on treatment strategies for the general population can be adopted for the older adults, with the same beneficial oncological and functional outcomes. This experts' consensus aims to refine current rectal cancer-specific guidelines for the elderly population in order to help to maximize rectal cancer therapeutic strategies while minimizing adverse impacts on functional outcomes and quality of life for these patients. Evidence in the present consensus document has been summarized taking into account the different baseline health conditions of elderly rectal cancer patients, although grouping of patients into surgically fit and unfit categories remains largely subjective.

## Methods

This consensus document has been created by a multi-societary collaboration between the SICG (Società Italiana di Chirurgia Geriatrica—Italian Society of Geriatric Surgery), the SIFIPAC (Società Italiana di Fisiopatologia Chirurgica—Italian Society of Surgical Physiopathology), the SICE (Società Italiana di Chirurgia Endoscopica e nuove tecnologie—Italian Society of Endoscopic Surgery and new technologies) and the WSES.It (World Society of Emergency Surgery—Italy Chapter). The discussion among the steering group of clinical experts and methodologists from the societies' expert panel involved clinicians practicing in general surgery, colorectal surgery, surgical oncology, geriatric oncology, geriatrics, gastroenterologists, radiologists, oncologists, radiation oncologists, and endoscopists.

## Topic elaboration and prioritization

The subject of rectal cancer in the elderly ( $\geq 70$  years old) was divided into nine main topics: epidemiology

(socioeconomic burden, screening strategies), pre-intervention strategies (improvement strategies for patient involvement in healthcare decision-making, frailty assessment and multidisciplinary evaluation, definition, and prioritization of patient-centered outcomes), diagnosis and staging, neoadjuvant chemoradiation (indication, timing, compliance, and outcomes of neoadjuvant chemoradiation), surgery (prehabilitation, enhanced recovery after surgery, oral antibiotic prophylaxis, local excision, minimally invasive surgery with laparoscopic/robotic TME and TaTME, early versus delayed ileostomy closure) watch and wait (indications and outcomes), adjuvant chemotherapy (indications and outcomes), liver disease (treatment of synchronous liver metastases) and emergency presentation (obstructing rectal cancer).

Research topics and questions were formulated, revised, and unanimously approved by all experts in two subsequent modified Delphi rounds in December 2020–January 2021. The steering committee was divided into nine teams following the main research field of members. Each conducted their literature search and drafted statements and recommendations on their research question.

#### Literature review

Based on the research questions, the literature review process was carried out conforming to the PRISMA statement standards for systematic reviews and meta-analyses [16] between December 22th 2020, and February 28th, 2021. MEDLINE (via PubMed), the Cochrane Central Register of Controlled Trials, and EMBASE were systematically searched for relevant studies. Study inclusion criteria included systematic reviews with or without meta-analyses, randomized controlled trials, and non-randomized cohort studies on the subject of rectal cancer in elderly patients ( $\geq 70$  years old) published in the English language without any restriction of publication date. Animal studies, case reports, narrative reviews, commentaries, and studies on colorectal cancer not including specific information on rectal localization of the cancer were excluded.

#### The GRADE methodology

The statements were formulated and graded according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) hierarchy of evidence [17], summarized in Table 1. The quality of evidence (QoE) was marked as high, moderate, low, or very low. This could be either downgraded in case of significant bias or upgraded when multiple high-quality studies showed consistent results. The highest quality of evidence studies (systematic reviews with meta-analysis of randomized controlled trials) was assessed first. If the

meta-analyses were of sufficient quality, they were used to answer the research question. If no meta-analysis of sufficient quality was found, randomized controlled trials (RCTs) and non-randomized cohort studies (n-RCS) were evaluated. The strength of the recommendation (SoR) was based on the level of evidence and qualified as weak or strong [18, 19]. Statements and recommendations were generated in response to each research question based on the literature review, using GRADE criteria for assigning strength. The content and strength of each statement and recommendation were reviewed by the panel group's systematic review team, taking into account the quality of the supporting evidence.

#### Agreement on statements and recommendations

A modified Delphi methodology was implemented to reach an agreement among the experts on all statements and recommendations [20]. Each was subject to voting by the experts' panel using the Google Forms online platform. When unanimous consensus was not reached, supporting evidence from the systematic review of the literature performed for the specific research question was presented and discussed, and, if necessary, a second round of voting was carried out. The statements and recommendations were approved only if  $\geq 70\%$  expert agreement was achieved (Table 2).

## Results

### Consensus Topic: A. Epidemiology

**Key Question 1.** Socioeconomic burden. In elderly patients with rectal cancer, how does pre-existing frailty affect the incidence of adverse events and healthcare costs?

**Statement.** Frailty should not be considered a contraindication to surgery in elderly patients with rectal cancer. It is instead a condition that requires a correct choice of the proper surgical technique and a careful peri-operative care to reduce complication rate and consequently healthcare costs.

**Recommendation.** No Recommendation.

**Agreement:** 94.1%

About 60% of colorectal cancers develop in patients over 65 years old [21, 22]. Around 25–45% of these patients can be considered frail [22–24]. Such a wide variability is due to the lack of consensus on the definition of “frailty.” Results of several studies regarding the post-operative outcome of frail patients showed that:

A. There is a higher risk of medical and surgical post-operative complications, especially severe ones, in this subgroup of patients than in the general population [21–28]. The incidence of these complications ranges from 6% [29, 30] to over 65% [29, 31].

B. There is a higher risk of sepsis in frail patients [21, 27].

**Table 1** GRADE quality of evidence and strength of recommendations

Quality of evidence and strength of recommendation	Clarity of balance between desirable and undesirable effects	Methodological quality of supporting evidence	Implications
<b>High-quality evidence, strong recommendation</b>	1.1.1.1.1.1.1.1. Desirable effects clearly outweigh undesirable effects, or vice versa	1.1.1.1.1.1.1.2. Consistent evidence from well-performed RCTs or exceptionally strong evidence from unbiased observational studies	1.1.1.1.1.1.1.3. Recommendation can apply to most patients in most circumstances. Further research is unlikely to change our confidence in the estimate effect
<b>Moderate quality evidence, strong recommendation</b>	1.1.1.1.1.1.1.4. Desirable effects clearly outweigh undesirable effects, or vice versa	1.1.1.1.1.1.1.5. Evidence from RCTs with important limitations (inconsistent results, methodological flaws, indirectness, imprecision) or exceptionally strong evidence from unbiased observational studies	1.1.1.1.1.1.1.6. Recommendation can apply to most patients in most circumstances. Further research (if performed) is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
<b>Low-quality evidence, strong recommendation</b>	1.1.1.1.1.1.1.7. Desirable effects clearly outweigh undesirable effects, or vice versa	1.1.1.1.1.1.1.8. Evidence for at least one critical outcome from observational studies, RCTs with serious flaws or indirect evidence	1.1.1.1.1.1.1.9. Recommendation may change when higher quality evidence becomes available. Further research (if performed) is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
<b>Very low-quality evidence, strong recommendation (rarely applicable)</b>	1.1.1.1.1.1.1.10. Desirable effects clearly outweigh undesirable effects, or vice versa	1.1.1.1.1.1.1.11. Evidence for at least one critical outcome from unsystematic clinical observations or very indirect evidence	1.1.1.1.1.1.1.12. Recommendation may change when higher quality evidence becomes available; any estimate of effect for at least one critical outcome is very uncertain
<b>High-quality evidence, weak recommendation</b>	1.1.1.1.1.1.1.13. Desirable effects closely balanced with undesirable effects	1.1.1.1.1.1.1.14. Consistent evidence from well-performed RCTs or exceptionally strong evidence from unbiased observational studies	1.1.1.1.1.1.1.15. The best action may differ depending on circumstances or patients or societal values. Further research is unlikely to change our confidence in the estimate effect
<b>Moderate-quality evidence, weak recommendation</b>	1.1.1.1.1.1.1.16. Desirable effects closely balanced with undesirable effects	1.1.1.1.1.1.1.17. Evidence from RCTs with important limitations (inconsistent results, methodological flaws, indirectness, imprecision) or exceptionally strong evidence from unbiased observational studies	1.1.1.1.1.1.1.18. Alternative approaches likely to be better for some patients under some circumstances. Further research (if performed) is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
<b>Low-quality evidence, weak recommendation</b>	1.1.1.1.1.1.1.19. Uncertainty in the estimates of desirable effects, harms, and burden; desirable effects, harms, and burden may be closely balanced	1.1.1.1.1.1.1.20. Evidence for at least one critical outcome from observational studies, RCTs with serious flaws or indirect evidence	1.1.1.1.1.1.1.21. Other alternatives may be equally reasonable. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
<b>Very low-quality evidence, weak recommendation</b>	1.1.1.1.1.1.1.22. Major uncertainty in the estimates of desirable effects, harms, and burden; desirable effects may or may not be balanced with undesirable effects	1.1.1.1.1.1.1.23. Evidence for at least one critical outcome from unsystematic clinical observations or very indirect evidence	1.1.1.1.1.1.1.24. Other alternatives may be equally reasonable. Any estimate of effect, for at least one critical outcome, is very uncertain

C. Frail elderly patients who underwent colorectal resection for cancer have a more prolonged hospital stay [21, 22], which ranges from 5 days [29, 32] to more than 20 days [29, 33].

D. There is higher postoperative mortality in elderly frail patients, especially in the first 30 days after the surgical intervention [21, 27, 28].

E. Elderly patients with colorectal cancer who underwent surgery have a higher hospital readmission rate within 30 days [21, 25].

Strong evidence emphasizes that postoperative complications lead to higher healthcare costs. The increment ranges from 1.500 USD to 18.000 USD [29, 33]. Length of hospital stay, obviously influenced by complications, is the first condition that causes an increment of costs [29, 30, 33–36]. There is less correlation between healthcare costs and the different surgical techniques [29]. Currently, a standardized approach for reporting costs associated with complications is lacking. Moreover, there are no results regarding the costs of surgery only in

**Table 2** Summary of the 2021 SICG-SIFIPAC-SICE-WSES multidisciplinary consensus on the management of rectal cancer in the elderly. Statements and recommendations**Consensus Topic: A. Epidemiology****Key Question: 1.** Socioeconomic burden. In elderly patients with rectal cancer, how does pre-existing frailty affect the incidence of adverse events and healthcare costs?**Statement:** Frailty should not be considered a contraindication to surgery in elderly patients with rectal cancer. It is instead a condition that requires a correct choice of the proper surgical technique and a careful peri-operative care to reduce complication rate and consequently health-care costs.**Agreement:** 94.1%**Consensus Topic: A. Epidemiology****Key Question: 2.** Screening strategies. In elderly patients with rectal cancer, how do the current screening strategies compared with no screening affect prognosis?**Statement:** The potential benefits of screening for rectal cancer in elderly patients may vary broadly with age, life expectancy, and screening modalities. Life expectancy and comorbidity should be carefully considered in this context. Subject testing negative for screening, especially after negative colonoscopy, could consider discontinuing screening tests at the age of 75 years.**Agreement:** 88.2%**Consensus Topic: B. Pre-intervention strategies****Key Question: 3.** Improvement strategies for patient involvement in healthcare decision-making. In elderly patients with rectal cancer, how do the strategies for patient involvement in healthcare decision-making compared with the standard decision-making pathways affect compliance to planned treatments?**Statement:** In elderly patients with rectal cancer, the will of the patient to be involved in the decision-making process should be investigated to improve patients' adherence to planned treatments.**Agreement:** 94.1%**Consensus Topic: B. Pre-intervention strategies****Key Question: 4.** Frailty assessment and multidisciplinary evaluation. In elderly patients with rectal cancer, how does the frailty assessment compared with standard assessment strategies influence the outcomes of neoadjuvant treatment, surgical care, recovery, and oncological outcomes?**Statement:** No study directly compared the outcomes of rectal cancer treatment after frailty vs. standard assessment in patients aged above 70 years; however, despite its limitations, the literature shows that frailty, but not age, is an independent risk factor for mortality, morbidity, and re-admissions after rectal cancer surgery, radiotherapy, and palliative chemotherapy for metastatic disease.**Agreement:** 97.1%**Consensus Topic: B. Pre-intervention strategies****Key Question: 5.** Definition and prioritization of patient-centered outcomes. In elderly patients with rectal cancer, how does the prioritization of patient-centered outcomes compared to standard reported outcomes influence the treatment strategies?**Statement:** When deciding the best therapy for elderly patients with rectal cancer, many factors should be considered, such as preoperative frailty and functional status, operative curability, tumor stage, comorbidities, life expectancy, and patient desire.**Agreement:** 97.1%**Consensus Topic: C. Diagnosis and staging****Key Question: 6.** In elderly patients with rectal cancer, how does pelvic Magnetic Resonance Imaging (MRI) perform, compared to Endoscopic Ultrasonography (EUS), in the staging and re-staging following neoadjuvant therapy?**Statement:** Both EUS and MRI provide reasonable diagnostic accuracy in the staging of rectal cancer. However, EUS outperforms MRI in overall T, overall N, T1 and T3 staging. Morphological re-assessment of T- or N-stage by MRI or EUS after neoadjuvant therapy is currently not accurate or consistent enough for clinical application. EUS is slightly superior to1.1.1.1.1.1.1.25. **No Recommendation**1.1.1.1.1.1.1.26. **Recommendation:** The experts' panel recommends against screening in patients older than 85 years. We suggest a careful selection on an individual basis for patients between the ages of 76 and 85 years, according to their health status (**Strong recommendation, Moderate quality of evidence—1B**).1.1.1.1.1.1.1.27. **Recommendation:** The experts' panel recommends the adoption of strategies for patient involvement in healthcare decision-making, the evaluation of the social background, and a discussion with the patient about therapeutic modalities for rectal cancer (**Strong recommendation, Moderate quality of evidence—1B**).1.1.1.1.1.1.1.28. **Recommendation:** The expert's panel suggests the use of a frailty score in the preoperative evaluation of rectal cancer patients above 70 years of age (**Weak recommendation, Low quality of evidence—2C**).1.1.1.1.1.1.1.29. **Recommendation:** The experts' panel recommends involving elderly patients with rectal cancer in a shared decision-making process for the therapeutic pathway with a "two-way communication" between healthcare-professionals and patients/caregivers (**Strong recommendation, Moderate quality of evidence—1B**).**Recommendation:** The experts' panel recommends that either EUS or MRI should be used based on local availability and expertise. MRI has relatively high diagnostic accuracy for preoperative circumferential resection margin assessment and should be used for accurate preoperative staging when muscularis propria invasion and adjacent

**Table 2** Summary of the 2021 SICG-SIFIPAC-SICE-WSES multidisciplinary consensus on the management of rectal cancer in the elderly. Statements and recommendations (*Continued*)

MRI in re-staging the T category after neoadjuvant therapy, whereas the re-assessment by MRI before surgery appears to have a clinical role in excluding circumferential resection margin involvement. The multidisciplinary team should be aware of advantages and disadvantages of both modalities and choose the appropriate method while considering diagnostic accuracy of each test in each specific condition.

**Agreement:** 85.3%

**Consensus Topic: D. Neoadjuvant therapy**

**Key Question: 7.** Indication, timing, compliance, and outcomes of neoadjuvant therapy. In elderly patients with locally advanced stage II-III resectable rectal cancer, how does short-course radiotherapy compared to standard neoadjuvant chemo-radiotherapy affect the oncological outcome?

**Statement:** Preoperative short-course radiotherapy (PSCRT) and preoperative long-course chemo-radiotherapy (PLCCRT) are both effective as neoadjuvant treatments for locally advanced stage II-III resectable rectal cancer. The primary advantage of PSCRT is its lower toxicity compared with PLCCRT. This advantage could be particularly relevant in frail elderly patients with rectal cancer. PSCRT with delayed (more than 4 weeks) surgery may be an effective strategy for elderly and frail patients with locally advanced stage II-III resectable rectal cancer who have a poor performance status or significant comorbidities.

**Agreement:** 87.9%

**Consensus Topic: E. Surgery**

**Key Question: 8.** Prehabilitation, Enhanced Recovery After Surgery (ERAS). In elderly patients with rectal cancer, how do ERAS pathways compared to standard practice affect early surgical outcomes and recovery?

**Statement:** As the ERAS protocol is conceived to improve postoperative outcomes independently from age, it is intuitive to conclude that older patients could benefit from the correct application of ERAS protocols. The importance of assessing frailty in surgical patients appears to be of crucial importance to assure the correct implementation and adherence to the protocols.

**Agreement:** 97.1%

**Consensus Topic: E. Surgery**

**Key Question: 9.** Oral antibiotic prophylaxis. In elderly patients with rectal cancer, how does oral plus intravenous antibiotic prophylaxis affect the rate of surgical site infection (SSI) compared to intravenous antibiotic prophylaxis only?

**Statement:** Current evidence suggests a potentially significant role for oral antibiotic prophylaxis, either in combination with mechanical bowel preparation or alone, in the prevention of postoperative complications in elective colorectal surgery. In elderly patients, oral plus intravenous antibiotic prophylaxis may improve the rate of surgical site infection.

**Agreement:** 94.1%

**Consensus Topic: E. Surgery**

**Key Question: 10.** Local excision. In elderly patients with T1 low rectal cancer, how does local excision with curative intent affect functional and oncological outcomes compared to rectal resection?

**Statement:** In elderly patients with T1 low rectal cancer, local excision with curative intent does not affect long-term functional outcomes. Patients aged > 70 do not show consistent variations of anorectal function after the excision of T1 low rectal cancer without neoadjuvant radiotherapy. Full thickness local excision of T1 rectal cancer can be applied safely in elderly patients with oncological results that are comparable to radical surgery if the pre-operative selection is accurate. If high risk features are present, the choice of local excision has to be made on a case by case basis and balanced with the operative risk. The possibility to administer adjuvant therapy in this case should be considered.

**Agreement:** 97.1%

**Consensus Topic: E. Surgery**

**Key Question: 11.** In elderly patients with a low invasive rectal cancer, how does local excision with palliative intent, if feasible, affect functional and oncological outcomes compared to rectal resection with TME?

organ invasion is suspected. Given the operating characteristics of EUS and MRI and lack of consensus in guidelines, clinical decision may ultimately be determined by access to resources, local expertise, and institutional policy (**Strong recommendation, Moderate quality of evidence—1B**).

1.1.1.1.1.1.1.30. **Recommendation:** The experts' panel suggests short-course radiotherapy with delayed surgery for more than 4 weeks in elderly frail patients with locally advanced stage II-III resectable rectal cancer (**Weak recommendation, Moderate quality of evidence—2B**).

1.1.1.1.1.1.1.31. **Recommendation:** The experts' panel suggests that ERAS protocols should be always implemented for elderly patients undergoing rectal surgery, regardless of age. A correct evaluation of frailty should be performed before surgery in order to obtain the maximum benefit from the application of the protocol in elderly frail population (**Weak recommendation, Moderate quality of evidence—2B**).

1.1.1.1.1.1.1.32. **Recommendation:** The experts' panel recommends that in elderly patients with rectal cancer, oral plus intravenous antibiotic prophylaxis should be preferred over intravenous antibiotic prophylaxis alone in order to reduce postoperative SSIs (**Strong recommendation, Moderate quality of evidence—1B**).

1.1.1.1.1.1.1.33. **Recommendation:** The experts' panel suggests to consider local excision as a valid alternative to Total Mesorectal Excision (TME) among the therapeutic options for T1 rectal cancer in elderly frail patients, due to promising functional and oncological outcomes (**Weak recommendation, Moderate quality of evidence—2B**).

**Table 2** Summary of the 2021 SICG-SIFIPAC-SICE-WSES multidisciplinary consensus on the management of rectal cancer in the elderly. Statements and recommendations (*Continued*)

<p><b>Statement:</b> Local excision is used in combination with neoadjuvant chemo-radiotherapy as an alternative tool to major resection in more advanced rectal cancer. Even if a study specifically addressing the elderly population does not currently exist, the mean age of patients undergoing such a management is higher than those receiving TME. In this case, anorectal function after excision may be affected by the radiation therapy but still seems to be better than in TME patients. Regarding oncological outcomes, there seems to be no difference between radical TME and local excision with palliative purposes.</p>	<p>1.1.1.1.1.1.1.34. <b>Recommendation:</b> The experts' panel suggests to consider local excision as a palliative approach in elderly patients when they are judged unfit for major surgery, in combination with neoadjuvant therapy, when feasible (<b>Weak recommendation, Low quality of evidence—2C</b>).</p>
<p><b>Agreement:</b> 91.2%</p>	
<p><b>Consensus Topic:</b> E. Surgery</p>	
<p><b>Key Question: 12.</b> Local Excision. In elderly patients with a cT2/T3 N0 low to rectal resection with TME affect functional and oncological outcomes?</p>	<p>rectal cancer, how does radiotherapy followed by local excision compared</p>
<p><b>Statement:</b> In elderly patients with a small cT2/T3 N0 low rectal cancer, radiotherapy followed by local excision in clinically good responders may offer no long term difference in oncological outcomes compared to TME. In elderly patients with a cT2/T3 N0 low rectal cancer, radiotherapy followed by local excision may offer impaired functional outcomes, but in any case better than after TME.</p>	<p>1.1.1.1.1.1.1.35. <b>Recommendation:</b> The panel recommends to consider elderly patients with small cT2/T3 N0 low rectal cancers suitable for neoadjuvant therapy and organ sparing transanal local excision following chemo-radiotherapy (<b>Strong recommendation, Moderate quality of evidence—1B</b>).</p>
<p><b>Agreement:</b> 91.2%</p>	
<p><b>Consensus Topic:</b> E. Surgery</p>	
<p><b>Key Question: 13.</b> Local Excision. In elderly patients who underwent local excision of a sessile polyp of the low rectum, with an unexpected result of a pT2/T3 Nx cancer on the resultant histopathology, how does postoperative radiotherapy compare to rectal resection with TME in terms of functional and oncological outcomes?</p>	<p>functional and oncological outcomes?</p>
<p><b>Statement:</b> In elderly fit patients who underwent local excision for a low rectal sessile polyp with final pathology of pT2/T3 rectal cancer, radical surgery with TME is the treatment of choice. However, in case of contraindication to major surgery due to comorbidities, other treatments should be considered including adjuvant radiotherapy. The accurate definition of the surgical risk is a key point to guide towards the most appropriate decision.</p>	<p>1.1.1.1.1.1.1.36. <b>Recommendation:</b> The experts' panel recommends radical surgery with TME as treatment of choice in elderly patients fit for surgery after the local excision of a sessile polyp of the low rectum subsequently confirmed as a pT2/T3 Nx cancer on the histopathology result (<b>Strong recommendation, Moderate quality of evidence—1B</b>).</p>
<p><b>Agreement:</b> 96.8%</p>	
<p><b>Consensus Topic:</b> E. Surgery</p>	
<p><b>Key Question: 14.</b> Minimally invasive surgery (laparoscopic/robotic TME, TaTME). In elderly patients with rectal cancer, how does minimally invasive surgery (laparoscopic/robotic-assisted) compared to open surgery affect recovery, functional and oncological outcomes?</p>	<p>functional and oncological outcomes?</p>
<p><b>Statement:</b> In elderly fit patients with rectal cancer, a consistent amount of evidence suggests that laparoscopic TME is safe and feasible and is associated with short-term benefits compared to open surgery. There is insufficient evidence to support potential benefits of robotic and transanal approaches for rectal cancer resection in elderly patients compared to laparoscopy or open surgery.</p>	<p>1.1.1.1.1.1.1.37. <b>Recommendation:</b> The experts' panel suggests laparoscopic TME in elderly fit patients with rectal cancer after a careful evaluation of patient's medical history, performance status, and tumor characteristics (<b>Weak recommendation, Moderate quality of evidence—2B</b>). Minimally invasive surgery approaches other than laparoscopy and open surgery may be considered for TME in elderly patients with rectal cancer after a careful evaluation of patient's medical history, performance status, and tumor characteristics. Open surgery may be appropriate in selected cases, including locally advanced tumors, multiple previous abdominal operations, or previous pelvic surgery. (<b>Neutral recommendation due to very limited and low-quality evidence</b>).</p>
<p><b>Agreement:</b> 96.8%</p>	
<p><b>Consensus Topic:</b> E. Surgery</p>	
<p><b>Key Question: 15.</b> Early versus delayed ileostomy closure. In elderly patients with low rectal cancer who underwent low anterior resection with diverting loop ileostomy, how does early ileostomy closure compared to delayed ileostomy closure affect complications and quality of life?</p>	<p>quality of life?</p>
<p><b>Statement:</b> In elderly patients with low rectal cancer who underwent low anterior resection with diverting loop ileostomy, early ileostomy closure is safe and feasible. Early closure is related with lower incidence of postoperative small bowel obstruction, stoma-related complications and better functional outcomes, despite a relatively higher surgical site infection rate compared with late closure.</p>	<p>1.1.1.1.1.1.1.38. <b>Recommendation:</b> The experts' panel suggests that in selected elderly fit patients, early (within 2 weeks) closure of ileostomy after rectal resection should be performed. (<b>Weak recommendation, Moderate quality of evidence—2B</b>).</p>
<p><b>Agreement:</b> 87.9%</p>	
<p><b>Consensus Topic:</b> F. Watch and wait</p>	



**Table 2** Summary of the 2021 SICG-SIFIPAC-SICE-WSES multidisciplinary consensus on the management of rectal cancer in the elderly. Statements and recommendations (*Continued*)

**Key Question: 16.** Watch and wait, indications and outcomes. In elderly patients with rectal cancer, how does the watch and wait strategy in case of absence of clinically detectable residual tumor after neoadjuvant therapy affect functional and oncological outcomes compared to rectal resection?

**Statement:** In elderly patients with rectal cancer, in case of complete clinical response after neoadjuvant therapy, watch and wait may be considered a safe strategy, especially in selected patients, such as frail patients and patients with low-rectal tumors, with comparable oncological outcomes and better functional results in comparison to surgery.

1.1.1.1.1.1.1.1.39. **Recommendation:** The experts' panel suggests a watch and wait strategy in selected frail elderly patients with low-rectal tumors in case of complete clinical response after neoadjuvant therapy. A stringent surveillance protocol, at least in the first 3 years, and a candid discussion with the patient about the potential risks of this strategy are recommended (**Weak recommendation, Low quality of evidence—2C**).

**Agreement:** 97.0%

#### Consensus Topic: G. Adjuvant chemotherapy

**Key Question: 17.** Adjuvant chemotherapy. In elderly patients with rectal cancer who underwent radical surgery with curative intent, does fluoropyrimidine-based adjuvant chemotherapy improve the oncological outcome compared with clinical and radiological follow-up?

**Statement:** There is little evidence to support benefit of adjuvant chemotherapy for elderly patients with rectal cancer who have undergone radical surgery with curative intent compared with clinical and radiological follow-up.

**Recommendation:** The experts' panel suggests that for selected stage III and stage II high-risk elderly patients with rectal cancer who underwent radical surgery with curative intent, a fluoropyrimidine-based adjuvant chemotherapy should be preferred to clinical and radiological follow-up. Decision to perform adjuvant chemotherapy (alone or associated with radiotherapy) has to be taken after a multidimensional and geriatric assessment and must be shared within the multidisciplinary board, taking into account individual cancer risk of recurrence, DYPD evaluation, previous treatment (surgery alone or preoperative chemo-radiotherapy), patient's performance status and comorbidities (**Weak recommendation, Low quality of evidence—2C**).

**Agreement:** 93.8%

#### Consensus Topic: H. Liver disease

**Key Question: 18.** Treatment of synchronous liver metastases: In elderly patients with rectal cancer, how do sequential resections (liver then rectum, or vice-versa) compared to simultaneous resection affect postoperative morbidity, mortality, and oncological outcomes?

**Statement:** Liver resections in elderly patients aged > 75 years with colorectal liver metastases show equivalent disease-free survival compared with younger patients, although in these patients perioperative mortality is almost doubled and overall morbidity rate seems to be higher. Simultaneous and staged colorectal and hepatic resections for synchronous liver metastases have comparable postoperative morbidity and mortality, recurrence rate, and 5-year overall survival. However, the simultaneous approach seems to be safe only in selected elderly patients with less severe liver disease. Patients with a high burden of liver disease may be more likely to benefit from early liver-first approach after down-staging therapy.

1.1.1.1.1.1.1.1.40. **Recommendation:** The experts' panel suggests staged or simultaneous liver resection for colorectal liver metastases in elderly patients depending on the burden of liver disease and patient's frailty status. Caution should be taken in performing major hepatectomies in patients aged > 75 years, given the increase in postoperative morbidity and mortality (**Weak recommendation, Moderate quality of evidence—2B**).

**Agreement:** 97.1%

#### Consensus Topic: I. Emergency presentations

**Key Question: 19.** Obstructing rectal cancer. In elderly patients with obstructing upper rectal cancer, how does bridge-to-surgery rectal stent placement compared to emergency surgery affect oncological outcomes and the rate of minimal access surgery?

**Statement:** In elderly patients with obstructing upper rectal cancer, bridge-to-surgery rectal stent placement (when possible) compared to emergency surgery could improve short-term results, even potentially increasing the rate of minimal access surgery, with similar disease-free and overall survival rates.

1.1.1.1.1.1.1.1.41. **Recommendation:** The experts' panel suggests that in elderly patients with obstructing upper rectal cancer, bridge-to-surgery rectal stent placement (when possible) should be preferred over emergency surgery (**Weak recommendation, Moderate quality of evidence—2B**).

**Agreement:** 82.4%

elderly patients. We can suppose that healthcare costs are higher in elderly patients, assuming that most of them are frail, and for this reason, they have a higher rate of postoperative complications. A standard definition of "frailty" is needed to adopt a better surgical approach for colorectal cancer in this group of patients.

#### Consensus Topic: A. Epidemiology

**Key Question 2.** Screening strategies. In elderly patients with rectal cancer, how do the current screening strategies compared with no screening affect prognosis?

**Statement.** The potential benefits of screening for rectal cancer in elderly patients may vary broadly with age,

life expectancy, and screening modalities. Life expectancy and comorbidity should be carefully considered in this context. Subject testing negative for screening, especially after negative colonoscopy, could consider discontinuing screening tests at the age of 75 years.

**Recommendation.** The experts' panel recommends against screening in patients older than 85 years. We suggest a careful selection on an individual basis for patients between the ages of 76 and 85 years, according to their health status (*Strong recommendation, Moderate quality of evidence—1B*).

**Agreement:** 88.2%

Colorectal cancer screening is recommended for average-risk individuals between the ages of 50 and 75 years. Once patients are older than 75 years, the risk-to-benefit ratio of ongoing screening begins to shift. The potential benefits of screening for rectal cancer in elderly patients may vary broadly with age, life expectancy, and screening modalities (i.e., stool-based, radiological, blood testing, and endoscopic screening). Current guidelines from the U.S. Preventive Services Task Force (USPSTF), and the American Cancer Society (ACS), recommend against screening patients for rectal cancer between the ages of 76 and 85. However, in this age group, screening could be suggested on an individual patient basis after personalized assessment. The USPSTF and the ACS also recommend against screening for individuals older than 85 years [37, 38]. Both the American Gastroenterology Association (AGA) and the American Society of Gastrointestinal Endoscopy (ASGE) guidelines reported the potential benefits of screening in patients up to 86 years if they had not been screened before. The cost-effectiveness analysis performed by van Hees et al. to assess whether screening should be considered in unscreened elderly subjects aged 76 to 90 years found that screening was cost-effective up to age 86 years. Screening with colonoscopy was indicated up to age 83 years, sigmoidoscopy was indicated at age 84 years, and the fecal immunochemical test was indicated at ages 85 and 86. Nevertheless, comorbidity should be carefully considered in this context. In unscreened individuals with severe comorbid conditions, screening was cost-effective up to age 80 years (colonoscopy indicated up to age 77 years, sigmoidoscopy at age 78 years, and fecal immunochemical test at ages 79 and 80) [39].

Subjects who tested negative for screening, especially after negative colonoscopy, could consider discontinuing screening tests at 75 years [40, 41]. A cross-sectional study showed that colonoscopy in subjects older than 80 years offered only 15% of extension in life expectancy compared to younger individuals. Therefore, it has been suggested that screening colonoscopy in very elderly patients should be carried out only after careful evaluation of risks, benefits, and patient preferences [42]. A

calculation model proposed by Inadomi and Sonnenberg suggested that screening and continuous surveillance should be carried out only on subjects who have a life expectancy of 10 years or more. This model showed a more significant reduction in longevity due to rectal cancer in younger patients compared to older age groups, thereby reflecting the influence of competing risks of death from other causes that increase with age [43]. Consensus guidelines from the ASGE recommended assessments of cognition and capacity in older adults to guarantee that patients are adequately able to engage in shared decision-making [40].

### Consensus Topic: B. Pre-intervention strategies

**Key Question 3.** Improvement strategies for patient involvement in healthcare decision-making. In elderly patients with rectal cancer, how do the strategies for patient involvement in healthcare decision-making compared with the standard decision-making pathways affect compliance to planned treatments?

**Statement.** In elderly patients with rectal cancer, the will of the patient to be involved in the decision-making process should be investigated to improve patients' adherence to planned treatments.

**Recommendation.** The experts' panel recommends the adoption of strategies for patient involvement in healthcare decision-making, the evaluation of the social background, and a discussion with the patient about therapeutic modalities for rectal cancer (*Strong recommendation, Moderate quality of evidence—1B*).

**Agreement:** 94.1%

The standard decision-making pathway for rectal cancer management is based on international guidelines' recommendations. However, the possibility to adhere to standard therapeutic schemes is not systematic for elderly patients due to higher risk for adverse events, complications, comorbidities, treatment-related mortality, and also due to explicit refusal of the patient to proceed or continue therapies, compared to younger patients [44–46]. European studies demonstrate that the proportion of patients with colorectal cancer treated following national guidelines varies between 53 and 90%, with patient preference (27%) and functional status (20%) the most commonly reported reasons for adjusted treatment [46]. Nonetheless, patient involvement in perceiving personal preferences about the treatment is not systematic, especially in older patients [47]. Diefenhardt et al. showed that in patients with rectal cancer, adherence to neoadjuvant chemo-radiotherapy was significantly associated with disease-free survival [44]. Mari et al. found that adjuvant chemotherapy for locally advanced rectal cancer was associated with improved overall survival, although RCTs showed a 43 to 73% compliance rate, which may affect efficacy [45]. Adherence is influenced

by treatment-related and by patient-related factors such as cognitive status and socioeconomic status. The decision-making process related to treatment should consider patients' preferences after receiving appropriate information about risks and benefits. In elderly patients, therapeutic decisions should always be preceded by a comprehensive geriatric assessment, an evaluation of the social background and social support of the patient, a discussion with the patient about therapeutic modalities, probability of having treatment-related toxicity, and side effects [48].

However, not all patients desire to be involved in the healthcare decision-making process. Elkin et al. reported that about half of the patients desire to decide their therapeutic pathway. Besides, physicians do not always correctly perceive the patient's will to be involved [49]. Elderly patients affected by rectal cancer should be carefully evaluated from an oncological point of view, but also the cognitive and social background should be considered. The patient's will to be involved in therapeutic decisions should be investigated. If positive, a shared decision-making process should be structured by integrating patients' and clinicians' values and beliefs to recognize the "best" outcome for each specific scenario, ultimately improving patients' outcomes [50].

#### **Consensus Topic: B. Pre-intervention strategies**

**Key Question 4.** Frailty assessment and multidisciplinary evaluation. In elderly patients with rectal cancer, how does the frailty assessment compared with standard assessment strategies influence the outcomes of neoadjuvant treatment, surgical care, recovery, and oncological outcomes?

**Statement.** No study directly compared the outcomes of rectal cancer treatment after frailty vs. standard assessment in patients aged above 70 years; however, despite its limitations, the

literature shows that frailty, but not age, is an independent risk factor for mortality, morbidity, and readmissions after rectal cancer surgery, radiotherapy, and palliative chemotherapy for metastatic disease.

**Recommendation.** The expert's panel suggests the use of a frailty score in the preoperative evaluation of rectal cancer patients above 70 years of age (*Weak recommendation, Low quality of evidence—2C*).

**Agreement:** 97.1%

No study directly compared the outcomes of rectal cancer treatment after frailty vs. standard assessment in elderly patients. In older general, cardiovascular and orthopedic surgical patients, frailty predicts postoperative mortality, complications, and prolonged length of hospital stay [51]. A few studies on colorectal surgery confirmed the prognostic value of several frailty scores,

but neither distinguished between colon and rectal surgery nor examined their use as a decision-making tool [26, 28, 52, 53].

The systematic review and meta-analysis by Boakye et al. included 37 cohort studies, of which 35 were on comorbidity and two on frailty. Compared to colorectal cancer patients without comorbidity, those with mild/moderate and severe comorbidity showed a higher risk of 30-day (OR = 1.71 and OR = 2.62), overall (HR = 1.41 and HR = 2.03), and cancer-specific mortality (HR = 1.06 and HR = 1.14). Similarly, higher overall mortality was reported in frail colorectal cancer patients than non-frail patients [54]. A geriatric frailty assessment can also predict 1-year and 5-year survival in older patients after colorectal surgery for cancer. In the study by Ommundsen et al., a pre-operative geriatric assessment was performed on a cohort of 178 colorectal cancer patients aged 70 and older who underwent elective surgery. The geriatric assessment resulted in patients being divided into two groups: frail or non-frail. One-year survival was 80% in the frail group and 92% in the non-frail group. Five-year survival was significantly lower in frail (24%) than non-frail patients (66%), and this difference was apparent both within the stratification on TNM stages 0–II and TNM stage III [55].

However, observational studies on rectal cancer focused on the prognostic value of frailty assessment without examining its use to tailor the management plan. They found that frailty, but not age, is an independent risk factor for mortality and morbidity [56–58] and readmissions after rectal cancer surgery [59], radiotherapy [60], and palliative chemotherapy for metastatic disease [61].

All the referenced studies also included patients younger than 80; this is an additional limitation to the available evidence. The large number of available frailty scores and the diversity of inclusion criteria seriously limit the possibility to compare studies.

The scarce, heterogeneous literature does not allow to propose a firm statement about the key question, but a more extensive use of a frailty assessment could be advisable.

The randomized phase II GERICO trial (NCT02748811) has recently been completed. This was designed to investigate whether geriatric assessment and intervention before and during treatment with chemotherapy in frail elderly patients with stages II-IV colorectal cancer patients would increase the number of patients completing chemotherapy. The findings from the GERICO trial are expected to provide valuable knowledge about whether it is beneficial for the elderly patient undergoing chemotherapy to be treated simultaneously by a geriatric specialist [62].

**Consensus Topic: B. Pre-intervention strategies**

**Key Question 5.** Definition and prioritization of patient-centered outcomes. In elderly patients with rectal cancer, how does the prioritization of patient-centered outcomes compared to standard reported outcomes influence the treatment strategies?

**Statement.** When deciding the best therapy for elderly patients with rectal cancer, many factors should be considered, such as preoperative frailty and functional status, operative curability, tumor stage, co-morbidities, life expectancy, and patient desire.

**Recommendation.** The experts' panel recommends involving elderly patients with rectal cancer in a shared decision-making process for the therapeutic pathway with a "two-way communication" between healthcare professionals and patients/caregivers (*Strong recommendation, Moderate quality of evidence—1B*).

**Agreement:** 97.1%

Even though rectal cancer is predominantly a disease of the elderly, the treatment is not straightforward nor standardized. When deciding the best therapy for an elderly patient with rectal cancer, many factors should be considered, including the preoperative frailty and functional status, operative curability, tumor stage, comorbidities, life expectancy, and patient desire: these must all be evaluated before recommending any therapy [15, 63]. Nowadays, the lack of standardized measurement hampers the widespread attainment of value-based care for rectal cancer patients.

Treatment strategy should focus mainly on patients' functional recovery and quality of life, rather than mere 5-year disease-free survival while maintaining appropriate oncological standards and minimizing adverse effects [64].

PROMs (patient-reported outcome measures) are crucial to be considered in real life. It is essential to choose a treatment or a combination of treatments that ensure excellent tumor control with minimal acute and late side effects to provide a personalized healthcare path and the best possible quality of life [15]. Patients should be actively involved in the decision-making with a "two-way communication" between healthcare professionals and patients/caregivers [65].

The International Consortium for Health Outcomes Measurement (ICHOM) working group has developed a consensus on the use of well-validated outcome measures, including PROMs [66]. A list of 40 outcomes was evaluated by the ICHOM working group and underwent voting. The final recommendation included survival and disease control outcomes, the disutility of care, degree of health, and quality of death. Moreover, selected case-mix factors were recommended to be collected at baseline to facilitate the comparison of results across treatments. Although age, taken as an independent variable, is not a

contraindication to any specific therapy, including radical surgery [67], elderly patients with rectal cancer may present psychological disorders and have a higher incidence of poor fecal continence following surgery. The surgical intervention should be based on an accurate balance between life-expectancy and comorbid conditions, performing a careful evaluation of the cardiovascular, pulmonary, renal, metabolic, and nutritional status.

**Consensus Topic: C. Diagnosis and staging**

**Key Question 6.** In elderly patients with rectal cancer, how does pelvic Magnetic Resonance Imaging (MRI) perform, compared to Endoscopic Ultrasonography (EUS), in the staging and re-staging following neoadjuvant therapy?

**Statement.** Both EUS and MRI provide reasonable diagnostic accuracy in the staging of rectal cancer. However, EUS outperforms MRI in overall T, overall N, T1 and T3 staging. Morphological re-assessment of T- or N-stage by MRI or EUS after neoadjuvant therapy is currently not accurate or consistent enough for clinical application. EUS is slightly superior to MRI in re-staging the T category after neoadjuvant therapy, whereas the re-assessment by MRI before surgery appears to have a clinical role in excluding circumferential resection margin involvement. The multidisciplinary team should be aware of advantages and disadvantages of both modalities and choose the appropriate method while considering diagnostic accuracy of each test in each specific condition.

**Recommendation.** The experts' panel recommends that either EUS or MRI should be used based on local availability and expertise. MRI has relatively high diagnostic accuracy for preoperative circumferential resection margin assessment and should be used for accurate preoperative staging when muscularis propria invasion and adjacent organ invasion are suspected. Given the operating characteristics of EUS and MRI and lack of consensus in guidelines, clinical decision may ultimately be determined by access to resources, local expertise, and institutional policy (*Strong recommendation, Moderate quality of evidence—1B*).

**Agreement:** 85.3%

Endoscopic Ultrasonography (EUS) and Magnetic Resonance Imaging (MRI) are used for locoregional staging of rectal cancer. There is a lack of consensus on the best modality of locoregional staging, especially for small tumors, with different studies supporting both EUS and MRI. The American Society for Gastrointestinal Endoscopy (ASGE) recommends EUS for the locoregional staging of rectal cancer to guide therapy [68]. The European Society of Medical Oncology (ESMO) suggests using EUS or MRI in early T staging and suggests MRI as the optimal modality of N staging [69]. The National

Comprehensive Cancer Network (NCCN) lists both MRI and EUS for clinical staging, although MRI is preferred [70].

According to some authors, MRI is the imaging of choice for the staging of locally advanced rectal cancer [71, 72] because it allows to select patients, guide the surgeon in surgical planning or for a “wait and see” approach, identify negative prognostic factors [73] such as mesorectum invasion (T3), lymph node involvement (N+), mesorectal fascia involvement and macroscopic perivascular infiltration [74].

Al-Sukhni et al. [75] and Zhang et al. [76] agree on the high specificity of MRI (93%) for identifying the infiltration of the perirectal fascia, the excellent accuracy of the method in the staging of T (T1–T2 vs. T3), differentiating the T3 initial ( $\leq$  5-mm extra-parietal infiltration) from T3 ( $>$  5-mm extra-parietal infiltration) with an accuracy of 91% and 88% respectively and, finally, in the high specificity of MRI (97%) in highlighting infiltration of adjacent organs and structures, defining the stage T4.

Chan et al. [77] performed a meta-analysis to compare, in the same patient population, the diagnostic accuracy, sensitivity, and specificity of EUS and MRI in the staging of rectal cancer. The pooled analysis included six studies with 234 patients. Pooled sensitivity and specificity in T staging were 0.79 and 0.89 for EUS and 0.79 and 0.85 for MRI. Pooled sensitivity and specificity in N staging were 0.81 and 0.88 for EUS and 0.83 and 0.90 for MRI, respectively. EUS outperformed MRI in overall T, overall N, T1, and T3 staging in the area under the curve analysis. Conversely, MRI was superior to EUS in T2 staging. The accuracy of EUS in detecting early-stage rectal cancer can have clinical applicability because a T1 rectal cancer can be treated by local excision.

Regarding the evaluation of local lymph node metastases, the sensitivity and specificity in patients with no neoadjuvant chemo-radiotherapy were 0.77 and 0.76 for MRI, 0.57 and 0.80 for EUS, and 0.79 and 0.76 for CT scan in the meta-analysis by Li et al. [78]. MRI showed higher accuracy than EUS for patients who did not receive neoadjuvant therapy. High-resolution MRI showed similar diagnostic accuracy compared to EUS and CT scan. The authors suggested the use of MRI rather than EUS for lymph node evaluation after neoadjuvant therapy. The pooled sensitivity and specificity of EUS to determine T1-stage rectal cancer was 87.8% and 98.3%, respectively, in the meta-analysis by Puli et al. [79]. For the T2 stage, EUS had a pooled sensitivity and specificity of 80.5% and 95.6%. To stage T3 rectal cancers, EUS had a pooled sensitivity and specificity of 96.4% and 90.6%. In determining the T4 stage, EUS had a pooled sensitivity of 95.4% and specificity of 98.3%.

MRI and EUS also play a role in the re-staging of locally advanced rectal cancer after preoperative chemo-

radiotherapy. The accuracy of re-staging imaging is different for different T stages, and it is highest for T3 tumors. However, morphological assessment of T- or N-stage by MRI or EUS is currently not accurate or consistent enough for clinical application. The diagnostic performance of MRI, EUS, and CT scan in predicting the response of locally advanced rectal cancer after neoadjuvant therapy was assessed in the meta-analysis by de Jong et al. [80]. Forty-six studies comprising more than 2,200 patients were included. The pooled accuracy in assessing tumor response after neoadjuvant therapy was 75% for MRI, 82% for EUS, and 83% for CT scan. Pooled accuracy in detecting T4 tumors with invasion to the circumferential resection margin was 88% and 94% for EUS. Pooled accuracy in predicting the presence of lymph node metastases was 72% for MRI, 72% for EUS, and 65% for CT.

In the systematic review and meta-analysis by Zhao et al. [81], EUS was superior to MRI in the re-staging T category. The sensitivity estimate for rectal cancer diagnosis (T0) by EUS was higher than the sensitivity estimate for MRI (37.0% vs. 15.3%). For T3–T4 cancers, sensitivity estimates of MRI and EUS were comparable (82.1% vs. 87.6%), whereas specificity estimates were poor (53.5% vs. 66.4%). For lymph node involvement, there was no significant difference between the sensitivity estimates for MRI and EUS (61.8% vs. 49.8%). Specificity estimates for MRI and EUS were 72.0% vs. 78.7%. For circumferential resection margin involvement, MRI sensitivity and specificity were 85.4% and 80.0%, respectively.

Sixty-three studies were included in the systematic review and meta-analysis by Memon et al. [82]. Twelve re-staging MRI studies and 18 re-staging EUS studies were eligible for meta-analysis of T-stage and N-stage and N-status re-staging accuracy. Overall, EUS T-stage re-staging accuracy (65%) was non-significantly higher than MRI T-stage accuracy (52%). Re-staging MRI was accurate at excluding circumferential resection margin involvement. Re-staging MRI and EUS were equivalent at the prediction of nodal status (72%), with over-staging and under-staging occurring in 10–15%.

#### **Consensus Topic: D. Neoadjuvant therapy**

**Key Question 7.** Indication, timing, compliance, and outcomes of neoadjuvant therapy. In elderly patients with locally advanced stage II–III resectable rectal cancer, how does short-course radiotherapy compared to standard neoadjuvant chemo-radiotherapy affect the oncological outcome?

**Statement.** Preoperative short-course radiotherapy (PSCRT) and preoperative long-course chemo-radiotherapy (PLCCRT) are both effective as neoadjuvant treatments for locally advanced stage II–III

resectable rectal cancer. The primary advantage of PSCRT is its lower toxicity compared with PLCCRT. This advantage could be particularly relevant in frail elderly patients with rectal cancer. PSCRT with delayed (more than 4 weeks) surgery may be an effective strategy for elderly and frail patients with locally advanced stage II–III resectable rectal cancer who have a poor performance status or significant comorbidities.

**Recommendation.** The experts' panel suggests short-course radiotherapy with delayed surgery for more than 4 weeks in elderly frail patients with locally advanced stage II–III resectable rectal cancer. (*Weak recommendation, Moderate quality of evidence—2B*).

**Agreement:** 87.9%

In terms of oncological outcomes, adding preoperative chemo-radiotherapy or radiotherapy alone shows obvious advantages for local control compared to surgery alone in patients with resectable rectal cancer. Either preoperative short-course radiotherapy (PSCRT) of 25 Gy in 5 consecutive days or preoperative long-course chemo-radiotherapy with 45–50 Gy, 1.8–2 Gy/fr with concomitant 5-FU-based chemotherapy (PLCCRT) followed by radical TME is effective for local control and are regarded as the two main standards of care for patients with high-risk rectal cancer [83, 84]. Recently, an alternative strategy known as total neoadjuvant therapy (TNT), that involves administration of CRT plus neoadjuvant chemotherapy before surgery with the goal of delivering uninterrupted systemic therapy to eradicate micrometastases, has shown promising results in locally advanced rectal cancer, with superior rates of pathologic complete response (pCR) compared with standard therapy [85].

The benefit of PSCRT, as proposed by the Swedish Rectal Cancer Trial, is a lower rate of early toxicity compared to chemo-radiotherapy [86, 87].

Five systematic reviews and meta-analyses that explored the effects of PSCRT and its optimized schemes compared to PLCCRT have been published to date.

The meta-analysis by Ma et al. [88] indicated that PSCRT could be considered the treatment of choice compared to PLCCRT when a complete response is not the primary aim. PLCCRT, in fact, showed a better pCR rate (OR = 0.05,  $P < 0.01$ ), although this benefit did not translate into a higher sphincter preservation rate (OR = 1.62,  $P = 0.25$ ). Moreover, this meta-analysis indicated that the insufficiency of PSCRT on pCR might be improved by delayed surgery or adding consolidation chemotherapy. The two strategies had equivalent rates of post-treatment complications (OR = 1.19,  $P = 0.30$ ), although patients who received PSCRT had a significantly lower incidence of total acute toxicities compared to PLCCRT (OR = 0.09,  $P < 0.01$ ). In terms of long-term oncological outcomes, the two strategies showed similar

tendencies of overall survival, disease-free survival, local recurrence, and distant metastases.

The systematic review and meta-analysis by Qiaoli et al. analyzed seven studies (4,973 patients) comparing PSCRT with delayed surgery (more than 4 weeks) and standard PLCCRT for locally resectable rectal cancer [89]. The pooled analysis showed that there was no statistically significant difference in overall survival (HR = 1.30,  $P = 0.52$ ), disease-free survival (HR = 1.10,  $P = 0.64$ ), pCR (RR = 0.74,  $P = 0.39$ ), early postoperative complications (RR = 1.21,  $P = 0.16$ ), treatment-related grade 3–4 toxicity (RR = 0.78,  $P = 0.68$ ), local recurrence (RR = 1.27,  $P = 0.70$ ) and distant metastasis (RR = 1.06,  $P = 0.58$ ). However, a subgroup analysis revealed that PSCRT without adjuvant chemotherapy resulted in lower treatment-related grade 3–4 toxicity than PLCCRT (RR = 0.19,  $P < 0.01$ ), but also resulted in significantly lower overall survival (HR = 2.05,  $P = 0.02$ ) and pCR (RR = 1.37,  $P = 0.14$ ). Regarding long-term survival, the 2018 meta-analysis by Wang et al. [90] found that there was no significant difference in overall survival (HR = 0.92,  $P = 0.44$ ), disease-free survival (HR = 0.94,  $P = 0.50$ ) and local recurrence (OR = 0.73,  $P = 0.73$ ) between PSCRT and PLCCRT (High overall quality of evidence in the subgroup analysis of RCTs).

Twelve trials were included in the meta-analysis by Zhou et al. [91] that demonstrated no significant difference in overall survival, disease-free survival, local recurrence rate, distant metastasis rate, sphincter preservation rate, R0 resection rate, and late toxicity comparing patients who underwent PSCRT and PLCCRT. Similarly to other meta-analyses, PLCCRT increased the rate of grade 3–4 acute toxicity (RR = 0.13,  $P < 0.00001$ ) and pCR (RR = 0.15,  $P = 0.003$ ). Similar outcomes have been found in a recent systematic review and meta-analysis performed by the Chinese group of Yu et al. [92]. Sixteen studies with a total of 2,773 rectal cancer patients were included in the pooled analysis. There were no significant differences between PSCRT and PLCCRT concerning pCR (RR = 0.54), tumor down-staging (RR = 0.83), local recurrences (RR = 0.55), distant metastases (RR = 1.03), mortality (RR = 0.95), and serious late toxicity (RR = 1.10). However, in the subgroup analysis of RCTs, PLCCRT had a better pCR and tumor down-staging rate than PSCRT.

All the analyzed studies also included patients younger than 80. This is a limitation to the available evidence, as no study included in the pooled analyses directly compared the outcomes of PSCRT and PLCCRT for elderly patients with rectal cancer.

Recently, the preliminary results of the phase III NACRE (Neoadjuvant Treatment for Advanced Rectal Carcinoma) trial have been published. The NACRE RCT enrolled patients aged 75 and older to compare PSCRT

only and standard PLCCRT. One hundred patients from 29 sites were randomized from 01/2016 to 08/2019. The median age was 80 years. The R0 resection rate in the two study arms was comparable. With a median follow-up of 15.8 months, the six-month death rate was 10.0% in the PLCCRT arm and 3.92% in the PSCRT arm. There was a significant difference in overall survival between the two arms in favor of the PSCRT arm ( $P = 0.04$ , LogRank test), and there was a trend in favor of the PSCRT arm for specific survival ( $P = 0.06$  LogRank test). Conversely, disease-free survival was not statistically different [93].

PSCRT might be related to better health-related quality of life outcomes, according to some authors. Wiltink et al. found that patients who received a short-course scheme had a lower level of nausea/vomiting [94]. Three trials included in the meta-analysis by Ma et al. used the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire to evaluate the quality of life in rectal cancer patients who received PSCRT or PLCCRT. All the trials showed no statistically significant difference in the quality of life outcomes comparing the two regimens based on the scores of QLQ-C30 [94–97].

Although both the NCCN guidelines [98] and the European Society for Medical Oncology (ESMO) guidelines [69] recommend PSCRT as one of the standard treatments for locally advanced stage II–III resectable rectal cancer, neither provides an optimal time interval between the end of radiotherapy and surgery. There are two standard time intervals at which PSCRT and surgery are performed: PSCRT followed by immediate surgery within ten days, and PSCRT followed by delayed surgery (at least 4 weeks after the last radiotherapy is completed). The meta-analysis by Wu et al. [99] analyzed five studies (1,244 patients) comparing the immediate surgery (< 4 weeks) and delayed surgery (> 4 weeks) strategies as optimal interval time after PSCRT for stage II–III resectable rectal cancer patients. The delayed surgery group had a markedly higher pCR (RR = 15.71,  $P = 0.007$ ), and down-staging rates (RR = 2.63,  $P < 0.00001$ ), a higher proportion of patients with adjuvant pathologic stage 0 + 1 disease (RR = 1.49,  $P < 0.0001$ ) and a lower incidence of postoperative complications (RR = 0.81,  $P = 0.008$ ) compared with the immediate surgery group. The survival rate, sphincter preservation rate, and R0 resection rate were equivalent between the two groups.

Patients who have just undergone neoadjuvant treatment, especially the elderly and frail ones, might be in poor physical condition, and a delay in surgery may enable these patients to recover and overcome the acute radiation toxicity. A long waiting period > 4 weeks can also enable patients to improve their lifestyle, such as cease smoking, control blood

pressure and diabetes, and obtain adequate nutritional support.

#### Consensus Topic: E. Surgery

**Key Question 8.** Prehabilitation, Enhanced Recovery After Surgery (ERAS). In elderly patients with rectal cancer, how do ERAS pathways compared to standard practice affect early surgical outcomes and recovery?

**Statement.** As the ERAS protocol is conceived to improve postoperative outcomes independently from age, it is intuitive to conclude that older patients could benefit from the correct application of ERAS protocols. The importance of assessing frailty in surgical patients appears to be of crucial importance to assure the correct implementation and adherence to the protocols.

**Recommendation.** The experts' panel suggests that ERAS protocols should be always implemented for elderly patients undergoing rectal surgery, regardless of age. A correct evaluation of frailty should be performed before surgery in order to obtain the maximum benefit from the application of the protocol in elderly population. (*Weak recommendation, Moderate quality of evidence—2B*).

**Agreement:** 97.1%

With an increase in life expectancy and improved quality of medical care, the number of elderly patients increases every year [100]. In a large database analysis, Jafari et al. [101] reported that 63.8% of surgical operations for colorectal cancer had been performed on patients 65 years or older and 22.6% on patients 80 years or older. Considering the increasing number of elderly patients, the safety of implementing ERAS protocols in this population has been questioned. Elderly patients may have more postoperative complications and take a longer time to recover [102–104]. However, with the implementation of ERAS protocols, patients have recovered from their operations faster, often with lower morbidity and mortality [105–107]. A systematic review of 16 studies confirmed the safety of ERAS in elderly patients who underwent colorectal surgery [108]. Before this, two RCTs found that the average length of hospital stay for elderly patients who underwent colorectal resections following an ERAS pathway was significantly lower than elderly non-ERAS patients (5.5 vs. 7 days and 9 vs. 13 days, respectively for each RCT) [109, 110].

Another retrospective study published in 2020 reviewed the outcomes of colectomy patients concerning the pre-operative assessment of frailty. The study found that with the implementation of newer modalities in the ERAS pathways, the median length of stay was three days for elderly patients and two days for non-elderly patients. The authors demonstrated that congestive heart failure increases the chances of a prolonged length of stay in elderly patients [111]. Therefore, they

concluded that it is crucial to ensure that patient's comorbidities are well controlled during hospital admission, especially among elderly patients. Furthermore, although the study showed that frail patients are discharged earlier than in other studies, the elderly patients' progress through the ERAS pathway is still slower than in the younger cohort, often requiring prolonged hospitalization. More frail patients with many comorbidities have exhibited higher morbidity and mortality with increased hospital services utilization due to their lowered functional status [111–113]. These findings emphasize the importance of an individualized ERAS approach to elderly patients and suggest that ERAS protocols should be modified for older patients with higher frailty scores before colorectal procedures.

Moreover, elderly patients with high frailty indices require close post-discharge follow-up and communication with their primary care physicians. Another more recent systematic review was aimed to analyze the outcomes of the ERAS care pathway in older patients. The authors found how the reported adherence to the protocol items in > 65 years old patients was low to moderate, and these data could invalidate the available results. However, from the available literature emerges how ERAS strategy has significantly better outcomes than conventional care, with comparable postoperative morbidity in the younger and older patient population in the majority of the studies. This review's most critical methodological flaw was that only six studies included older patients or subgroups of older patients. Furthermore, the older patients included may be subject to selection bias, as mainly physically and mentally fit patients tend to be recruited in the included studies [114].

#### Consensus Topic: E. Surgery

**Key Question 9.** Oral antibiotic prophylaxis. In elderly patients with rectal cancer, how does oral plus intravenous antibiotic prophylaxis affect the rate of surgical site infection (SSI) compared to intravenous antibiotic prophylaxis only?

**Statement.** Current evidence suggests a potentially significant role for oral antibiotic prophylaxis, either in combination with mechanical bowel preparation or alone, in the prevention of postoperative complications in elective colorectal surgery. In elderly patients, oral plus intravenous antibiotic prophylaxis may improve the rate of surgical site infection.

**Recommendation.** The experts' panel recommends that in elderly patients with rectal cancer, oral plus intravenous antibiotic prophylaxis should be preferred over intravenous antibiotic prophylaxis alone in order to reduce postoperative SSIs (*Strong recommendation, Moderate quality of evidence—1B*).

**Agreement:** 94.1%

Surgical site infection (SSI) is a common complication after colorectal surgery. SSI represents not only a costly expense to health services but, more importantly, influences patient recovery and survival [115]. Various strategies have been adopted in attempts to reduce postoperative SSI rates. The value of i.v. antibiotics in the immediate preoperative period is established, and they are currently used worldwide. To reduce the risk of infection after colorectal surgery, the role of oral antibiotic preparation (OAP) with or without mechanical bowel preparation (MBP) has been a matter of debate in the last ten years.

In the meta-analysis by Bellows et al., which included sixteen RCTs published between 1979 and 2007, patients randomly assigned to an oral non-absorbable antibiotic in addition to an intravenous antibiotic had a reduced risk of SSI (RR = 0.57, P = 0.0002) compared with patients receiving only intravenous antibiotics. Moreover, the use of oral non-absorbable antibiotics in addition to intravenous antibiotics had no significant effect on organ-space infections or the risk of the anastomotic leak [116].

Similarly, current evidence from the largest meta-analysis published to date on the argument suggests a potentially significant role for OAP preparation, either in combination with MBP or alone, in the prevention of postoperative complications in elective colorectal surgery. The pooled analysis was conducted on a total of 40 studies with 69,517 patients (28 randomized controlled trials and 12 cohort studies). The combination of MBP plus OAP versus MBP alone was associated with a significant reduction in SSI (RR = 0.51, P < 0.00001), anastomotic leak (RR = 0.62, P < 0.00001), 30-day mortality (RR = 0.58, P < 0.0001), overall morbidity (RR = 0.67, P < 0.00001), and postoperative ileus (RR = 0.72, P = 0.04), with no difference in *Clostridium difficile* infection rates. When a combination of MBP+OAP was compared with OAP alone, no significant difference was seen in SSI or anastomotic leak rates, but there was a significant reduction in 30-day mortality and postoperative ileus incidence with the combination [117].

Concerns regarding hospital-acquired infections (HAIs), including *Clostridium difficile*, are relevant, especially in elderly patients. However, meta-analyses [118, 119] have demonstrated the effectiveness of OAP in association with i.v. antibiotic prophylaxis with or without MBP regarding SSI risk.

In the meta-analysis by Khorasani et al., the incidence of postoperative *Clostridium difficile* infection in adults receiving oral antibiotics versus no oral antibiotics was used as the primary outcome. Fourteen RCTs and 13 cohort studies comparing bowel preparation with oral antibiotics to those without oral antibiotics were identified. The pooled OR from 4 eligible RCTs was suggestive of a



greater odds of *Clostridium difficile* infection in the oral antibiotic group (OR = 4.46), with an extremely low absolute incidence of *Clostridium difficile* infection (total 11 events among 2753 patients). Conversely, the pooled OR from 6 eligible cohort studies did not demonstrate a significant difference in the odds of *Clostridium difficile* infection with, again, a very low absolute incidence of infection (total 830 events among 59,960 patients). Since the incidence of *Clostridium difficile* infection in patients who undergo colorectal surgery is very low regardless of bowel preparation regimen used, considering the beneficial role of oral antibiotics in reducing SSI, the fear for *Clostridium difficile* infection is not sufficient to omit oral antibiotics in patients undergoing colorectal resection [120].

Most studies have used the combination of an aminoglycoside (neomycin or kanamycin) with a macrolide such as erythromycin or with metronidazole. The use of such antibiotics limited to the day before surgery would reduce the risk of HAIs and antimicrobial resistance. Recently, an RCT (ORALEV) [121] about the use of OAP in the setting of elective colorectal resections was published, demonstrating that the administration of oral antibiotics as prophylaxis the day before colon surgery significantly reduces the incidence of SSI without mechanical bowel preparation and should be routinely adopted before elective colorectal surgery.

### Consensus Topic: E. Surgery

**Key Question 10.** Local excision. In elderly patients with T1 low rectal cancer, how does local excision with curative intent affect functional and oncological outcomes compared to rectal resection?

**Statement.** In elderly patients with T1 low rectal cancer, local excision with curative intent does not affect long-term functional outcomes. Patients aged > 70 do not show consistent variations of anorectal function after the excision of T1 low rectal cancer without neoadjuvant radiotherapy. Full-thickness local excision of T1 rectal cancer can be applied safely in elderly patients with oncological results that are comparable to radical surgery if the pre-operative selection is accurate. If high-risk features are present, the choice of local excision has to be made on a case by case basis and balanced with the operative risk. The possibility to administer adjuvant therapy in this case should be considered.

**Recommendation.** The experts' panel suggests to consider local excision as a valid alternative to total mesorectal excision (TME) among the therapeutic options for T1 rectal cancer in elderly frail patients, due to promising functional and oncological outcomes (*Weak recommendation, Moderate quality of evidence—2B*).

**Agreement:** 97.1%

The current literature available on the topic consists of small and heterogeneous studies. No RCTs were found and while there is a systematic review it does not explicitly address the elderly population. Even if the target population was not specifically addressed, the published studies' mean age ranges from 59 to 71 years. A recent systematic review analyzed functional outcomes after curative local excision of rectal cancer [122]. Of the available articles, 23 (79%) reported on pre- and postoperative fecal continence. Of them, 18 studies evaluated changes after transanal endoscopic microsurgery (TEM) and five after transanal minimally invasive surgery (TAMIS), with a mean follow-up of 15.9 months. Ten studies reported results using the Wexner score, seven used the Fecal Incontinence Severity Index (FISI), one study used the colorectal functional outcome (COREFO) questionnaire, one study used both Wexner and COREFO scores, and one study used an individualized interview. The remaining studies used the Kirwan-Fazio scale, the Williams score, and the Pescatori scale. Two studies found an increase in Wexner score after surgery (worsening of continence status) [123, 124], two studies found no changes in pre- and postoperative values [125–127], and one found a decrease in the Wexner score (better continence) [128]. When an alteration of anorectal function was reported in other studies, the effect on anorectal function was mostly transient, with restoration of functional status within a year from the operation. When compared with total mesorectal excision (TME), the patients who underwent local excision for rectal malignancies reported fewer defecation problems. Half of the retrieved articles reported improvement in Quality of Life (QoL) [125, 129–132], four remained comparable with preoperative values [133–136], and only one study had worsening in some QoL components [137]. Fifteen studies (51%) investigated manometric variables pre- and postoperatively. When manometry was used, no impairment or a transient impairment was observed, but not associated with a worsening of the continence status [123, 138].

There are five systematic reviews and meta-analyses that analyzed oncological results of local excision with curative intent of early rectal cancer, one comparing Transanal Excision (TAE) and TEM [139], four TEM and TME [140–143], and three RCTs [144–146]. Even in this case, rarely the considered studies mentioned a specific population. The mean age of the included patients ranged from 58.3 to 75 years. In one observational study, age was not considered a risk factor for recurrence [147]. A recent study [148] analyzed the oncological outcomes of 2,996 patients with pT1 and pT2 distal rectal adenocarcinomas who underwent local excision (1,795) and low anterior resection. The authors concluded that local excision is an acceptable oncologic

treatment for T1 rectal cancer, while local excision with chemo-radiotherapy could be acceptable for T2 distal cancers. All the meta-analyses but one agreed that the oncological outcomes between local excision and TME are comparable in overall survival, five-year disease-free survival, and distant recurrence. Five-year disease-free survival reported by Kidane et al. using unadjusted risk ratios from 10 studies comparing local resection to radical resection ranged from 0.31 to 8.31 [140]. For the patients who received TAE (5 studies), the risk ratio ranged from 0.31 to 2.17, and for those who received TEM (5 studies), the risk ratio ranged from 0.49 to 8.31. The two RCTs comparing oncological results for early rectal cancer after local excision and TME found no differences in overall and five-year disease-free survival [144–146]. Chen et al. reported 100% overall survival for both groups at one year [145], while Winde et al. [144] reported 96% overall survival after a mean follow-up of 45.8 months in the radical resection group and 40.9 months after TEM. The meta-analysis by Kidane et al. [140] concluded that local excision does not offer oncologic control comparable to radical surgery. However, this finding might be driven by the higher prevalence of cancers with a poorer prognosis in local excision groups. Another meta-analysis comparing TEM, TME, and TAE concluded that while no survival advantage was observed in favor of either procedure, TEM had a lower rate of positive margins and more prolonged disease-free survival when compared with TAE [143]. An observational study [149] found that male gender, age, and surgical technique were significant risk factors for death after surgery in both univariate and multivariate analyses. An ongoing multicenter RCT, the TESAR, aims to determine the optimal treatment strategy for patients with a locally excised rectal lesion revealing an early stage rectal cancer with post excision pathology predicting intermediate (5–20%) risk of recurrence. The patients will be randomized, after local excision, to receive either adjuvant chemo-radiotherapy or standard completion TME surgery [150].

#### Consensus Topic: E. Surgery

**Key Question 11.** Local excision. In elderly patients with a low invasive rectal cancer, how does local excision with palliative intent, if feasible, affect functional and oncological outcomes compared to rectal resection with TME?

**Statement.** Local excision is used in combination with neoadjuvant chemo-radiotherapy as an alternative tool to major resection in more advanced rectal cancer. Even if a study specifically addressing the elderly population does not currently exist, the mean age of patients undergoing such a management is higher than those receiving TME. In this case, anorectal function after excision may

be affected by the radiation therapy but still seems to be better than in TME patients. Regarding oncological outcomes, there seems to be no difference between radical TME and local excision with palliative purposes.

**Recommendation.** The experts' panel suggests to consider local excision as a palliative approach in elderly patients when they are judged unfit for major surgery, in combination with neoadjuvant therapy, when feasible (*Weak recommendation, Low quality of evidence—2C*).

**Agreement:** 91.2%

While local excision is generally considered a potentially curative procedure for early rectal cancer, its use with palliative intent has been rarely investigated in the current literature. To this end, several published series have analyzed mixed populations that underwent local excision for either palliative or curative intent, making it challenging to analyze the outcomes. A retrospective review published in 2001 compared the palliation achieved with endoscopic transanal resection (ETAR) with transabdominal resection [151]. Twenty-four patients who underwent local excision were matched with 25 patients who underwent palliative low anterior resection (LAR), Abdominoperineal resection (APR), or Hartmann's procedure. Survival was similar in the two groups, and there was significantly higher morbidity in the group receiving open surgery, with a significantly higher stoma rate. The authors suggested that local excision may be considered a palliative option for low fixed rectal tumors that may be difficult to treat with LAR and for very elderly patients who may not be candidates for general anesthesia [151]. Since frail patients are more likely to experience postoperative complications, and the type of surgery is a determinant of postoperative adverse outcomes, the likelihood of confounding by indication needed to be accounted for [152]. Notably, the consequences of complications are far more severe and life-threatening in elderly patients than in younger patients. Rutten et al. [153], who assessed the data from a Dutch study on TME, showed in a comparative age analysis that older patients had increased 30-day and 6-month mortality and questioned how treatment-related mortality might obscure the oncological advantage of advanced surgical treatments in patients >75 years old.

A nationwide propensity score-matched study published in 2020 by Hoendervangers et al. [154] showed how patient and disease characteristics might influence patients' selection for neoadjuvant and subsequent surgical treatment. The study involved 2,926 patients, and the primary goal was to investigate the effect of short-course radiotherapy delay on postoperative outcomes compared with standard chemo-radiation in both the general and the frail population. The study's primary bias resides in the confounding indication of radiation therapy. The RCT by Lezoche et al. compared local excision following

chemo-radiotherapy to TME in cT2N0M0 patients with rectal cancer, and it concluded that oncologic results were similar in the two groups with a median follow-up of 9.6 years [155]. The mean age of the enrolled patients was 66 years in both the study groups. A subsequent meta-analysis confirmed these results, finding no statistical difference in local recurrence, overall survival, and disease-free survival rates in patients who underwent local excision following chemo-radiotherapy or radical surgery for rectal cancer, despite the variability regarding the observational nature and the high heterogeneity in the selection criteria of most of the studies under consideration [156]. In the ACOSOG Z6041 trial, the estimated 3-year disease-free survival for the intention-to-treat group was 88.2% and for the per-protocol group (ypT0–2 tumors with negative margins) 86.9%; local recurrence rate was 4%, and 72 of 79 patients (91%) had rectal preservation [157]. In the GRECCAR 2 trial, patients were randomized in two study arms: the local resection group and the TME group [158]. The study concluded that there was no significant difference in local recurrence and disease-free survival at 3 years between the local excision group and the TME group (5% and 6% of local recurrence and 78% and 76%, respectively). In the CARTS study, the 5-year local recurrence rate was 7.7% with 5-year disease-free survival and overall survival rates of 81.6 and 82.8%, respectively, preserving the rectum in 64% of patients with cT1–3N0 tumor [159]. As for functional outcomes, transanal local excision following chemo-radiotherapy may involve a significant decrease in anal resting and squeeze pressures, rectal capacity, and sensitivity compromising fecal continence. The alteration of anorectal function seemed to be related to neoadjuvant chemo-radiotherapy since it has been demonstrated how chemo-radiotherapy could affect the overall morbidity rate after TEM in the early postoperative period. However, it does not seem to affect the continence status after one year from surgery [158–161]. Age and gender could be additional factors to influence anorectal function [134].

#### Consensus Topic: E. Surgery

**Key Question 12.** Local Excision. In elderly patients with a cT2/T3 N0 low rectal cancer, how does radiotherapy followed by local excision compared to rectal resection with TME affect functional and oncological outcomes?

**Statement.** In elderly patients with a small cT2/T3 N0 low rectal cancer, radiotherapy followed by local excision in clinically good responders may offer no long-term difference in oncological outcomes compared to TME. In elderly patients with a cT2/T3 N0 low rectal cancer, radiotherapy followed by local excision may offer

impaired functional outcomes, but in any case better than after TME.

**Recommendation.** The panel recommends to consider elderly patients with small cT2/T3 N0 low rectal cancers suitable for neoadjuvant therapy and organ sparing transanal local excision following chemo-radiotherapy (*Strong recommendation, Moderate quality of evidence—1B*).

**Agreement:** 91.2%

The elderly are generally less inclined to undergo major surgery, especially when there is a considerable risk either of a temporary or permanent stoma. They are, therefore, potentially good candidates for a less invasive transanal approach. To attain a curative intent, it was proposed 25 years ago [162] to perform TEM after neoadjuvant therapy. This generally includes both radio and chemotherapy. Radiotherapy may be administered both as long and short course.

Recently the data at 5-years of the first multicenter randomized phase 3 trial to compare organ preservation with radical surgery were made available [163]. The GRECCAR 2 study shows that in good clinical responders (i.e., when a > 50% reduction of the primitive tumor is observed), the rate of local recurrence, disease-free, and overall survival are comparable to the TME group. It has to be noticed that about  $\frac{1}{3}$  of patients randomized for the local excision group received a TME for lack of sufficient local response. Therefore, the GRECCAR 2 study also advances the hypothesis that ypT2 cancers, mainly N0 at preoperative MRI, do not require a TME. These findings are in line with the ACOSOG phase 2 trial [157]. Similar results favoring chemo-radiotherapy and TEM were obtained after short-course radiotherapy in the TREC trial [164]. It is also known that the most extensive tumors have difficulties having an excellent response to chemo-radiotherapy, but this is today the object of the STAR TREC trial (NCT02945566) [165].

In a recent individual participant data pooled-analysis of published studies on rectal cancer surgery, logistic regression models were estimated for the risk of local, systemic and overall recurrence, showing a higher local and overall recurrences for ypT3 stage, tumor size after radiotherapy > 10 mm and lack of combined chemotherapy, while ypT3 was the only factor correlated with systemic recurrence [166].

Pucciarelli et al. [167] reported better overall Health-related quality of life (HRQL), constipation scores, and bowel function after local excision vs. TME following chemo-radiotherapy. Martens et al. [168] demonstrated that patients undergoing watch-and-wait procedures generally had good functional outcomes compared with seven patients undergoing TEM who experienced

moderate outcomes. Major incontinence was seen in 42.8% of patients undergoing TEM. Finally, the CART study [159] analyzed long-term oncological outcomes and HRQL in patients with cT1-3N0M0 rectal cancer who underwent neoadjuvant CRT followed by TEM. HRQL during follow-up was equal to baseline, with improved emotional well-being in patients treated with local excision. Major, minor, and no low anterior resection syndrome was experienced in 50%, 28%, and 22%, respectively, in patients with successful organ preservation, confirming a reasonable rate of bowel dysfunction.

### Consensus Topic: E. Surgery

**Key Question 13.** Local Excision. In elderly patients who underwent local excision of a sessile polyp of the low rectum, with an unexpected result of a pT2/T3 Nx cancer on the resultant histopathology, how does post-operative radiotherapy compare to rectal resection with TME in terms of functional and oncological outcomes?

**Statement.** In elderly fit patients who underwent local excision for a low rectal sessile polyp with final pathology of pT2/T3 rectal cancer, radical surgery with TME is the treatment of choice. However, in case of contraindication to major surgery due to comorbidities, other treatments should be considered including adjuvant radiotherapy. The accurate definition of the surgical risk is a key point to guide towards the most appropriate decision.

**Recommendation.** The experts' panel recommends radical surgery with TME as treatment of choice in elderly patients fit for surgery after the local excision of a sessile polyp of the low rectum subsequently confirmed as a pT2/T3 Nx cancer on the histopathology result (*Strong recommendation, Moderate quality of evidence—1B*).

**Agreement:** 96.8%

In the past, radical surgery with TME for rectal cancer in elderly patients has been questioned, suggesting more conservative approaches, including local excision combined with adjuvant (chemo)-radiotherapy even for T2-3 tumors [153].

However, new evidence demonstrated a similar life expectancy for patients undergoing rectal cancer surgery compared to the same age's general population, even for patients > 80 years [8].

Two meta-analyses investigated oncological outcomes between different management after local excision for pT1–T2 rectal cancer. Van Oostendorp et al. compared no additional treatment (NAT), adjuvant (chemo)-radiotherapy (CRT) and completion TME (cTME): in 1.059 pT2 patients, local recurrence rate (LR) was 28.9% in NAT group, 14.7% in aCRT and 4% in cTME. Distant recurrence rate was respectively 6.2%, 5.8%, and 7% [169].

Borstlap et al. compared aCRT with cTME: in 341 pT2 patients, local recurrence was 15% in CRT the group and 10% in the cTME group [170].

These two meta-analyses have some limitations: no RCT was found comparing different treatments, and the included studies show heterogeneity regarding the local excision technique and CRT. Furthermore, the included studies are not specific for elderly patients.

A recent retrospective cohort study compared surgical outcomes between 10.631 patients (9.006 < 80 years and 1.625 > 80 years) with rectal cancer. Older patients showed higher ASA score than the younger counterpart (ASA 3: 52.4% vs. 25.4%; ASA 4: 6.4% vs. 2.1%;  $P < 0.001$ ) and the rate of primary anastomosis was lower (75.5% vs. 83.6%;  $P < 0.001$ ). There was no difference in overall surgical complications, but medical complications were higher in the older age group (25.2% vs. 11.2%;  $P < 0.001$ ). Thirty-day mortality in the older group was higher than for patients < 80 years (3.1% vs. 0.4%;  $P < 0.001$ ), but the multivariate analysis did not confirm any association between age alone and mortality rate [169]. We can recommend cTME after local excision of a pT2/T3 rectal cancer as the treatment of choice even in elderly patients, but it is crucial to assess, for an appropriate decision, specific risk, oncological risk, and life expectancy [8, 171].

### Consensus Topic: E. Surgery

**Key Question 14.** Minimally invasive surgery (laparoscopic/robotic TME, TaTME). In elderly patients with rectal cancer, how does minimally invasive surgery (laparoscopic/robotic-assisted) compared to open surgery affect recovery, functional and oncological outcomes?

**Statement.** In elderly fit patients with rectal cancer, a consistent amount of evidence suggests that laparoscopic TME is safe and feasible and is associated with short-term benefits compared to open surgery. There is insufficient evidence to support potential benefits of robotic and transanal approaches for rectal cancer resection in elderly patients compared to laparoscopy or open surgery.

**Recommendation.** The experts' panel suggests laparoscopic TME in elderly fit patients with rectal cancer after a careful evaluation of patient's medical history, performance status, and tumor characteristics (*Weak recommendation, Moderate quality of evidence—2B*). Minimally invasive surgery approaches other than laparoscopy and open surgery may be considered for TME in elderly patients with rectal cancer after a careful evaluation of patient's medical history, performance status, and tumor characteristics. Open surgery may be appropriate in selected cases, including locally advanced tumors, multiple previous abdominal operations, or

previous pelvic surgery. (*Neutral recommendation due to very limited and low-quality evidence*).

**Agreement:** 96.8%

Although short-term benefits and oncological adequacy of minimally invasive surgery (MIS), particularly laparoscopic resection, for rectal cancer is nowadays broadly investigated [172, 173], only limited evidence is available about the effectiveness of MIS approaches for elderly patients with rectal cancer.

Laparoscopic approaches to rectal cancer have increased over the past 30 years with laparoscopy providing shorter hospital stay, decreased postoperative pain, and faster return to normal daily activity compared to open surgery [174, 175].

Evidence for laparoscopic surgery for colorectal cancer in elderly patients suggests that laparoscopy is associated with fewer postoperative complications, shorter time to oral diet, and shorter hospital stay compared to open surgery, thus offering the same MIS-related advantages that are observed in patients of younger ages [176, 177]. When focusing on rectal cancer in octogenarian patients, a recent retrospective study demonstrated that laparoscopic rectal resection is as safe as open surgery. However, the known short-term advantages of laparoscopy may be lost in patients over 80 years due to a high rate of medical complications (40.4%), leaving open resection as an option in elderly patients with significant comorbidities [178].

Manceau et al. evaluated 446 consecutive rectal cancer patients grouping them into 10-year intervals from under 45 to older than 64 years. Elderly patients presented significantly higher ASA score, higher Charlson comorbidity index, and more frequent cardiovascular, pulmonary, and neurological comorbidities. Despite these baseline differences, there was no difference in postoperative complications and age was not a significant independent risk factor for postoperative morbidity [179]. Octogenarians rectal cancer patients were matched to controls between the ages of 60–69 in the study by Otsuka et al. They similarly found that the ASA score was significantly higher in the octogenarian group, but this did not correlate with increased postoperative complications and long-term rectal cancer-specific survival [180].

In the AlaCaRT trial, the primary end point was a composite of oncological factors (complete total mesorectal excision, a clear circumferential resection margin  $\geq 1$ mm, a clear distal resection margin  $\geq 1$ mm) indicating an adequate surgical resection, with a noninferiority boundary of  $\Delta = -8\%$ . The primary outcome was achieved in 194 patients (82%) in the laparoscopic surgery group and 208 patients (89%) in the open surgery group, the circumferential resection margin was clear in 222 patients (93%) in the laparoscopic surgery group

and in 228 patients (97%) in the open surgery group, the distal margin was clear in 236 patients (99%) in the laparoscopic surgery group and in 234 patients (99%) in the open surgery group, and total mesorectal excision was complete in 206 patients (87%) in the laparoscopic surgery group and 216 patients (92%) in the open surgery group. The study concluded that, among patients with T1–T3 rectal tumors, noninferiority of laparoscopic surgery compared with open surgery for successful resection was not established [181]. Similarly, in the ACOSOG Z6051 trial, the primary outcome of efficacy was a composite of circumferential radial margin  $\geq 1$  mm, distal margin without tumor, and completeness of total mesorectal excision. A 6% noninferiority margin was chosen according to clinical relevance estimation. Two hundred forty patients with laparoscopic resection and 222 with open resection were evaluable for analysis of the 486 enrolled. The primary outcome occurred in 81.7% of laparoscopic resection cases and 86.9% of open resection cases and did not support noninferiority [182]. However, subsequent analyses of the ACOSOG Z6051 trial found that laparoscopic-assisted resection of rectal cancer was not found to be significantly different to open resection of rectal cancer based on the outcomes of disease-free survival and recurrence. The 2-year disease-free survival was 79.5% in the laparoscopic group and 83.2% in the open group. Local and regional recurrence was 4.6% in the laparoscopic group and 4.5% in the open group. Distant recurrence was 14.6% in the laparoscopic group and 16.7% in the open group [183].

In general, elderly patients are considered at increased risk of postoperative morbidity and mortality and less likely to undergo laparoscopy or receive adjuvant chemotherapy after surgery compared with younger patients [184, 185].

Paucity of data on the oncological outcomes for laparoscopic versus open TME in the elderly has been recently remarked in the Bi-National Colorectal Cancer Cancer Audit (BCCA). MIS was performed in just over half of elderly rectal cancer patients who were selected for elective rectal resection surgery in Australia and New Zealand, but when performed in the elderly, MIS appeared safe and was associated with fewer wound complications and a shorter length of hospital stay at the propensity-score matched analysis, with comparable short-term oncological outcomes [186].

Several studies support that age is not a predictor of postoperative morbidity on its own, and rectal cancer resection can be safely performed by laparoscopy also in elderly ( $\geq 75$  years) or very elderly ( $\geq 80$  years) patients [179, 187–189]. Careful patient selection is advocated to choose the adequate surgical approach based on the patient's performance status and tumor characteristics [179, 185, 187–189].

The majority of the available clinical data in elderly rectal cancer patients relates to the outcomes of laparoscopy compared to open surgery. Minimal evidence supports the use of robotic surgery, whereas TaTME remains essentially unexplored in the specific population of elderly patients. Some studies compared open vs. MIS surgery, which may include laparoscopy, robotic or transanal approaches with or without subgroup analyses describing the outcomes and advantages of a specific surgical technique.

The role of robotic surgery for colorectal cancer resection is still under investigation [190]. However, some evidence suggested that it may be associated with potential benefits over laparoscopy in terms of conversion rate, intraoperative blood loss, and hospital stay in general adult populations [191], which are also confirmed in studies analyzing rectal cancer patients only [192]. However, the evaluation of robotic surgery in elderly patients is rare. In a propensity score match study comparing robotic and laparoscopic colorectal cancer resections, de'Angelis et al. [193] showed that robotic surgery has similar operative and oncologic outcomes than laparoscopy in patients aged 70 years or more, despite longer operative times.

By examining the outcomes of robotic surgery versus laparoscopic surgery for rectal cancer based on evidence from 8 RCTs (1,305 patients), a recent systematic review and meta-analysis reported that age is positively associated with operative time and negatively associated with the length of hospital stay [194]. The longer operative time associated with robotic surgery might be seen as a clinically relevant disadvantage for elderly patients, but, surprisingly, a diminished trend of correlation has been observed as patients get older [194], meaning that in older patients the operative time difference between laparoscopic and robotic approach diminishes. Thus, these findings suggest that MIS should be preferred regardless of the patient's age. Similar results were found in the most recent systematic review and meta-analysis comparing laparoscopic vs. robotic TME [195], which did not show any significant age difference and confirmed the downside of having longer operative times when performing robotic TME. This study also highlighted a decreased conversion rate to open surgery for robotic TME compared to laparoscopic TME and higher chances of being approached by MIS with robotic TME for patients with higher BMI, more distal rectal cancers, and after neoadjuvant treatments.

The NICE Guidelines [196] recommended laparoscopic surgery as the appropriate technique for most patients with surgically resectable rectal cancer. However, open surgery may be clinically indicated in locally advanced tumors or in patients with multiple previous abdominal operations or previous pelvic surgery (e.g.,

prostatectomy), which may likely be the case of elderly patients. NICE advised that robotic surgery should only be considered within established robotic programs and TaTME within structured and supervised programs, and data should be collected in a registry. Nonetheless, further studies are needed to confirm these promising results, and concern has been raised in both the UK and Norway in terms of oncological outcomes and complications in relation to TaTME [197].

#### Consensus Topic: E. Surgery

**Key Question 15.** Early versus delayed ileostomy closure. In elderly patients with low rectal cancer who underwent low anterior resection with diverting loop ileostomy, how does early ileostomy closure compared to delayed ileostomy closure affect complications and quality of life?

**Statement.** In elderly patients with low rectal cancer who underwent low anterior resection with diverting loop ileostomy, early ileostomy closure is safe and feasible. Early closure is related with lower incidence of postoperative small bowel obstruction, stoma-related complications, and better functional outcomes, despite a relatively higher surgical site infection rate compared with late closure.

**Recommendation.** The experts' panel suggests that in selected elderly fit patients, early (within 2 weeks) closure of ileostomy after rectal resection should be performed. (*Weak recommendation, Moderate quality of evidence—2B*).

**Agreement:** 87.9%

Anastomotic leakage (AL) represents a severe and common complication after rectal resection, whose incidence ranges between 2.0% and 10.3%, with peaks of up to 25% [198].

A study that focused on analyzing AL risk factors after anterior resection for rectal cancer in elderly patients over 80 years old found that the number of stapler firings  $\geq$  three and coronary artery disease were independent risk factors for AL [199].

To decrease the severity of septic complications associated with AL in high-risk anastomoses and reduce the reoperation rate in the case of AL, a temporary diverting ileostomy (DI) is often performed at index surgery [200, 201].

The DI itself is associated with relevant morbidity, including skin irritation, parastomal hernias, stomal prolapse or retraction, and decreased quality of life (QoL) for the patient. DI-related morbidity rates reported in randomized controlled trials (RCTs) range from 2.9% to 62.2%, with a median rate of 14.3% [202]. As morbidity rates increase with time to ileostomy closure [203], it has been suggested that early closure (EC) of the DI

could reduce adverse outcomes while still preserving the protective effect of the DI [204].

DI formation in higher risk elderly patients is independently associated with kidney injury, with an increased risk persisting after stoma closure [205]. Dehydration or renal failure following DI is common in elderly patients with metabolic disorders, leading to a 17% to 30% readmission rate [206]. Moreover, a DI during adjuvant chemotherapy is a predictor of severe chemotherapy-induced diarrhea and the need for modifications in the chemotherapy regimen. This may have significant consequences for long-term survival [207]. According to some authors, DI should be closed as early as possible because of their high morbidity, especially if adjuvant chemotherapy is planned [208].

There is no firm consensus as to the optimal timing of the closure of the DI, although the majority of centers classically choose to perform closure of DI at 8–12 weeks following rectal resection, once the integrity of the anastomosis is ensured [209]. To improve QoL, early stoma closure within 2 weeks from the index operation has been proposed. Six randomized controlled trials [204, 210–214] published over the past 10 years, and four systematic reviews with meta-analysis published over the past 2 years [202, 215–217] were evaluated by the meta-analysis team.

None of the studies performed sub-group analyses on clinical outcomes after early closure (EC) versus late closure (LC) in elderly patients, although both study groups included patients over 80 years of age. For this reason, the statement coming from the analysis performed in the general population has been downgraded due to some degree of indirectness and reported in this consensus on the elderly population with rectal cancer.

The meta-analysis by Wang et al. [215], that included four RCTs involving a total of 324 patients found that EC tended to result in more postoperative complications than LC for rectal cancer patients with DI (31.7% vs. 18.8%, RR = 1.70,  $P = 0.004$ ), although the rate of severe complications was comparable (6.1% vs. 1%, RR = 4.41,  $P = 0.10$ ). This difference was mainly influenced by the wound complication rate (20.4% vs. 9.7%, RR = 1.92,  $P = 0.07$ ). LC resulted in more complications than EC before closure, such as leakage outside the appliance bag and skin irritation. The meta-analysis by Cheng et al. [216], that included a total of six RCTs, demonstrated that EC (within 2 weeks) of DI reduces the incidence of small bowel obstruction/postoperative ileus (3.0% vs. 7.8%, OR = 0.37,  $P = 0.01$ ) and required shorter operative time (MD = - 9.68,  $P = 0.03$ ), but increased the incidence of surgical site infection (11.3% vs. 3.6%, OR = 3.10,  $P = 0.004$ ) compared with LC. Weak evidence showed that there was no difference between EC and LC in morbidity (20.1% vs. 20.0%, OR = 1.05,  $P = 0.84$ ), reoperation (6.3%

vs. 4.7%, OR = 1.40,  $P = 0.38$ ) or leak of the rectal anastomosis (8.8% vs. 7.0%, OR = 1.28,  $P = 0.52$ ) rates.

Ng et al. [217], in their pooled analysis of 667 patients from nine studies, confirmed the safety of EC, with an associated reduction in stoma-related complications (8.4% vs. 33.4%, RD = - 0.28,  $P = 0.001$ ) despite a higher wound infection rate (18.6% vs. 7.1%, RD = 0.10,  $P = 0.047$ ). The meta-analysis showed no significant difference in the postoperative morbidity rate, anastomotic leak rate, rates of small bowel obstruction, bleeding, and ileus between EC and LC. Also, the meta-analysis of six RCTs performed by Clausen et al. [202] could not discern a statistically significant difference in postoperative complications when comparing EC (within 2 weeks) and LC of DI. Overall postoperative morbidity in the EC group was 20.2% compared with 18.9% in the LC (RR = 1.13,  $P = 0.66$ ), major complications (Clavien-Dindo grade  $\geq 3$ ) in the EC group was 5.2% compared with 3.6% in the LC group (RR = 1.12,  $P = 0.86$ ), anastomotic leakage in the EC group was 3.3% compared with 3.5% in the LC group (RR = 0.89,  $P = 0.83$ ). Reoperation rate was 5.9% in the EC group compared with 3.9% in the LC (RR = 1.35,  $P = 0.45$ ). The authors performed a sub-group analysis of very early closure (defined as closure  $\leq 3$  weeks after index surgery) compared with late closure (closure  $> 6$  weeks). The analysis did not provide a statistically significant difference between the two groups for any analyzed outcomes.

A meta-analysis that included four RCTs with 319 participants showed that the pursestring closure technique compared with the conventional primary closure group resulted in a significant decrease in surgical site infection (RD = - 0.25;  $P < 0.00001$ ) [218, 219].

A substantial proportion of patients have severe bowel dysfunction many months after DI closure. A secondary analysis of the multicenter EASY (Early Closure of Temporary Ileostomy) RCT showed that patients undergoing EC had fewer problems with soiling and reduced risk of a permanent stoma, whereas patients undergoing LC have higher rates of bowel dysfunction, with an incidence of LARS (Low Anterior Resection Syndrome) of up to 73% of patients who had an ileostomy closed after 12 weeks [220]. However, although the EASY trial found that EC of the DI was associated with significantly fewer complications, this clinical advantage did not affect the patients' health-related quality of life [221].

#### **Consensus Topic: F. Watch and wait**

**Key Question 16.** Watch and wait, indications and outcomes. In elderly patients with rectal cancer, how does the watch and wait strategy in case of absence of clinically detectable residual tumor after neoadjuvant therapy affect functional and oncological outcomes compared to rectal resection?

**Statement.** In elderly patients with rectal cancer, in case of complete clinical response after neoadjuvant therapy, watch and wait may be considered a safe strategy, especially in selected patients, such as frail patients and patients with low-rectal tumors, with comparable oncological outcomes and better functional results in comparison to surgery.

**Recommendation.** The experts' panel suggests a watch and wait strategy in selected frail elderly patients with low-rectal tumors in case of complete clinical response after neoadjuvant therapy. A stringent surveillance protocol, at least in the first 3 years, and a candid discussion with the patient about the potential risks of this strategy are recommended (*Weak recommendation, Low quality of evidence—2C*).

**Agreement:** 97.0%

The currently available literature is mainly observational, with no studies primarily focused on elderly populations. The first study by Habr-Gama et al. [222] in 2004 compared 71 patients who had complete clinical regression (cCR) after neoadjuvant chemo-radiotherapy undergoing watch and wait vs. 194 patients without complete response referred for surgery. The 5-year overall survival and disease-free survival rates were 100% and 92% in the watch and wait group vs. 88% and 83% in the surgery group. Overall recurrence and cancer-related mortality rates were 7.0% and 0% in the watch and wait group vs. 13.6% and 9% in the surgical group, respectively. Other single-center observational studies [223–226], albeit heterogeneous in diagnostic criteria and follow-up strategies, have confirmed similar results in terms of overall survival and disease-free survival in comparison to surgical resection with a follow-up ranging from 2 to 5 years. The first multi-institutional study on watch and wait strategies [227] included a cohort of 880 non-operatively managed patients from 47 institutions in Europe over a 25-year period with a median follow-up time of 3.3 years. Five-year overall survival and 5-year disease-specific survival were 85% and 94%, respectively. The 2-year local regrowth rate was 25.2%, most of these (88%) were diagnosed in the first 2 years. Distant metastases were identified in 8% of cases. In a retrospective analysis of the same international registry [228], using a conditional survival model, the probability of remaining free from local recurrence for an additional 2 years, after a sustained clinical response, was estimated around 88.1%, 97.3%, and 98.6% at 1, 3, and 5 years respectively with analog results about the risk of distance metastatic disease highlighting the need of active surveillance especially in the first 3 years of follow-up.

A meta-analysis by Li et al. [229] comparing 251 patients with rectal cancer managed with a watch and wait approach vs. 344 patients that underwent surgical

resection confirmed similar outcomes in terms of overall survival, disease-free survival, and distant metastasis rate but with a higher local recurrence rate at 1, 2, 3, and 5 years in the watch and wait group. These data were not confirmed in the meta-analysis by Dossa et al. [230]. This meta-analysis, published in 2020, aimed to quantify the additional risk of local recurrence for the watch and wait strategy, estimated a maximum additional risk of 6.5% at five years. However, the estimation was considered uncertain due to the high risk of bias in the current literature. Haak et al. [231] evaluated functional and oncological outcomes of patients aged  $\geq 75$  years from a collaborative Dutch database undergoing the watch and wait approach. Forty-three patients with at least 2 years of follow-up were included. The 3-year local recurrence-free rate was 88%, with a 3-year non-recurrence disease-free survival of 91% and overall survival of 97%. Functional outcomes (both defecations and urinary) at 3, 12, and 24 months were satisfying in most patients. Five patients (12%) had a local recurrence, but all underwent surgery with only one pelvic recurrence. Distant metastases occurred in 3 patients, and four patients died, but only one death was cancer-related.

In terms of functional outcomes, Maas et al. [223], in a prospective study of 21 patients with complete clinical response who underwent watch and wait vs. a control group of 20 patients submitted to surgical resection, reported more favorable functional outcomes with better quality of life and lower incontinence score, bowel function score, and mean defecation frequency in the watch and wait group. Smith et al. [232] used a model to compare three cohorts of men: 60-year-olds with mild comorbidities, 80-year-olds with minor comorbidities, and 80-year-olds with significant comorbidities (Charlson score  $> 3$ ). Patients with a complete clinical response after chemo-radiotherapy were followed by a watch and wait protocol or offered radical surgery (TME). In both fit 80-year olds and those with comorbidities, there was a 10.1% survival advantage at one year in those who underwent a watch and wait approach. There were no differences between groups in disease-free survival or quality-adjusted life years. This model suggests elderly patients may have the most benefit from the watch and wait after a complete clinical response.

The current literature on watch and wait protocols in elderly patients is scarce and inadequate to formulate solid recommendations. Due to the absence of RCTs, standardized diagnostic and surveillance protocols, and the few studies tailored to the elderly population, the watch and wait strategy cannot replace surgery in the elderly. However, this approach may be offered as a safe option in high-risk patients, patients that would otherwise be potential candidates for abdominal-perineal resection, and patients refusing surgery, highlighting the



potential higher risk of local recurrence and the need for a stricter follow-up in comparison with surgical therapy.

### Consensus Topic: G. Adjuvant chemotherapy

**Key Question 17.** Adjuvant chemotherapy. In elderly patients with rectal cancer who underwent radical surgery with curative intent, does fluoropyrimidine-based adjuvant chemotherapy improve the oncological outcome compared with clinical and radiological follow-up?

**Statement.** There is little evidence to support benefit of adjuvant chemotherapy for elderly patients with rectal cancer who have undergone radical surgery with curative intent compared with clinical and radiological follow-up.

**Recommendation.** The experts' panel suggests that for selected stage III and stage II high-risk elderly patients with rectal cancer who underwent radical surgery with curative intent, a fluoropyrimidine-based adjuvant chemotherapy should be preferred to clinical and radiological follow up. Decision to perform adjuvant chemotherapy (alone or associated with radiotherapy) has to be taken after a multidimensional and geriatric assessment and must be shared within the multidisciplinary board, taking into account individual cancer risk of recurrence, DYPD evaluation, previous treatment (surgery alone or preoperative chemo-radiotherapy), patient's performance status and comorbidities (*Weak recommendation, Low quality of evidence—2C*).

**Agreement:** 93.8%

According to the AIOM (Associazione Italiana di Oncologia Medica) ESMO (European Society for Medical Oncology) and NCCN (National Comprehensive Cancer Network) guidelines, adjuvant chemotherapy is recommended for patients with stage II/III rectal cancer, after preoperative chemo-radiotherapy and surgery [69, 233, 234].

Choice of adjuvant treatment regimen should be evaluated based on clinical and pathological risk factors, depending on both initial clinical staging and response to the preoperative treatment.

In those patients who underwent surgery without preoperative chemo-radiotherapy, adjuvant chemotherapy should be associated with radiotherapy treatment, leading to reduced local recurrence [235–238]. In contrast, RCTs and meta-analyses have failed to demonstrate a significant benefit for 5-FU chemotherapy alone as adjuvant treatment if a preoperative chemo-radiation strategy was performed [239–241].

Two recent RCTs suggest that adding oxaliplatin to 5-FU/leucovorin improves relapse-free survival and overall survival in high-risk rectal cancers [242, 243].

However, elderly patients with cancer are poorly represented in clinical trials constituting less than 10% of all the patients enrolled [244]. Consequently, most data on

older patients with rectal cancer come from retrospective analyses and are often conflicting.

Results of a retrospective review of 286 patients suggest that patients with locally advanced rectal cancer who underwent surgery with curative intent (with or without preoperative therapy) gain a survival benefit from adjuvant 5-FU based chemotherapy, regardless of age [245].

These results are consistent with those from a large study by Xu et al., in which results from 14,742 patients with stage II and III rectal cancer from the U.S. National Cancer Database found that adjuvant 5-FU based chemotherapy was an independent predictor of survival, regardless of patients' factors, including age and comorbidity load [246].

The impact of age on clinical outcomes in patient with locally advanced rectal cancer receiving neoadjuvant chemo-radiation was also evaluated in a large multi-institutional retrospective review: the authors found that elderly patients > 70 years have similar outcomes compared with younger patients in term of disease-free survival, overall survival, and cancer-specific survival [247].

Many studies have shown that older patients are less likely to receive standard oncological treatments: reduced organ function and preexisting comorbidities can increase treatments' toxicity that might contraindicate the use of chemotherapy [248–251].

To individualize the oncological therapies, a geriatric assessment is mandatory: current NCCN-ESMO guidelines suggest formal geriatric assessment before any treatment for patients over 70 years having cancer. Similarly, the International Society of Geriatric Oncology (SIOG) has recommended the use of systematic comprehensive cancer geriatric assessment [252]. In conclusion, retrospective population-based analyses and the absence of prospective randomized trials make it difficult to draw conclusions on the impact of adjuvant chemotherapy on oncological outcomes in elderly patients. Chronological age should not be a criterion for excluding standard treatment, and fit elderly patients should be treated according to standard guidelines. Multidimensional and geriatric assessments are mandatory, and decisions should be taken after multidisciplinary board discussion to evaluate risk-benefit balance.

Elderly patients with rectal cancer may benefit more from 3 vs. 6 months of adjuvant chemotherapy. For those with stage III rectal cancer (pT1–4, pN1–2, M0) treated with short-course radiotherapy or no preoperative treatment, capecitabine in combination with oxaliplatin (CAPOX) for 3 months or, if this is not suitable, oxaliplatin in combination with 5-fluorouracil and folinic acid (FOLFOX) for 3 to 6 months, might be considered a valid alternative to a 6-months single-agent fluoropyrimidine regimen [196].

**Consensus Topic: H. Liver disease**

**Key Question 18.** Treatment of synchronous liver metastases: In elderly patients with rectal cancer, how do sequential resections (liver then rectum, or vice-versa) compared to simultaneous resection affect postoperative morbidity, mortality, and oncological outcomes?

**Statement.** Liver resections in elderly patients aged >75 years with colorectal liver metastases show equivalent disease-free survival compared with younger patients, although in these patients perioperative mortality is almost doubled and overall morbidity rate seems to be higher. Simultaneous and staged colorectal and hepatic resections for synchronous liver metastases have comparable postoperative morbidity and mortality, recurrence rate, and 5-year overall survival. However, the simultaneous approach seems to be safe only in selected elderly patients with less severe liver disease. Patients with a high burden of liver disease may be more likely to benefit from early liver-first approach after down-staging therapy.

**Recommendation.** The experts' panel suggests staged or simultaneous liver resection for colorectal liver metastases in elderly patients depending on the burden of liver disease and patient's frailty status. Caution should be taken in performing major hepatectomies in patients aged >75 years, given the increase in postoperative morbidity and mortality (*Weak recommendation, Moderate quality of evidence—2B*).

**Agreement:** 97.1%

In up to 25% of cases, colorectal cancer presents with simultaneous liver metastases, and 85% of these lesions are not resectable at diagnosis [253]. Liver resection is currently the treatment that offers the highest cure rate in patients with colorectal liver metastases (CRLM), with an overall 5- and 10-year survival rate ranging from 16 to 74% (median 38%) and 9 to 69% (median 26%), respectively [254]. The current literature on this issue lacks RCTs, whereas only retrospective studies with heterogeneous design, population, and outcomes are available.

In elderly patients, several observational studies have suggested that liver resection for CRLM is a safe treatment, with the 5-year survival rate reaching up to 40% [255]. However, treating elderly patients with CRLM is a challenge to date, as there is still a relevant lack of guidelines to support the decision of the optimal therapeutic strategy in these subgroups of patients.

The analysis of pooled data has shown that the weighted 5-year overall survival appears to be lower in patients aged > 70 years compared with their young counterparts (40 vs. 32%,  $P < 0.001$ ), although the 5-year disease-free survival is comparable [256]. These results may justify a resectional approach in selected elderly patients with CRLM. On the other hand, the higher

postoperative mortality rate found in elderly patients undergoing liver resection is more likely explained by the fact that this age population more frequently has coexisting chronic morbidity and has a more limited survival expectancy. The observation can support this assumption that the disease-free survival does not differ between the elderly and younger population in several systematic reviews and meta-analyses published to date, therefore suggesting that older patients die of different causes other than complications following the liver resection [185].

Several studies and meta-analyses compared both short-term and long-term outcomes in younger and elderly patients undergoing liver resection for CRLM. Elderly patients undergo significantly fewer major hepatectomies and are less likely to receive perioperative chemotherapy [185]. The systematic review and meta-analysis by van Tuil et al., with eleven studies that compared patients aged < 70 years with patients > 70 years and four studies that compared patients aged < 75 years with patients aged > 75 years, found that there were no significant differences in postoperative morbidity and 5-year disease-free survival for patients aged < 70 years and patients aged > 70 years, although postoperative morbidity and mortality both seem to be significantly higher in patients aged > 75 years. Postoperative morbidity was equivalent in patients aged >70 years (27 vs. 30%;  $P = 0.35$ ), but higher in patients aged > 75 (21 vs. 32%;  $P = 0.001$ ). Conversely, postoperative mortality was higher in both patient groups aged > 70 years (2 vs. 4%,  $P = 0.01$ ) and in patients aged >75 years (1 vs. 6%,  $P = 0.02$ ). In this meta-analysis, major hepatectomy was more frequently performed in patients aged < 75 years (61%) compared with patients aged > 75 years (53%) [256]. Similarly, de'Angelis et al., assessed the outcomes of 7579 older patients, 179 very old patients, and 15,904 young patients undergoing liver resection for CRLM in a pooled data analysis of postoperative outcomes, and showed that older patients were at 2 to 3-fold increased risk of postoperative mortality compared to younger patients [ $RR = 2.53$ ] and found shorter overall survival [ $HR = 1.17$ ] in older patients. However, no differences in operative outcomes, postoperative complications (bile leak, liver failure, pulmonary complications), and disease-free survival were found. Similarly, the occurrence of major postoperative complications (Clavien-Dindo III or more) was equivalent between older and younger patients. The majority of the studies included in the meta-analysis by de'Angelis et al. found that age was not an independent predictive factor of overall survival and disease-free survival, supporting the conclusion that advanced chronological age should not be

regarded as a medical contraindication to liver resection for CRLM [185].

The ideal treatment strategy for colorectal cancer with synchronous CRLM remains a matter of debate due to the lack of RCTs and due to the rapidly changing systemic treatment modalities. The initial treatment is usually determined by the extent, resectability, and symptomatic burden of colorectal cancer and the concomitant metastatic liver load. Patients with rectal primaries have been shown to present most commonly with a higher metastatic liver load and undergoing a liver-first strategy following preoperative chemotherapy.

Four systematic reviews and meta-analyses comparing simultaneous and staged colorectal and liver resections for colorectal cancer with synchronous CRLM have been published over the last ten years, showing different strategies achieve nearly comparable outcomes.

According to the literature, patients with synchronous rectal cancer and liver metastases needing major hepatic resections are selected more frequently for staged operations. All the studies published to date on this topic show a significant selection bias associated with colorectal cancer site (right-sided vs. left-sided vs. rectum), the extension of liver resection, and use of neoadjuvant chemotherapy [257]. Hajibandeh et al. found that there was significantly lower use of neoadjuvant chemotherapy and minor hepatic resection in patients treated with a simultaneous colorectal and liver resection. No significant difference was found in postoperative morbidity (OR = 1.04), mortality (RD = 0.00), and 5-year overall survival (OR = 0.88) between the two strategies [258].

Although a network meta-analysis published in 2014 by Kelly et al. [259] found that the 5-year overall survival and the 30-day mortality rates did not show significant differences between the colorectal first, simultaneous, and liver-first approaches, an updated network meta-analysis on 44 retrospective studies reporting on 10,848 patients showed that, compared to the other two approaches, the simultaneous one resulted in a higher risk of major morbidity and 30-day mortality. From this analysis, it also appears that the liver-first approach is increasingly used in colorectal cancer patients with synchronous CRLM, specifically in those with rectal primaries and those with a high load of metastatic disease [260].

Recently, laparoscopy has been shown to confer better outcomes for liver resections compared with open surgery in older CRLM patients. Minimizing surgical trauma in this subgroup of frail patients can facilitate the patient's recovery [261]. The comparison between laparoscopic and open surgery for liver resection in CRLM elderly patients performed by de'Angelis et al. showed that the operative approach is not a predictor of 5-year overall survival and 5-year disease-free survival.

However, a significantly lower postoperative morbidity was found in association with laparoscopic hepatectomy, particularly in the age group < 80 years [185]. A systematic review and meta-analysis of high-quality studies demonstrated an unexpected survival benefit in favor of laparoscopic over open liver resection for CRLM in the long term [262]. A subgroup analysis exclusively focused on outcomes of elderly patients performed in the same study found that median survival was 53.1 months and 44.9 months in the laparoscopy compared to the open liver resection groups, with a longer 3-year average life expectancy among elderly patients with laparoscopically resected CRLM. Non-surgical local ablation therapies, such as radiofrequency ablation and radioembolization, can be selected in potentially resectable metastases only if patients have unfavorable performance status and/or severe comorbidities, or if patients refuse surgery.

#### **Consensus Topic: I. Emergency presentations**

**Key Question 19.** Obstructing rectal cancer. In elderly patients with obstructing upper rectal cancer, how does bridge-to-surgery rectal stent placement compared to emergency surgery affect oncological outcomes and the rate of minimal access surgery?

**Statement.** In elderly patients with obstructing upper rectal cancer, bridge-to-surgery rectal stent placement (when possible) compared to emergency surgery could improve short-term results, even potentially increasing the rate of minimal access surgery, with similar disease-free and overall survival rates.

**Recommendation.** The experts' panel suggests that in elderly patients with obstructing upper rectal cancer, bridge-to-surgery rectal stent placement (when possible) should be preferred over emergency surgery (*Weak recommendation, Moderate quality of evidence—2B*).

**Agreement:** 82.4%

Self-expandable metallic stent (SEMS) positioning is a well-recognized treatment for malignant colonic obstruction [263–265]. Nevertheless, SEMS placement for tumors close to the anal verge is difficult because of the probability of severe pain resulting from the proximity to the dentate line [266]. Moreover, although technological improvements increase the possibility of SEMS placement in the lower rectum [267], precise deployment of a stent for tumors close to the anal verge is technically tricky [268]. The premise relevant to the statement in question is that, although five systematic reviews and meta-analyses of randomized controlled trials have been published to date in the literature [269–273] that analyze bridge-to-surgery SEMS placement vs. emergency surgery in the treatment of obstructing left colon cancer, unfortunately, such systematic reviews show relevant limitations including the fact that they did not consider the elderly subpopulation in the analysis of

the results, and that only a tiny proportion of the patients included in the RCTs were affected by rectal cancers. Therefore, the statement is the result of an extrapolation of evidence, albeit of medium-high level, not necessarily obtained on the reference population. Keeping these limitations in mind, bridge-to-surgery SEMs provides favorable short-term outcomes by reducing the overall complications and stoma formation in treating malignant left-sided colonic obstruction, although the 30-day mortality rate of SEMs is comparable to emergency surgery. Although SEMs could be associated with a higher incidence of systemic and overall recurrence rates in terms of long-term outcomes, both interventions have similar disease-free and overall survival rates. In the general population, the short-term advantages of bridge-to-surgery SEMs should be weighed against the potential long-term oncological hazards. However, it must be emphasized that, in an elderly population, especially over 80 years, the short-term advantages may be relatively more important than the long-term disadvantages.

SEMs is associated with lower short-term overall morbidity and lower rates of a temporary and permanent stoma in the literature. Arezzo et al. performed a systematic review and meta-analysis of RCTs comparing SEMs as bridge-to-surgery and emergency surgery for acute symptomatic malignant left-sided large bowel obstruction, having for primary outcome the overall morbidity within 60 days after surgery. This meta-analysis that included eight RCTs and 497 patients showed that overall morbidity within 60 days after surgery was 33.9% in SEMs-treated patients and 51.2% in ES-treated patients (RR = 0.59;  $P = 0.023$ ). The temporary stoma rate was 33.9% after SEMs and 51.4% after ES (RR = 0.67;  $P < 0.001$ ), while the permanent stoma rate was 22.2% after SEMs and 35.2% after ES (RR = 0.66;  $P = 0.003$ ). Primary anastomosis was successful in 70.0% of SEMs-treated patients and 54.1% of ES-treated patients (RR = 1.29;  $P = 0.043$ ) [269]. A systematic review of studies involving long-term tumor outcomes comparing SEMs with emergency surgery was conducted by Cao et al. Overall, the analysis of outcomes from 24 articles and 2,508 patients, including five RCTs, three prospective studies, and 16 retrospective studies showed that the 3-year survival rate (OR = 0.88,  $P = 0.05$ ), 5-year survival rate (OR = 0.91,  $P = 0.67$ ), 3-year disease-free survival rate (OR = 1.14,  $P = 0.65$ ), 5-year disease-free survival rate (OR = 1.35,  $P = 0.17$ ), overall recurrence rate (OR = 1.04,  $P = 0.14$ ), and local recurrence rate (OR = 1.37,  $P = 0.92$ ) were comparable between the two management strategies. Long-term survival results, including 5-year disease-free survival and overall survival, are equivalent between SEMs and emergency surgery [274, 275]. Regarding the safety profile of SEMs as bridge-to-surgery

based on pathology, it has been shown that the presence of perineural invasion (RR = 0.58,  $P < 0.00001$ ), lymphovascular invasion (RR = 0.68,  $P = 0.004$ ) and vascular invasion (RR = 0.66,  $P = 0.04$ ) in SEMs-treated patients were higher than those in patients treated with emergency surgery, although the difference in lymphatic invasion (RR = 0.92, 95% CI 0.77, 1.09,  $P = 0.33$ ) in the meta-analysis by Hu et al. Conversely, the number of lymph nodes harvested in SEMs group was higher than that in the emergency surgery group (MD = -3.18,  $P < 0.00001$ ). The authors concluded that SEMs implantation in patients with acute malignant obstructive colorectal cancer might increase all those adverse tumor pathological characteristics that are mostly related to the poor prognosis of colorectal cancer. However, not only the adverse effect of SEMs on long-term survival has not been demonstrated, but also, and especially when patients are elderly, these aspects could be overshadowed by more important outcomes in this patient group, such as the quality of remaining life [276]. SEMs could also provide possible palliation for patients with bowel obstructions and unresectable colorectal cancer. Controlled trials that compared SEMs with surgical interventions as palliative treatments in unresectable obstructive colorectal cancer patients were analyzed by Takahashi et al. SEMs was shown to reduce the risk of early complications (OR = 0.34;  $P < 0.01$ ), mortality (OR = 0.31;  $P < 0.01$ ), and stoma creation (OR = 0.19;  $P < 0.01$ ). However, SEMs placement was significantly associated with a higher risk of perforation of the large bowel in this pooled analysis (OR = 5.25;  $P < 0.01$ ) and late complications (OR = 1.94;  $P = 0.03$ ), it contributed significantly to better long-term survival (HR = 0.46;  $P < 0.01$ ) [274].

## Conclusions

Although rectal cancer is predominantly a disease of older patients, current guidelines do not incorporate optimal treatment recommendations for the elderly and address only partially the associated specific challenges encountered in this population. The present 2021 SICG-SIFIPAC-SICE-WSES consensus for the multidisciplinary management of elderly patients with rectal cancer summarizes the results of an extensive analysis of the consistent evidence about the multidisciplinary management of elderly patients.

We recommend the adoption of strategies for patient involvement in healthcare decision-making, the evaluation of the social background, and a discussion with the patient about therapeutic modalities for rectal cancer. We also recommend against colorectal cancer screening in patients older than 85 years, whereas a careful selection on an individual basis for patients between the ages

of 76 and 85 years, according to their health status, is advisable.

The decision to pursue or withhold radical surgery requires estimation not only regarding individual perioperative mortality, but also life expectancy, healthcare priorities, and the patient's primary goals, such as prolongation of life versus maintenance of independence and symptom relief.

For the fit elderly patient with acceptable sphincter tone, standard of care therapy should be pursued, whereas frail patients with more advanced disease could benefit from local excision as a palliative approach in combination with neoadjuvant therapy, or more intensive radiotherapy options. For elderly patients who retain a good physical and mental condition, treatment that is given to younger patients is deemed appropriate, whereas for those with diminished physiological reserves and comorbid conditions, alternative treatments that keep surgical trauma to a minimum.

From this perspective, properly selected elderly patients with rectal cancer should be always considered for surgical resection. We suggest laparoscopic TME after a careful evaluation of patient's medical history, performance status, and tumor characteristics. Conversely, local excision can be implemented when balancing frailty, oncological outcomes, functional outcomes, and life expectancy. A watch and wait strategy can be considered in selected frail elderly patients with low-rectal tumors in case of complete clinical response after neoadjuvant therapy. In these cases, we suggest a stringent surveillance protocol, at least in the first 3 years, and a candid discussion with the patient about the potential risks of this strategy is recommended. The above recommendations have been made based on the best available evidence to help to maximize rectal cancer therapeutic strategies while minimizing adverse impacts on functional outcomes and quality of life for these patients.

#### Abbreviations

ACS: American Cancer Society; AGA: American Gastroenterology Association; AIOM: Associazione Italiana di Oncologia Medica; AL: Anastomotic leak; APR: Abdominoperineal resection; ASGE: American Society of Gastrointestinal Endoscopy; BCCA: Bi-National Colorectal Cancer Audit; cCR: Clinical complete response; COREFO: Colorectal functional outcome; CRLM: Colorectal liver metastases; CT: Computed tomography; DI: Diverting ileostomy; EC: Early closure; EORTC: European Organisation for Research and Treatment of Cancer; ERAS: Enhanced recovery after surgery; ES: Emergency surgery; ESMO: European Society for Medical Oncology; ETAR: Endoscopic transanal resection; EURECCA: European Registration of Cancer Care; EUS: Endoscopic ultrasonography; FISI: Fecal Incontinence Severity Index; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; HAI: Hospital-acquired infections; HR: Hazard ratio; HRQL: Health-related quality of life; ICHOM: International Consortium for Health Outcomes Measurement; LAR: Low anterior resection; LARS: Low anterior resection syndrome; MBP: Mechanical bowel preparation; MIS: Minimally invasive surgery; MD: Mean difference; MRI: Magnetic resonance imaging; NAT: Non-adjuvant treatments; NCCN: National Comprehensive Cancer Network; nCRT: Neoadjuvant chemo-radiotherapy; NICE: National Institute for Health and Care Excellence; n-RCS: Non-randomized controlled study; OAP: Oral

antibiotic prophylaxis; OR: Odds ratio; pCR: Pathology complete response; PLCCRT: Preoperative long-course chemo-radiotherapy; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PROMs: Patient-reported outcome measures; PSCRT: Preoperative short-course radiotherapy; QLQ-C30: Quality-of-Life Questionnaire-C30; QoE: Quality of evidence; QoL: Quality of life; RCT: Randomized controlled trial; RD: Risk difference; RR: Risk ratio; SEMs: Self-expanding metal stent; SICE: Società Italiana di Chirurgia Endoscopica e nuove tecnologie; SICG: Società Italiana di Chirurgia Geriatrica; SIFIPAC: Società Italiana di Fisiopatologia Chirurgica; SIOG: International Society of Geriatric Oncology; SoR: Strength of recommendation; SSI: Surgical-site infection; TAE: Transanal excision; TaTME: Transanal total mesorectal excision; TAMIS: Transanal minimally invasive surgery; TEM: Transanal endoscopic microsurgery; TME: Total mesorectal excision; TNT: Total neoadjuvant therapy; USD: United States dollars; USPSTF: U.S. Preventive Services Task Force; WHO: World Health Organization; WSES: World Society of Emergency Surgery

#### Acknowledgements

The authors thank the members of the Board of Governors of the Società Italiana di Chirurgia Geriatrica (SICG), Società Italiana di Fisiopatologia Chirurgica (SIFIPAC), Società Italiana di Chirurgia Endoscopica e nuove tecnologie (SICE) and the World Society of Emergency Surgery (WSES) for the crucial contribution in the development of the Consensus. This study was supported by a grant from the University of Brescia (Italy), that covered the cost of the Open Access publication.

#### Authors' contributions

FC and MP: Conception and design of the Consensus. FC, MP, and PC: Coordination of the Consensus. MP, MO, FP: Evidence review team. The Chairs were supported by the Scientific Secretariat in establishing the timetable of the Consensus process and choosing the clinical experts who were asked to participate in the Steering Committee. The Steering Committee had the assignment to select the literature and to elaborate, in co-working to Scientific Secretariat and Organization Committee, the statements and recommendations. FG, NA, FR, AB, MV, FG, FC, TM, MdF, CC, NDA, AP, MS, MG, FC, AA, DP, NdA, SDS, FA, AC, SB, AP, LA: Members of the Steering Committee. The experts' panel voted on the statements and recommendations drafted during the Consensus. PS, GB, MA, BdS, VA, WB, GIdA, AG, GE, GF, YK, AL, EEM, AP, GP, DP, NS, MS, PT: Members of the experts' panel. MP, FG, GB, NA, FR, AP, AB, MV, FG, FC, TM, MdF, NDA, AP, MS, MG, FC, AA, DP, NdA, SDS, FA, AC, SB, AP, LA, PC, FC: Drafted the manuscript and revised it for relevant intellectual contents. External reviewers (Independent): JD, GB, GP. The authors read and approved the final manuscript.

#### Availability of data and materials

Not Applicable.

#### Declarations

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

#### Competing interests

JD was topic advisor for the NICE Colorectal Cancer Guidelines NG151. The other authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Department of Emergency Surgery, Cagliari University Hospital "D. Casula", Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy. <sup>2</sup>Division of Colon and Rectal Surgery, Mount Sinai Hospital, New York, NY, USA. <sup>3</sup>ASST Cremona, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. <sup>4</sup>Department of Colorectal Surgery, Cantonal Hospital of Winterthur, Winterthur - University of Basel, Basel, Switzerland. <sup>5</sup>ICU Department, Bufalini Hospital, Cesena, Italy. <sup>6</sup>Department of General Surgery, Vittorio Veneto Hospital, AULSS2 Trevigiana del Veneto, Vittorio Veneto, Italy. <sup>7</sup>1st General Surgery Unit, University of Pavia, Pavia, Italy. <sup>8</sup>Department of Surgical Sciences, University of Torino, Torino, Italy. <sup>9</sup>SC Chirurgia Generale e Specialità Chirurgiche Azienda Ospedaliera Santa Maria, Università degli Studi

di Perugia, Terni, Italy. <sup>10</sup>Trauma and Acute Care Surgery, Scripps Memorial Hospital, La Jolla, CA, USA. <sup>11</sup>Department of General Surgery and Medical - Surgical Specialties, University of Catania, Catania, Italy. <sup>12</sup>Department of Medical Oncology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy. <sup>13</sup>Department of Surgery, ASL VT - Ospedale "San Giovanni Decollato - Andosilla", Civita Castellana, Italy. <sup>14</sup>Department of Surgery, Unit of General Surgery, University Hospital of Ferrara, University of Ferrara, Ferrara, Italy. <sup>15</sup>Department of Radiology, University Hospital of Parma, Parma, Italy. <sup>16</sup>General and Minimally Invasive Surgery Unit, Cristo Re Hospital and Catholic University, Rome, Italy. <sup>17</sup>Unit of Minimally Invasive and Robotic Digestive Surgery, Regional General Hospital F. Miulli, Acquaviva delle Fonti, Bari, Italy. <sup>18</sup>Department of Medicine and Surgery, Gastroenterology and Endoscopy Unit, University of Parma, Parma, Italy. <sup>19</sup>Department of General and Metabolic Surgery, Poissy and Saint Germain en Laye Hospitals, Poissy, France. <sup>20</sup>Department of Surgery, University of Insubria, Varese, Italy. <sup>21</sup>General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy. <sup>22</sup>Division of Trauma Surgery, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil. <sup>23</sup>University of Milano Bicocca, Milano, Italy. <sup>24</sup>Università Politecnica delle Marche, Ancona, Italy. <sup>25</sup>Division of General Surgery, Rambam Health Care Campus, Haifa, Israel. <sup>26</sup>Helsinki University Hospital, University of Helsinki, Helsinki, Finland. <sup>27</sup>UOC Chirurgia Generale - AOU san Giovanni di Dio e Ruggi d'Aragona, Università di Salerno, Salerno, Italy. <sup>28</sup>Department of Medicine and Surgery, University of Parma Geriatric-Rehabilitation Department, Parma University Hospital, Parma, Italy. <sup>29</sup>Ernest E Moore Shock Trauma Center at Denver Health, Denver, USA. <sup>30</sup>Ospedale Nicola Giannettasio, Corigliano-Rossano, Italy. <sup>31</sup>Santa Maria della Misericordia Hospital, Rovigo, Italy. <sup>32</sup>Surgery of the Alimentary Tract, Sant'Orsola Hospital, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. <sup>33</sup>Dipartimento di Chirurgia Pietro Valdoni Policlinico Umberto I, Sapienza Università degli Studi di Roma, Rome, Italy. <sup>34</sup>Department of Surgery, Macerata Hospital, Macerata, Italy. <sup>35</sup>Exeter Hospital, Exeter, UK. <sup>36</sup>Letterkenny University Hospital and CPM sEUBP Interreg Project, Letterkenny, Ireland. <sup>37</sup>University Hospital 'Gregorio Marañón', Madrid, Spain. <sup>38</sup>General, Emergency and Trauma Surgery Department, Pisa University Hospital, Pisa, Italy. <sup>39</sup>Cambridge Colorectal Unit, Addenbrooke's Hospital, Cambridge, UK. <sup>40</sup>Department of Emergency Surgery, Parma Maggiore Hospital, Parma, Italy.

Received: 16 April 2021 Accepted: 18 June 2021

Published online: 02 July 2021

## References

- World Health Organization GLOBOCAN database <https://gco.iarc.fr/today/home>. Accessed 8 Mar 2021.
- Babaei M, Jansen L, Balavarcu Y, Sjövall A, Bos A, van de Velde T, et al. Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes. *Clin Colorectal Cancer*. 2018;17(1):e129–42. <https://doi.org/10.1016/j.clcc.2017.09.002>.
- Shahir MA, Lemmens VE, van de Poll-Franse LV, Voogd AC, Martijn H, Janssen-Heijnen ML. Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. *Eur J Cancer*. 2006;42(17):3015–21. <https://doi.org/10.1016/j.ejca.2005.10.032>.
- Costa G, Fransvea P, Podda M, Pisanu A, Carrano FM, Iossa A, et al. The use of emergency laparoscopy for acute abdomen in the elderly: the FRAILESEL Italian Multicenter Prospective Cohort Study. *Updates Surg*. 2020;72(2):513–25. <https://doi.org/10.1007/s13304-020-00726-5>.
- Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynn-Jones R, Haller D, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. *Ann Oncol*. 2015;26(3):463–76. <https://doi.org/10.1093/annonc/mdu253>.
- Claassen YHM, Vermeer NCA, Iversen LH, van Eycken E, Guren MG, Mroczkowski P, et al. Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. *Br J Cancer*. 2018;119(4):517–22. <https://doi.org/10.1038/s41416-018-0215-6>.
- Thiels CA, Bergquist JR, Meyers AJ, Johnson CL, Behm KT, Hayman AV, et al. Outcomes with multimodal therapy for elderly patients with rectal cancer. *Br J Surg*. 2016;103(2):e106–14. <https://doi.org/10.1002/bjs.10057>.
- Montroni I, Ugolini G, Saur NM, Spinelli A, Rostoft S, Millan M, Wolthuis A, Daniels IR, Hompes R, Penna M, Fürst A, Papamichael D, Desai AM, Cascinu S, Gérard JP, Myint AS, Lemmens VEPP, Berho M, Lawler M, De Liguori Carino N, Potenti F, Nanni O, Altini M, Beets G, Rutten H, Winchester D, Wexner SD, Audisio RA. Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. *Eur J Surg Oncol*. 2018;44(11):1685–702. <https://doi.org/10.1016/j.ejso.2018.08.003>.
- Manceau G, Karoui M, Werner A, Mortensen NJ, Hannoun L. Comparative outcomes of rectal cancer surgery between elderly and non-elderly patients: a systematic review. *Lancet Oncol*. 2012;13(12):e525–36. [https://doi.org/10.1016/S1470-2045\(12\)70378-9](https://doi.org/10.1016/S1470-2045(12)70378-9).
- Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. *Lancet Gastroenterol Hepatol*. 2018;3(12):825–36. [https://doi.org/10.1016/S2468-1253\(18\)30301-7](https://doi.org/10.1016/S2468-1253(18)30301-7).
- Smith FM, Ahad A, Perez RO, Marks J, Bujko K, Heald RJ. Local excision techniques for rectal cancer after neoadjuvant chemoradiotherapy: what are we doing? *Dis Colon Rectum*. 2017;60(2):228–39. <https://doi.org/10.1097/DCR.0000000000000749>.
- Monsellato I, Alongi F, Bertocchi E, Gori S, Ruffo G, Cassinotti E, et al. Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after Neoadjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). *BMC Cancer*. 2019;19(1):1215. <https://doi.org/10.1186/s12885-019-6271-3>.
- Balducci L, Extermann M. Management of cancer in the older person: a practical approach. *Oncologist*. 2000;5(3):224–37. <https://doi.org/10.1634/theoncologist.5-3-224>.
- Hathout L, Maloney-Patel N, Malhotra U, Wang SJ, Chokhvatia S, Dalal I, et al. Management of locally advanced rectal cancer in the elderly: a critical review and algorithm. *J Gastrointest Oncol*. 2018;9(2):363–76. <https://doi.org/10.21037/jgo.2017.10.10>.
- Spinelli A, Montroni I. Personalized treatments for elderly patients affected by rectal cancer. *Colorectal Dis*. 2017;19(10):879–80. <https://doi.org/10.1111/codi.13841>.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535. <https://doi.org/10.1136/bmj.b2535>.
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924–6. <https://doi.org/10.1136/bmj.39489.470347.AD>.
- Brožek JL, Akl EA, Compalati E, Kreis J, Terracciano L, Fiocchi A, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. *Allergy*. 2011;66(5):588–95. <https://doi.org/10.1111/j.1398-9995.2010.02530.x>.
- Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ*. 2008;336(7653):1106–10. <https://doi.org/10.1136/bmj.39500.677199.AE>.
- Di Saverio S, Podda M, De Simone B, Ceresoli M, Augustin G, Gori A, Boermeester M, Sartelli M, Coccolini F, Tarasconi A, De'Angelis N, Weber DG, Tolonen M, Birindelli A, Biffi W, Moore EE, Kelly M, Soreide K, Kashuk J, Ten Broek R, Gomes CA, Sugrue M, Davies RJ, Damaskos D, Leppäniemi A, Kirkpatrick A, Peitzman AB, Fraga GP, Maier RV, Coimbra R, Chiarugi M, Sganga G, Pisanu A, De' Angelis GL, Tan E, Van Gooch H, Pata F, Di Carlo I, Chiara O, Litvin A, Campanile FC, Sakakushiev B, Tomadze G, Demetrasvili Z, Latifi R, Abu-Zidan F, Romeo O, Segovia-Lohse H, Baiocchi G, Costa D, Rizoli S, Balogh ZJ, Bendinelli C, Scalea T, Ivatury R, Velmahos G, Andersson R, Kluger Y, Ansaloni L, Catena F. Diagnosis and treatment of acute appendicitis: 2020 update of the WSES Jerusalem guidelines. *World J Emerg Surg*. 2020;15(1):27. <https://doi.org/10.1186/s13017-020-00306-3>.
- Fagard K, Leonard S, Deschodt M, Devriendt E, Wolthuis A, Prenen H, et al. The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: a systematic review. *J Geriatr Oncol*. 2016;7(6):479–91. <https://doi.org/10.1016/j.jgo.2016.06.001>.
- Howlander N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2012. Bethesda: National Cancer Institute; 2015. (updated based on November 2014 SEER data submission, posted to the SEER web site, April 2015). Available from: [http://seer.cancer.gov/csr/1975\\_2012/](http://seer.cancer.gov/csr/1975_2012/)

23. Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. *Ann Oncol*. 2015;26(6):1091–101. <https://doi.org/10.1093/annonc/mdl540>.
24. Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. *Ann Oncol*. 2015;26(2):288–300. <https://doi.org/10.1093/annonc/mdl210>.
25. Robinson TN, Wu DS, Pointer L, Dunn CL, Cleveland JC Jr, Moss M. Simple frailty score predicts postoperative complications across surgical specialties. *Am J Surg*. 2013;206(4):544–50. <https://doi.org/10.1016/j.amjsurg.2013.03.012>.
26. Kristjansson SR, Nesbakken A, Jordhøy MS, Skovlund E, Audisio RA, Johannessen HO, et al. Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: a prospective observational cohort study. *Crit Rev Oncol Hematol*. 2010;76(3):208–17. <https://doi.org/10.1016/j.critrevonc.2009.11.002>.
27. Reisinger KW, van Vugt JL, Tegels JJ, Sniijders C, Hulsewé KW, Hoofwijk AG, et al. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. *Ann Surg*. 2015;261(2):345–52. <https://doi.org/10.1097/SLA.0000000000000628>.
28. Tan KY, Kawamura YJ, Tokomitsu A, Tang T. Assessment for frailty is useful for predicting morbidity in elderly patients undergoing colorectal cancer resection whose comorbidities are already optimized. *Am J Surg*. 2012;204(2):139–43. <https://doi.org/10.1016/j.amjsurg.2011.08.012>.
29. Johnston S, Louis M, Churilov L, Ma R, Christophi C, Weinberg L. Health costs of post-operative complications following rectal resection: a systematic review. *ANZ J Surg*. 2020;90(7-8):1270–6. <https://doi.org/10.1111/ans.15708>.
30. Floodeen H, Hallböök O, Hagberg LA, Matthiessen P. Costs and resource use following defunctioning stoma in low anterior resection for cancer - a long-term analysis of a randomized multicenter trial. *Eur J Surg Oncol*. 2017;43(2):330–6. <https://doi.org/10.1016/j.ejso.2016.12.003>.
31. Woodfield J, Hulme-Moir M, Ly J. A comparison of the cost of primary closure or rectus abdominis myocutaneous flap closure of the perineum after abdominoperineal excision. *Colorectal Dis*. 2017;19(10):934–41. <https://doi.org/10.1111/codi.13690>.
32. Zogg CK, Ottesen TD, Kebaish KJ, Galivanche A, Murthy S, Changoor NR, et al. The Cost of Complications Following Major Resection of Malignant Neoplasia. *J Gastrointest Surg*. 2018;22(11):1976–86. <https://doi.org/10.1007/s11605-018-3850-6>.
33. Ashraf SQ, Burns EM, Jani A, Altman S, Young JD, Cunningham C, et al. The economic impact of anastomotic leakage after anterior resections in English NHS hospitals: are we adequately remunerating them? *Colorectal Dis*. 2013;15(4):e190–8. <https://doi.org/10.1111/codi.12125>.
34. Fukuda H, Morikane K, Kuroki M, Kawai S, Hayashi K, Ieiri Y, et al. Impact of surgical site infections after open and laparoscopic colon and rectal surgeries on postoperative resource consumption. *Infection*. 2012;40(6):649–59. <https://doi.org/10.1007/s15010-012-0317-7>.
35. Kim CW, Baik SH, Roh YH, Kang J, Hur H, Min BS, et al. Cost-effectiveness of robotic surgery for rectal cancer focusing on short-term outcomes: a propensity score-matching analysis. *Medicine (Baltimore)*. 2015;94(22):e823. <https://doi.org/10.1097/MD.0000000000000823>.
36. Manecke GR, Asemota A, Michard F. Tackling the economic burden of postsurgical complications: would perioperative goal-directed fluid therapy help? *Crit Care*. 2014;18(5):566. <https://doi.org/10.1186/s13054-014-0566-1>.
37. Qaseem A, Denberg TD, Hopkins RH Jr, Humphrey LL, Levine J, Sweet DE, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. *Ann Intern Med*. 2012;156(5):378–86. <https://doi.org/10.7326/0003-4819-156-5-201203060-00010>.
38. Wolf AMD, Fonhtam ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin*. 2018;68(4):250–81. <https://doi.org/10.3322/caac.21457>.
39. van Hees F, Habbema JD, Meester RG, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. *Ann Intern Med*. 2014;160(11):750–9. <https://doi.org/10.7326/M13-2263>.
40. Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. *Gastrointest Endosc*. 2017;86(1):18–33. <https://doi.org/10.1016/j.gjie.2017.04.003>.
41. Nee J, Chippendale RZ, Feuerstein JD. Screening for colon cancer in older adults: risks, benefits, and when to stop. *Mayo Clin Proc*. 2020;95(1):184–96. <https://doi.org/10.1016/j.mayocp.2019.02.021>.
42. Lin OS, Kozarek RA, Schembre DB, Ayub K, Gluck M, Drennan F, et al. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. *JAMA*. 2006;295(20):2357–65. <https://doi.org/10.1001/jama.295.20.2357>.
43. Inadomi JM, Sonnenberg A. The impact of colorectal cancer screening on life expectancy. *Gastrointest Endosc*. 2000;51(5):517–23. [https://doi.org/10.1016/s0016-5107\(00\)70282-3](https://doi.org/10.1016/s0016-5107(00)70282-3).
44. Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, et al. Association of treatment adherence with oncologic outcomes for patients with rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase 3 randomized clinical trial. *JAMA Oncol*. 2020;6(9):1416–21. <https://doi.org/10.1001/jamaoncol.2020.2394>.
45. Mari GM, Maggioni D, Crippa J, Costanzi ATM, Scotti MA, Giardini V, et al. Compliance to adjuvant chemotherapy of patients who underwent surgery for rectal cancer: report from a multi-institutional research network. *World J Surg*. 2019;43(10):2544–51. <https://doi.org/10.1007/s00268-019-05060-5>.
46. Scheepers ERM, Schiphorst AH, van Huis-Tanja LH, Emmelot-Vonk MH, Hamaker ME. Treatment patterns and primary reasons for adjusted treatment in older and younger patients with stage II or III colorectal cancer. *Eur J Surg Oncol*. 2021;50748-7983(21):00059-7. <https://doi.org/10.1016/j.ejso.2021.01.029>.
47. Pieterse AH, Kunnean M, van den Hout WB, Baas-Thijssen M, Geijssen ED, Ceha HM, et al. Patient explicit consideration of tradeoffs in decision making about rectal cancer treatment: benefits for decision process and quality of life. *Acta Oncol*. 2019;58(7):1069–76. <https://doi.org/10.1080/0284186X.2019.1594363>.
48. Antonio M, Carmona-Bayonas A, Saldaña J, Navarro V, Tebé C, Salazar R, et al. Factors predicting adherence to a tailored-dose adjuvant treatment on the basis of geriatric assessment in elderly people with colorectal cancer: a prospective study. *Clin Colorectal Cancer*. 2018;17(1):e59–68. <https://doi.org/10.1016/j.clcc.2017.09.003>.
49. Elkin EB, Kim SH, Casper ES, Kissane DW, Schrag D. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. *J Clin Oncol*. 2007;25(33):5275–80. <https://doi.org/10.1200/JCO.2007.11.1922>.
50. Bailo L, Vergani L, Pravettoni G. Patient preferences as guidance for information framing in a medical shared decision-making approach: the bridge between nudging and patient preferences. *Patient Prefer Adherence*. 2019;13:2225–31. <https://doi.org/10.2147/PPA.S205819>.
51. Lin HS, Watts JN, Peel NM, Hubbard RE. Frailty and post-operative outcomes in older surgical patients: a systematic review. *BMC Geriatr*. 2016;16(1):157. <https://doi.org/10.1186/s12877-016-0329-8>.
52. Indrakusuma R, Dunker MS, Peetoom JJ, Schreurs WH. Evaluation of preoperative geriatric assessment of elderly patients with colorectal carcinoma. A retrospective study. *Eur J Surg Oncol*. 2015;41(1):21–7. <https://doi.org/10.1016/j.ejso.2014.09.005>.
53. Rønning B, Wyller TB, Jordhøy MS, Nesbakken A, Bakka A, Seljeflot I, et al. Frailty indicators and functional status in older patients after colorectal cancer surgery. *J Geriatr Oncol*. 2014;5(1):26–32. <https://doi.org/10.1016/j.jgo.2013.08.001>.
54. Boakye D, Rillmann B, Walter V, Jansen L, Hoffmeister M, Brenner H. Impact of comorbidity and frailty on prognosis in colorectal cancer patients: a systematic review and meta-analysis. *Cancer Treat Rev*. 2018;64:30–9. <https://doi.org/10.1016/j.ctrv.2018.02.003>.
55. Ommundsen N, Wyller TB, Nesbakken A, Jordhøy MS, Bakka A, Skovlund E, et al. Frailty is an independent predictor of survival in older patients with colorectal cancer. *Oncologist*. 2014;19(12):1268–75. <https://doi.org/10.1634/theoncologist.2014-0237>.
56. Miller SM, Wolf J, Katlic M, D'Adamo CR, Coleman J, Ahuja V. Frailty is a better predictor than age for outcomes in geriatric patients with rectal cancer undergoing proctectomy. *Surgery*. 2020;168(3):504–8. <https://doi.org/10.1016/j.surg.2020.05.027>.
57. Mima K, Miyanari N, Morito A, Yumoto S, Matsumoto T, Kosumi K, et al. Frailty is an independent risk factor for recurrence and mortality following curative resection of stage I-III colorectal cancer. *Ann Gastroenterol Surg*. 2020;4(4):405–12. <https://doi.org/10.1002/ags3.12337>.
58. Tamura K, Matsuda K, Fujita Y, Iwashita M, Mori K, Yamada N, et al. Optimal Assessment of Frailty Predicts Postoperative Complications in Older Patients

- with Colorectal Cancer Surgery. *World J Surg.* 2021. <https://doi.org/10.1007/s00268-020-05886-4>.
59. Tatar C, Benlice C, Delaney CP, Holubar SD, Liska D, Steele SR, et al. Modified frailty index predicts high-risk patients for readmission after colorectal surgery for cancer. *Am J Surg.* 2020;220(1):187–90. <https://doi.org/10.1016/j.amjsurg.2019.11.016>.
  60. Middelburg JG, Middelburg RA, van Zwielen M, Mast ME, Bhawanie A, Jobsen JJ, et al. LPRO (Dutch National Organization for Radiotherapy in the Elderly). Impaired Geriatric 8 Score is associated with worse survival after radiotherapy in older patients with cancer. *Clin Oncol (R Coll Radiol).* 2021; 33(4):e203–10. <https://doi.org/10.1016/j.clon.2020.09.002>.
  61. Aaldriks AA, van der Geest LG, Giltay EJ, Le Cessie S, Portielje JE, Tanis BC, et al. Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. *J Geriatr Oncol.* 2013;4(3):218–26. <https://doi.org/10.1016/j.jgo.2013.04.001>.
  62. Lund CM, Vistisen KK, Dehlendorff C, Rønholdt F, Johansen JS, Nielsen DL. The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO). *BMC Cancer.* 2017;17(1):448. <https://doi.org/10.1186/s12885-017-3445-8>.
  63. Abir F, Alva S, Longo WE. The management of rectal cancer in the elderly. *Surg Oncol.* 2004;13(4):223–34. <https://doi.org/10.1016/j.suronc.2004.08.008>.
  64. Endreseth BH, Romundstad P, Myrvold HE, Bjerkeset T, Wibe A, Norwegian Rectal Cancer Group. Rectal cancer treatment of the elderly. *Colorectal Dis.* 2006;8(6):471–9. <https://doi.org/10.1111/j.1463-1318.2005.00921.x>.
  65. Lawler M, Alsina D, Adams RA, Anderson AS, Brown G, Fearnhead NS, et al. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. *Gut.* 2018;67(1): 179–93. <https://doi.org/10.1136/gutjnl-2017-315333>.
  66. Zerillo JA, Schouwenburg MG, van Bommel ACM, Stowell C, Lippa J, Bauer D, et al. An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal Cancer. *JAMA Oncol.* 2017;3(5):686–94. <https://doi.org/10.1001/jamaoncol.2017.0417>.
  67. Puig-La Calle J Jr, Quayle J, Thaler HT, Shi W, Paty PB, Quan SH, et al. Favorable short-term and long-term outcome after elective radical rectal cancer resection in patients 75 years of age or older. *Dis Colon Rectum.* 2000;43(12):1704–9. <https://doi.org/10.1007/BF02236854>.
  68. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *CA Cancer J Clin.* 2008;58(3):130–60. <https://doi.org/10.3322/CA.2007.0018>.
  69. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2017;28(suppl\_4):iv22–40. <https://doi.org/10.1093/annonc/mdx224>.
  70. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2018;16(7):874–901. <https://doi.org/10.6004/jnccn.2018.0061>.
  71. van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. *Eur J Cancer.* 2014;50(1):1. e1–1.e34. <https://doi.org/10.1016/j.ejca.2013.06.048>.
  72. Beets-Tan RGH, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Curvo-Semedo L, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. *Eur Radiol.* 2018;28(4):1465–75. <https://doi.org/10.1007/s00330-017-5026-2>.
  73. Horvat N, Carlos Tavares Rocha C, Clemente Oliveira B, Petkovska I, Gollub MJ. MRI of rectal cancer: tumor staging, imaging techniques, and management. *Radiographics.* 2019;39(2):367–87. <https://doi.org/10.1148/rg.2019180114>.
  74. Tudyka V, Blomqvist L, Beets-Tan RG, Boelens PG, Valentini V, van de Velde CJ, et al. EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review. *Eur J Surg Oncol.* 2014;40(4):469–75. <https://doi.org/10.1016/j.ejso.2013.10.029>.
  75. Al-Sukhni E, Milot L, Fruitman M, Beyene J, Victor JC, Schmockler S, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. *Ann Surg Oncol.* 2012;19(7):2212–23. <https://doi.org/10.1245/s10434-011-2210-5>.
  76. Zhang G, Cai YZ, Xu GH. Diagnostic Accuracy of MRI for assessment of T category and circumferential resection margin involvement in patients with rectal cancer: a meta-analysis. *Dis Colon Rectum.* 2016;59(8):789–99. <https://doi.org/10.1097/DCR.0000000000000611>.
  77. Chan BPH, Patel R, Mbuagbaw L, Thabane L, Yaghoobi M. EUS versus magnetic resonance imaging in staging rectal adenocarcinoma: a diagnostic test accuracy meta-analysis. *Gastrointest Endosc.* 2019;90(2):196–203.e1. <https://doi.org/10.1016/j.gie.2019.04.217>.
  78. Li XT, Zhang XY, Sun YS, Tang L, Cao K. Evaluating rectal tumor staging with magnetic resonance imaging, computed tomography, and endoluminal ultrasound: a meta-analysis. *Medicine (Baltimore).* 2016;95(44):e5333. <https://doi.org/10.1097/MD.0000000000005333>.
  79. Puli SR, Reddy JB, Bechtold ML, Choudhary A, Antillon MR, Brugge WR. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review. *Ann Surg Oncol.* 2009;16(5): 1255–65. <https://doi.org/10.1245/s10434-009-0337-4>.
  80. de Jong EA, ten Berge JC, Dworkasing RS, Rijkers AP, van Eijck CH. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: a meta-analysis. *Surgery.* 2016;159(3):688–99. <https://doi.org/10.1016/j.surg.2015.10.019>.
  81. Zhao RS, Wang H, Zhou ZY, Zhou Q, Mulholland MW. Restaging of locally advanced rectal cancer with magnetic resonance imaging and endoluminal ultrasound after preoperative chemoradiotherapy: a systemic review and meta-analysis. *Dis Colon Rectum.* 2014;57(3):388–95. <https://doi.org/10.1097/DCR.0000000000000022>.
  82. Memon S, Lynch AC, Bressel M, Wise AG, Heriot AG. Systematic review and meta-analysis of the accuracy of MRI and endorectal ultrasound in the restaging and response assessment of rectal cancer following neoadjuvant therapy. *Colorectal Dis.* 2015;17(9):748–61. <https://doi.org/10.1111/codi.12976>.
  83. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. *Br J Surg.* 2006;93(10):1215–23. <https://doi.org/10.1002/bjs.5506>.
  84. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. *J Clin Oncol.* 2012;30(31):3827–33. <https://doi.org/10.1200/JCO.2012.42.9597>.
  85. Kasi A, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. *JAMA Netw Open.* 2020;3(12): e2030097. <https://doi.org/10.1001/jamanetworkopen.2020.30097>.
  86. Trial SRC, Cedermark B, Dahlberg M, Glimelius B, Pålman L, Rutqvist LE, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. *N Engl J Med.* 1997;336(14):980–7. <https://doi.org/10.1056/NEJM199704033361402>.
  87. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med.* 2004;351(17):1731–40. <https://doi.org/10.1056/NEJMoa040694>.
  88. Ma B, Gao P, Song Y, Huang X, Wang H, Xu Q, et al. Short-course radiotherapy in neoadjuvant treatment for rectal cancer: a systematic review and meta-analysis. *Clin Colorectal Cancer.* 2018;17(4):320–330.e5. <https://doi.org/10.1016/j.clcc.2018.07.014>.
  89. Qiaoli W, Yongping H, Wei X, Guoqiang X, Yunhe J, Qiuyan L, et al. Preoperative short-course radiotherapy (5 × 5 Gy) with delayed surgery versus preoperative long-course radiotherapy for locally resectable rectal cancer: a meta-analysis. *Int J Colorectal Dis.* 2019;34(12):2171–83. <https://doi.org/10.1007/s00384-019-03433-9>.
  90. Wang X, Zheng B, Lu X, Bai R, Feng L, Wang Q, et al. Preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer: meta-analysis with trial sequential analysis of long-term survival data. *Plos One.* 2018;13(7):e0200142. <https://doi.org/10.1371/journal.pone.0200142>.
  91. Zhou ZR, Liu SX, Zhang TS, Chen LX, Xia J, Hu ZD, et al. Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and meta-analysis. *Surg Oncol.* 2014;23(4):211–21. <https://doi.org/10.1016/j.suronc.2014.10.003>.
  92. Yu Y, Li Y, Xu C, Zhang Z, Zhang X. Comparison of long course and short course preoperative radiotherapy in the treatment of locally advanced



- rectal cancer: a systematic review and meta-analysis. *Rev Esp Enferm Dig.* 2019;111(1):17–27. <https://doi.org/10.17235/reed.2018.5674/2018>.
93. Francois E, Pernot M, Ronchin P, Nouhaud E, Martel Lafay I, Pascal A, et al. NACRE: a randomized study comparing short course radiotherapy with radiochemotherapy for locally advanced rectal cancers in the elderly—Preliminary results. *J Clin Oncol.* 2021;39(3\_suppl):4–4.
94. Wiltink LM, Nout RA, van der Voort van Zyp JR, Ceha HM, Fiocco M, Meershoek-Klein Kranenbarg E, et al. Long-term health-related quality of life in patients with rectal cancer after preoperative short-course and long-course (chemo) radiotherapy. *Clin Colorectal Cancer.* 2016;15(3):e93–9. <https://doi.org/10.1016/j.clcc.2016.02.012>.
95. McLachlan SA, Fisher RJ, Zalberg J, Solomon M, Burmeister B, Goldstein D, et al. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). *Eur J Cancer.* 2016;55:15–26. <https://doi.org/10.1016/j.ejca.2015.10.060>.
96. Pietrzak L, Bujko K, Nowacki MP, Kepka L, Oledzki J, Rutkowski A, et al. Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial. *Radiother Oncol.* 2007;84(3):217–25. <https://doi.org/10.1016/j.radonc.2007.07.007>.
97. Chen TY, Wiltink LM, Nout RA, Meershoek-Klein Kranenbarg E, Laurberg S, Marijnen CA, et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. *Clin Colorectal Cancer.* 2015;14(2):106–14. <https://doi.org/10.1016/j.clcc.2014.12.007>.
98. NCCN Guidelines Insights: Rectal Cancer. Version 6. 2020. <https://jnccn.org/view/journals/jnccn/18/7/article-p806.xml>. Accessed 11 Mar 2021.
99. Wu H, Fang C, Huang L, Fan C, Wang C, Yang L, Li Y, Zhou Z. Short-course radiotherapy with immediate or delayed surgery in rectal cancer: a meta-analysis. *Int J Surg.* 2018;56:195–202. <https://doi.org/10.1016/j.ijsu.2018.05.031>.
100. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. *Lancet.* 2009;374(9696):1196–208. [https://doi.org/10.1016/S0140-6736\(09\)61460-4](https://doi.org/10.1016/S0140-6736(09)61460-4).
101. Jafari MD, Jafari F, Halabi WJ, Nguyen VQ, Pigazzi A, Carmichael JC, et al. Colorectal cancer resections in the aging US population: a trend toward decreasing rates and improved outcomes. *JAMA Surg.* 2014;149(6):557–64. <https://doi.org/10.1001/jamasurg.2013.4930>.
102. Turrentine FE, Wang H, Simpson VB, Jones RS. Surgical risk factors, morbidity, and mortality in elderly patients. *J Am Coll Surg.* 2006;203(6):865–77. <https://doi.org/10.1016/j.jamcollsurg.2006.08.026>.
103. Hamel MB, Henderson WG, Khuri SF, Daley J. Surgical outcomes for patients aged 80 and older: morbidity and mortality from major noncardiac surgery. *J Am Geriatr Soc.* 2005;53(3):424–9. <https://doi.org/10.1111/j.1532-5415.2005.53159.x>.
104. Ivanov J, Weisel RD, David TE, Naylor CD. Fifteen-year trends in risk severity and operative mortality in elderly patients undergoing coronary artery bypass graft surgery. *Circulation.* 1998;97(7):673–80. <https://doi.org/10.1161/01.cir.97.7.673>.
105. Haverkamp MP, de Roos MA, Ong KH. The ERAS protocol reduces the length of stay after laparoscopic colectomies. *Surg Endosc.* 2012;26(2):361–7. <https://doi.org/10.1007/s00464-011-1877-9>.
106. Pędziwiatr M, Mavrikis J, Witowski J, Adamos A, Major P, Nowakowski M, et al. Current status of enhanced recovery after surgery (ERAS) protocol in gastrointestinal surgery. *Med Oncol.* 2018;35(6):95. <https://doi.org/10.1007/s12032-018-1153-0>.
107. Damanian R, Cocieru A. Impact of enhanced recovery after surgery protocols on postoperative morbidity and mortality in patients undergoing routine hepatectomy: review of the current evidence. *Ann Transl Med.* 2017;5(17):341. <https://doi.org/10.21037/atm.2017.07.04>.
108. Bagnall NM, Malietzis G, Kennedy RH, Athanasiou T, Faiz O, Darzi A. A systematic review of enhanced recovery care after colorectal surgery in elderly patients. *Colorectal Dis.* 2014;16(12):947–56. <https://doi.org/10.1111/codi.12718>.
109. Wang Q, Suo J, Jiang J, Wang C, Zhao YQ, Cao X. Effectiveness of fast-track rehabilitation vs conventional care in laparoscopic colorectal resection for elderly patients: a randomized trial. *Colorectal Dis.* 2012;14(8):1009–13. <https://doi.org/10.1111/j.1463-1318.2011.02855.x>.
110. Jia Y, Jin G, Guo S, Gu B, Jin Z, Gao X, et al. Fast-track surgery decreases the incidence of postoperative delirium and other complications in elderly patients with colorectal carcinoma. *Langenbecks Arch Surg.* 2014;399(1):77–84. <https://doi.org/10.1007/s00423-013-1151-9>.
111. Studniarek A, Borsuk DJ, Marecik SJ, Park JJ, Kochar K. Enhanced recovery after surgery protocols. Does frailty play a role? *Am Surg.* 2020: 3134820956357. <https://doi.org/10.1177/0003134820956357>.
112. Baek SJ, Kim SH, Kim SY, Shin JW, Kwak JM, Kim J. The safety of a “fast-track” program after laparoscopic colorectal surgery is comparable in older patients as in younger patients. *Surg Endosc.* 2013;27(4):1225–32. <https://doi.org/10.1007/s00464-012-2579-7>.
113. Gilardi F, Scarcella P, Proietti MG, Capobianco G, Rocco G, Capanna A, et al. Frailty as a predictor of mortality and hospital services use in older adults: a cluster analysis in a cohort study. *Eur J Public Health.* 2018;28(5):842–6. <https://doi.org/10.1093/eurpub/cky006>.
114. Fagard K, Wolthuis A, D’Hoore A, Verhaegen M, Tournoy J, Flamaing J, et al. A systematic review of the intervention components, adherence and outcomes of enhanced recovery programmes in older patients undergoing elective colorectal surgery. *BMC Geriatr.* 2019;19(1):157. <https://doi.org/10.1186/s12877-019-1158-3>.
115. Garner BH, Anderson DJ. Surgical site infections: an update. *Infect Dis Clin North Am.* 2016;30(4):909–29. <https://doi.org/10.1016/j.idc.2016.07.010>.
116. Bellows CF, Mills KT, Kelly TN, Gagliardi G. Combination of oral non-absorbable and intravenous antibiotics versus intravenous antibiotics alone in the prevention of surgical site infections after colorectal surgery: a meta-analysis of randomized controlled trials. *Tech Coloproctol.* 2011;15(4):385–95. <https://doi.org/10.1007/s10151-011-0714-4>.
117. Rollins KE, Javanmard-Emamghissi H, Acheson AG, Lobo DN. The role of oral antibiotic preparation in elective colorectal surgery: a meta-analysis. *Ann Surg.* 2019;270(1):43–58. <https://doi.org/10.1097/SLA.0000000000003145>.
118. Mulder T, Kluytmans JAJW. Oral antibiotics prior to colorectal surgery: do they have to be combined with mechanical bowel preparation? *Infect Control Hosp Epidemiol.* 2019;40(8):922–7. <https://doi.org/10.1017/ice.2019.157>.
119. McSorley ST, Steele CW, McMahon AJ. Meta-analysis of oral antibiotics, in combination with preoperative intravenous antibiotics and mechanical bowel preparation the day before surgery, compared with intravenous antibiotics and mechanical bowel preparation alone to reduce surgical-site infections in elective colorectal surgery. *BJS Open.* 2018;2(4):185–94. <https://doi.org/10.1002/bjs5.68>.
120. Khorasani S, Dossa F, McKechnie T, Englesakis M, Brar MS, de Buck van Overstraeten A. Association between preoperative oral antibiotics and the incidence of postoperative clostridium difficile infection in adults undergoing elective colorectal resection: a systematic review and meta-analysis. *Dis Colon Rectum.* 2020;63(4):545–61. <https://doi.org/10.1097/DCR.0000000000001619>.
121. Espin Basany E, Solís-Peña A, Pellino G, Kreisler E, Fracalvieri D, Muñelo-Lorenzo M, et al. Preoperative oral antibiotics and surgical-site infections in colon surgery (ORALEV): a multicentre, single-blind, pragmatic, randomised controlled trial. *Lancet Gastroenterol Hepatol.* 2020;5(8):729–38. [https://doi.org/10.1016/S2468-1253\(20\)30075-3](https://doi.org/10.1016/S2468-1253(20)30075-3).
122. Marinello FG, Curell A, Tapiolas I, Pellino G, Vallrbera F, Espin E. Systematic review of functional outcomes and quality of life after transanal endoscopic microsurgery and transanal minimally invasive surgery: a word of caution. *Int J Colorectal Dis.* 2020;35(1):51–67. <https://doi.org/10.1007/s00384-019-03439-3>.
123. Kennedy ML, Lubowski DZ, King DW. Transanal endoscopic microsurgery excision: is anorectal function compromised? *Dis Colon Rectum.* 2002;45(5):601–4. <https://doi.org/10.1007/s10350-004-6252-7>.
124. Mora López L, Serra Aracil X, Hermoso Bosch J, Rebaso P, Navarro SS. Study of anorectal function after transanal endoscopic surgery. *Int J Surg.* 2015;13:142–7. <https://doi.org/10.1016/j.ijsu.2014.11.021>.
125. Allaix ME, Rebecchi F, Giaccone C, Mistrangelo M, Morino M. Long-term functional results and quality of life after transanal endoscopic microsurgery. *Br J Surg.* 2011;98(11):1635–43. <https://doi.org/10.1002/bjs.7584>.
126. Restivo A, Zorcolo L, D’Alia G, Cocco F, Cossu A, Scintu F, et al. Risk of complications and long-term functional alterations after local excision of rectal tumors with transanal endoscopic microsurgery (TEM). *Int J Colorectal Dis.* 2016;31(2):257–66. <https://doi.org/10.1007/s00384-015-2371-y>.
127. Jin Z, Yin L, Xue L, Lin M, Zheng Q. Anorectal functional results after transanal endoscopic microsurgery in benign and early malignant tumors. *World J Surg.* 2010;34(5):1128–32. <https://doi.org/10.1007/s00268-010-0475-7>.

128. Barendse RM, Oors JM, de Graaf EJ, Bemelman WA, Fockens P, Dekker E, et al. The effect of endoscopic mucosal resection and transanal endoscopic microsurgery on anorectal function. *Colorectal Dis.* 2013;15(9):e534–41. <https://doi.org/10.1111/codi.12311>.
129. Doornebosch PG, Tollenaar RA, Gosselink MP, Stassen LP, Dijkhuis CM, Schouten WR, et al. Quality of life after transanal endoscopic microsurgery and total mesorectal excision in early rectal cancer. *Colorectal Dis.* 2007;9(6):553–8. <https://doi.org/10.1111/j.1463-1318.2006.01186.x>.
130. Planting A, Phang PT, Raval MJ, Brown CJ. Transanal endoscopic microsurgery: impact on fecal incontinence and quality of life. *Can J Surg.* 2013;56(4):243–8. <https://doi.org/10.1503/cjs.028411>.
131. Verseveld M, Barendse RM, Gosselink MP, Verhoef C, de Graaf EJ, Doornebosch PG. Transanal minimally invasive surgery: impact on quality of life and functional outcome. *Surg Endosc.* 2016;30(3):1184–7. <https://doi.org/10.1007/s00464-015-4326-3>.
132. Lezoche E, Paganini AM, Fabiani B, Balla A, Vestri A, Pescatori L, et al. Quality-of-life impairment after endoluminal locoregional resection and laparoscopic total mesorectal excision. *Surg Endosc.* 2014;28(1):227–34. <https://doi.org/10.1007/s00464-013-3166-2>.
133. Cataldo PA, O'Brien S, Osler T. Transanal endoscopic microsurgery: a prospective evaluation of functional results. *Dis Colon Rectum.* 2005;48(7):1366–71. <https://doi.org/10.1007/s10350-005-0031-y>.
134. Ghiselli R, Ortenzi M, Cardinali L, Skrami E, Gesuita R, Guerrieri M. Functional outcomes after TEM in patients with complete clinical response after neoadjuvant chemoradiotherapy. *Surg Endosc.* 2017;31(7):2997–3003. <https://doi.org/10.1007/s00464-016-5321-z>.
135. Hompes R, Ashraf SQ, Gosselink MP, van Dongen KW, Mortensen NJ, Lindsey I, et al. Evaluation of quality of life and function at 1 year after transanal endoscopic microsurgery. *Colorectal Dis.* 2015;17(2):054–61. <https://doi.org/10.1111/codi.12858>.
136. D'Ambrosio G, Balla A, Mattei F, Quaresima S, De Laurentis F, Paganini AM. Quality of life after endoluminal loco-regional resection (ELRR) by transanal endoscopic microsurgery (TEM). *Ann Ital Chir.* 2015;86(1):56–60.
137. Arezzo A, Arolfo S, Allai ME, Munoz F, Cassoni P, Monagheddu C, et al. Results of neoadjuvant short-course radiation therapy followed by transanal endoscopic microsurgery for T1-t2 n0 extraperitoneal rectal cancer. *Int J Radiat Oncol Biol Phys.* 2015;92(2):299–306. <https://doi.org/10.1016/j.ijrobp.2015.01.024>.
138. Karakayali FY, Tezcaner T, Moray G. Anorectal function and outcomes after transanal minimally invasive surgery for rectal tumors. *J Minim Access Surg.* 2015;11(4):257–62. <https://doi.org/10.4103/0972-9941.152094>.
139. Veereman G, Vluyen J, Robays J, Fairon N, Stordeur S, Rolfo C, et al. Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage I rectal cancer: a real standard? *Crit Rev Oncol Hematol.* 2017;114:43–52. <https://doi.org/10.1016/j.critrevonc.2017.03.008>.
140. Kidane B, Chadi SA, Kanters S, Colquhoun PH, Ott MC. Local resection compared with radical resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis. *Dis Colon Rectum.* 2015;58(1):122–40. <https://doi.org/10.1097/DCR.0000000000000293>.
141. Lu JY, Lin GL, Qiu HZ, Xiao Y, Wu B, Zhou JL. Comparison of transanal endoscopic microsurgery and total mesorectal excision in the treatment of T1 rectal cancer: a meta-analysis. *Plos One.* 2015;10(10):e0141427. <https://doi.org/10.1371/journal.pone.0141427>.
142. Sajid MS, Farag S, Leung P, Sains P, Miles WF, Baig MK. Systematic review and meta-analysis of published trials comparing the effectiveness of transanal endoscopic microsurgery and radical resection in the management of early rectal cancer. *Colorectal Dis.* 2014;16(1):2–14. <https://doi.org/10.1111/codi.12474>.
143. Sgourakis G, Lanitis S, Gockel I, Kontovounisios C, Karaliotis C, Tsiptsis K, et al. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes. *Am Surg.* 2011;77(6):761–72.
144. Winde G, Blasius G, Herwig R, Lügering N, Keller R, Fischer R. Benefit in therapy of superficial rectal neoplasms objectivized: Transanal endoscopic microsurgery (TEM) compared to surgical standards. *Minim Invasive Ther Allied Technol.* 1997;6:4315–23. <https://doi.org/10.3109/13645709709153083>.
145. Chen YY, Liu ZH, Zhu K, Shi PD, Yin L. Transanal endoscopic microsurgery versus laparoscopic lower anterior resection for the treatment of T1-2 rectal cancers. *Hepatogastroenterology.* 2013;60(124):727–32. <https://doi.org/10.5754/hge12868>.
146. De Graaf EJ, Doornebosch PG, Tollenaar RA, Meershoek-Klein Kranenbarg E, de Boer AC, Bekkering FC, et al. Transanal endoscopic microsurgery versus total mesorectal excision of T1 rectal adenocarcinomas with curative intention. *Eur J Surg Oncol.* 2009;35(12):1280–5. <https://doi.org/10.1016/j.ejso.2009.05.001>.
147. Oh BY, Yun HR, Kim SH, Yun SH, Kim HC, Lee WY, et al. Features of late recurrence following transanal local excision for early rectal cancer. *Dis Colon Rectum.* 2015;58(11):1041–7. <https://doi.org/10.1097/DCR.0000000000000456>.
148. Melnitchouk N, Fields AC, Lu P, Scully RE, Powell AC, Maldonado L, et al. Local versus radical excision of early distal rectal cancers: a National Cancer Database analysis. *Ann Surg Oncol.* 2020;27(7):2169–76. <https://doi.org/10.1245/s10434-019-08155-4>.
149. Saraste D, Gunnarsson U, Janson M. Local excision in early rectal cancer—outcome worse than expected: a population based study. *Eur J Surg Oncol.* 2013;39(6):634–9. <https://doi.org/10.1016/j.ejso.2013.01.004>.
150. Borstlap WA, Tanis PJ, Koedam TW, Marijnen CA, Cunningham C, Dekker E, et al. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. *BMC Cancer.* 2016;16:513. <https://doi.org/10.1186/s12885-016-2557-x>.
151. Chen H, George BD, Kaufman HS, Malaki MB, Mortensen NJ, Kettlewell MG. Endoscopic transanal resection provides palliation equivalent to transabdominal resection in patients with metastatic rectal cancer. *J Gastrointest Surg.* 2001;5(3):282–6. [https://doi.org/10.1016/s1091-255x\(01\)80049-4](https://doi.org/10.1016/s1091-255x(01)80049-4).
152. Peltrini R, Sacco M, Luglio G, Bucci L. Local excision following chemoradiotherapy in T2-T3 rectal cancer: current status and critical appraisal. *Updates Surg.* 2020;72(1):29–37. <https://doi.org/10.1007/s13304-019-00689-2>.
153. Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. *Lancet Oncol.* 2008;9(5):494–501. [https://doi.org/10.1016/S1470-2045\(08\)70129-3](https://doi.org/10.1016/S1470-2045(08)70129-3).
154. Hoendevangers S, Sparreboom CL, Intven MPW, Lange JF, Verkooyen HM, Doornebosch PG, van Grevenstein WMU; Dutch ColoRectal Audit. The effect of neoadjuvant short-course radiotherapy and delayed surgery versus chemoradiation on postoperative outcomes in locally advanced rectal cancer patients - a propensity score matched nationwide audit-based study. *Eur J Surg Oncol.* 2020;46(9):1605–12. <https://doi.org/10.1016/j.ejso.2020.03.002>.
155. Lezoche E, Baldarelli M, Lezoche G, Paganini AM, Gesuita R, Guerrieri M. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. *Br J Surg.* 2012;99(9):1211–8. <https://doi.org/10.1002/bjs.8821>.
156. Shaikh I, Askari A, Ouri S, Warusavitarne J, Athanasiou T, Faiz O. Oncological outcomes of local excision compared with radical surgery after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis. *Int J Colorectal Dis.* 2015;30(1):19–29. <https://doi.org/10.1007/s00384-014-2045-1>.
157. Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. *Lancet Oncol.* 2015;16(15):1537–46. [https://doi.org/10.1016/S1470-2045\(15\)00215-6](https://doi.org/10.1016/S1470-2045(15)00215-6).
158. Rullier E, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. *Lancet.* 2017;390(10093):469–79. [https://doi.org/10.1016/S0140-6736\(17\)31056-5](https://doi.org/10.1016/S0140-6736(17)31056-5).
159. Stijns RCH, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens JJME, van Meerten E, et al. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS study. *JAMA Surg.* 2019;154(1):47–54. <https://doi.org/10.1001/jamasurg.2018.3752>.
160. D'Ambrosio G, Paganini AM, Balla A, Quaresima S, Ursi P, Bruzzone P, et al. Quality of life in non-early rectal cancer treated by neoadjuvant radiochemotherapy and endoluminal loco-regional resection (ELRR) by transanal endoscopic microsurgery (TEM) versus laparoscopic total mesorectal excision. *Surg Endosc.* 2016;30(2):504–11. <https://doi.org/10.1007/s00464-015-4232-8>.
161. D'Ambrosio G, Picchetto A, Campo S, Palma R, Panetta C, De Laurentis F, et al. Quality of life in patients with loco-regional rectal cancer after ELRR by TEM versus VLS TME after nChRT: long-term results. *Surg Endosc.* 2019;33(3):941–8. <https://doi.org/10.1007/s00464-018-6583-4>.

162. Lezoche E, Guerrieri M, Paganini AM, Baldarelli M, De Sanctis A, Lezoche G. Long-term results in patients with T2-3 N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic microsurgery. *Br J Surg*. 2005; 92(12):1546–52. <https://doi.org/10.1002/bjs.1178>.
163. Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech JJ, Valverde A, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. *Lancet Gastroenterol Hepatol*. 2020;5(5):465–74. [https://doi.org/10.1016/S2468-1253\(19\)30410-8](https://doi.org/10.1016/S2468-1253(19)30410-8).
164. Rombouts AJM, Al-Najami I, Abbott NL, Appelt A, Baatrup G, Bach S, Bhangu A, Garm Spindler KL, Gray R, Handley K, Kaur M, Kerkhof E, Kronborg CJ, Magill L, Marijnen CAM, Nagtegaal ID, Nyvang L, Peters FP, Pfeiffer P, Punt C, Quirke P, Sebag-Montefiore D, Teo M, West N, de Wilt JHW; for STAR-TREC Collaborative Group. Can we save the rectum by watchful waiting or TRAN SANAL microsurgery following (chemo) radiotherapy versus total mesorectal excision for early rectal cancer (STAR-TREC study)? protocol for a multicentre, randomised feasibility study. *BMJ Open*. 2017;12(2):e019474. <https://doi.org/10.1136/bmjopen-2017-019474>.
165. Bach SP, Gilbert A, Brock K, Korsgen S, Geh I, Hill J, et al. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. *Lancet Gastroenterol Hepatol*. 2021; 6(2):92–105. [https://doi.org/10.1016/S2468-1253\(20\)30333-2](https://doi.org/10.1016/S2468-1253(20)30333-2).
166. Arezzo A, Lo Secco G, Passera R, Esposito L, Guerrieri M, Orteni M, et al. Individual participant data pooled-analysis of risk factors for recurrence after neoadjuvant radiotherapy and transanal local excision of rectal cancer: the PARTLE study. *Tech Coloproctol*. 2019;23(9):831–42. <https://doi.org/10.1007/s10151-019-02049-z>.
167. Pucciarelli S, Giandomenico F, De Paoli A, Gavaruzzi T, Lotto L, Mantello G, et al. Bowel function and quality of life after local excision or total mesorectal excision following chemoradiotherapy for rectal cancer. *Br J Surg*. 2017;104(1):138–47. <https://doi.org/10.1002/bjs.10318>.
168. Martens MH, Maas M, Heijnen LA, Lambregts DM, Leijtens JW, Stassen LP, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. *J Natl Cancer Inst*. 2016;108(12):djw171. <https://doi.org/10.1093/jnci/djw171>.
169. van Oostendorp SE, Smits LJH, Vroom Y, Detering R, Heymans MW, Moons LMG, et al. Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment. *Br J Surg*. 2020;107(13):1719–30. <https://doi.org/10.1002/bjs.12040>.
170. Borstlap WA, Coeymans TJ, Tanis PJ, Marijnen CA, Cunningham C, Bemelman WA, et al. Meta-analysis of oncological outcomes after local excision of pT1-2 rectal cancer requiring adjuvant (chemo)radiotherapy or completion surgery. *Br J Surg*. 2016;103(9):1105–16. <https://doi.org/10.1002/bjs.10163>.
171. Cross AJ, Kornfalt P, Lidin J, Buchwald P, Frizelle FA, Eglinton TW. Surgical outcomes following colorectal cancer resections in patients aged 80 years and over: results from the Australia and New Zealand Binational Colorectal Cancer Audit. *Colorectal Dis*. 2020. <https://doi.org/10.1111/codi.15445>.
172. Martínez-Pérez A, Carra MC, Brunetti F, de'Angelis N. Pathologic Outcomes of laparoscopic vs open mesorectal excision for rectal cancer: a systematic review and meta-analysis. *JAMA Surg*. 2017 Apr 19;152(4):e165665. <https://doi.org/10.1001/jamasurg.2016.5665>.
173. Zheng J, Feng X, Yang Z, Hu W, Luo Y, Li Y. The comprehensive therapeutic effects of rectal surgery are better in laparoscopy: a systematic review and meta-analysis. *Oncotarget*. 2017;8(8):12717–29. <https://doi.org/10.18632/oncotarget.14215>.
174. Lujan J, Valero G, Hernandez Q, Sanchez A, Frutos MD, Parrilla P. Randomized clinical trial comparing laparoscopic and open surgery in patients with rectal cancer. *Br J Surg*. 2009;96(9):982–9. <https://doi.org/10.1002/bjs.6662>.
175. van der Pas MH, Haglund E, Cuesta MA, Fürst A, Lacy AM, Hop WC, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *Lancet Oncol*. 2013;14(3):210–8. [https://doi.org/10.1016/S1470-2045\(13\)70016-0](https://doi.org/10.1016/S1470-2045(13)70016-0).
176. Devoto L, Celentano V, Cohen R, Khan J, Chand M. Colorectal cancer surgery in the very elderly patient: a systematic review of laparoscopic versus open colorectal resection. *Int J Colorectal Dis*. 2017;32(9):1237–42. <https://doi.org/10.1007/s00384-017-2848-y>.
177. Zhou S, Wang X, Zhao C, Liu Q, Zhou H, Zheng Z, et al. Laparoscopic vs open colorectal cancer surgery in elderly patients: short- and long-term outcomes and predictors for overall and disease-free survival. *BMC Surg*. 2019;19(1):137. <https://doi.org/10.1186/s12893-019-0596-3>.
178. Landi F, Vallibera F, Rivera JP, Bertoli P, Armengol M, Espín E. Morbidity after laparoscopic and open rectal cancer surgery: a comparative analysis of morbidity in octogenarians and younger patients. *Colorectal Dis*. 2016;18(5): 459–67. <https://doi.org/10.1111/codi.13136>.
179. Manceau G, Hain E, Maggiori L, Mongin C, Prost À la Denise J, Panis Y. Is the benefit of laparoscopy maintained in elderly patients undergoing rectal cancer resection? An analysis of 446 consecutive patients. *Surg Endosc*. 2017;31(2):632–42. <https://doi.org/10.1007/s00464-016-5009-4>.
180. Otsuka K, Kimura T, Hakozaki M, Yaegashi M, Matsuo T, Fujii H, et al. Comparative benefits of laparoscopic surgery for colorectal cancer in octogenarians: a case-matched comparison of short- and long-term outcomes with middle-aged patients. *Surg Today*. 2017;47(5):587–94. <https://doi.org/10.1007/s00595-016-1410-9>.
181. Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebbski VJ, et al. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. *JAMA*. 2015;314(13):1356–63. <https://doi.org/10.1001/jama.2015.12009> PMID: 26441180.
182. Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, et al. Effect of Laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. *JAMA*. 2015;314(13):1346–55. <https://doi.org/10.1001/jama.2015.10529>.
183. Fleshman J, Branda ME, Sargent DJ, Boller AM, George V, Abbas MA, et al. Disease-free survival and local recurrence for laparoscopic resection compared with open resection of stage II to III rectal cancer: follow-up results of the ACOSOG Z6051 randomized controlled trial. *Ann Surg*. 2019; 269(4):589–95. <https://doi.org/10.1097/SLA.0000000000003002>.
184. Sung SY, Jang HS, Kim SH, Jeong JU, Jeong S, Song JH, et al. Oncologic outcome and morbidity in the elderly rectal cancer patients after preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional and case-matched control study. *Ann Surg*. 2019;269(1):108–13. <https://doi.org/10.1097/SLA.0000000000002443>.
185. de'Angelis N, Baldini C, Brustia R, Pessaux P, Sommacale D, Laurent A, Le Roy B, Tacher V, Kobeiter H, Luciani A, Paillaud E, Aparicio T, Canui-Poitrine F, Liuu E. Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis. *PLoS One*. 2020 Apr 22;15(4):e0230914. <https://doi.org/10.1371/journal.pone.0230914>.
186. van Harten MJ, Greenwood EB, Bedrikovetski S, Duci-Venkata NN, Hunter RA, Kroon HM, et al. Minimally invasive surgery in elderly patients with rectal cancer: an analysis of the Bi-National Colorectal Cancer Audit (BCCA). *Eur J Surg Oncol*. 2020;46(9):1649–55. <https://doi.org/10.1016/j.ejso.2020.03.224>.
187. Hoshino N, Fukui Y, Hida K, Sakai Y. Short-term outcomes of laparoscopic surgery for colorectal cancer in the elderly versus non-elderly: a systematic review and meta-analysis. *Int J Colorectal Dis*. 2019;34(3):377–86. <https://doi.org/10.1007/s00384-019-03234-0>.
188. Peltrini R, Imperatore N, Carannante F, Cucurullo D, Capolupo GT, Bracale U, Caricato M, Corcione F. Age and comorbidities do not affect short-term outcomes after laparoscopic rectal cancer resection in elderly patients. A multi-institutional cohort study in 287 patients. *Updates Surg*. 2021. <https://doi.org/10.1007/s13304-021-00990-z>.
189. Roscio F, Boni L, Clerici F, Frattini P, Cassinotti E, Scandroglio I. Is laparoscopic surgery really effective for the treatment of colon and rectal cancer in very elderly over 80 years old? A prospective multicentric case-control assessment. *Surg Endosc*. 2016;30(10):4372–82. <https://doi.org/10.1007/s00464-016-4755-7>.
190. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. *JAMA*. 2017;318(16):1569–80. <https://doi.org/10.1001/jama.2017.7219>.
191. Zhang X, Wei Z, Bie M, Peng X, Chen C. Robot-assisted versus laparoscopic-assisted surgery for colorectal cancer: a meta-analysis. *Surg Endosc*. 2016; 30(12):5601–14. <https://doi.org/10.1007/s00464-016-4892-z>.
192. Wang X, Cao G, Mao W, Lao W, He C. Robot-assisted versus laparoscopic surgery for rectal cancer: A systematic review and meta-analysis. *J Cancer Res Ther*. 2020;16(5):979–89. [https://doi.org/10.4103/jcrt.JCRT\\_533\\_18](https://doi.org/10.4103/jcrt.JCRT_533_18).
193. de'Angelis N, Abdalla S, Bianchi G, Memeo R, Charpy C, Petruccianni N, Sobhani I, Brunetti F. Robotic versus laparoscopic colorectal cancer surgery in elderly

- patients: a propensity score match analysis. *J Laparoendosc Adv Surg Tech A*. 2018;28(11):1334–45. <https://doi.org/10.1089/lap.2018.0115>.
194. Huang YJ, Kang YN, Huang YM, Wu AT, Wang W, Wei PL. Effects of laparoscopic vs robotic-assisted mesorectal excision for rectal cancer: an update systematic review and meta-analysis of randomized controlled trials. *Asian J Surg*. 2019;42(6):657–66. <https://doi.org/10.1016/j.asjsur.2018.11.007> Epub 2019 Jan 2. Erratum in: *Asian J Surg*. 2021 Jan;44(1):429.
195. Gavriilidis P, Wheeler J, Spinelli A, de'Angelis N, Simopoulos C, Di Saverio S. Robotic vs laparoscopic total mesorectal excision for rectal cancers: has a paradigm change occurred? A systematic review by updated meta-analysis. *Colorectal Dis*. 2020;22(11):1506–17. <https://doi.org/10.1111/codi.15084>.
196. Bromham N, Kallioinen M, Hoskin P, Davies RJ, Guideline Committee. Colorectal cancer: summary of NICE guidance. *BMJ*. 2020;368:m461. <https://doi.org/10.1136/bmj.m461>.
197. Fearhead NS, Acheson AG, Brown SR, Hancock L, Harikrishnan A, Kelly SB, et al. The ACPGBI recommends pause for reflection on transanal total mesorectal excision. *Colorectal Dis*. 2020;22(7):745–8. <https://doi.org/10.1111/codi.15143>.
198. Park JS, Choi GS, Kim SH, Kim HR, Kim NK, Lee KY, et al. Multicenter analysis of risk factors for anastomotic leakage after laparoscopic rectal cancer excision: the Korean laparoscopic colorectal surgery study group. *Ann Surg*. 2013;257(4):665–71. <https://doi.org/10.1097/SLA.0b013e31827b8ed9>.
199. Zhou S, Zhou H, Zheng Z, Liang J, Zhou Z, Wang X. Predictive risk factors for anastomotic leakage after anterior resection of rectal cancer in elderly patients over 80 years old: an analysis of 288 consecutive patients. *World J Surg Oncol*. 2019;17(1):112. <https://doi.org/10.1186/s12957-019-1655-z>.
200. Montedori A, Cirocchi R, Farinella E, Sciannoneo F, Abraha I. Covering ileo- or colostomy in anterior resection for rectal carcinoma. *Cochrane Database Syst Rev*. 2010;5:CD006878. <https://doi.org/10.1002/14651858.CD006878.pub2>.
201. Sparreboom CL, van Groningen JT, Lingsma HF, Wouters MWJM, Menon AG, Kleinrensink GJ, et al. Different Risk Factors for Early and Late Colorectal Anastomotic Leakage in a Nationwide Audit. *Dis Colon Rectum*. 2018;61(11):1258–66. <https://doi.org/10.1097/DCR.00000000000001202>.
202. Clausen FB, Dohrn N, Hölmich ER, Klein M, Gögenur I. Safety of early ileostomy closure: a systematic review and meta-analysis of randomized controlled trials. *Int J Colorectal Dis*. 2021;36(2):203–12. <https://doi.org/10.1007/s00384-020-03761-1>.
203. Robertson I, Leung E, Hughes D, Spiers M, Donnelly L, Mackenzie I, et al. Prospective analysis of stoma-related complications. *Colorectal Dis*. 2005;7(3):279–85. <https://doi.org/10.1111/j.1463-1318.2005.00785.x>.
204. Alves A, Panis Y, Lelong B, Doussset B, Benoist S, Vicaut E. Randomized clinical trial of early versus delayed temporary stoma closure after proctectomy. *Br J Surg*. 2008;95(6):693–8. <https://doi.org/10.1002/bjs.6212>.
205. Fielding A, Woods R, Moosvi SR, Wharton RQ, Speakman CTM, Kapur S, et al. Renal impairment after ileostomy formation: a frequent event with long-term consequences. *Colorectal Dis*. 2020;22(3):269–78. <https://doi.org/10.1111/codi.14866>.
206. Justiniano CF, Temple LK, Swanger AA, Xu Z, Speranza JR, Cellini C, et al. Readmissions With Dehydration After Ileostomy Creation: Rethinking Risk Factors. *Dis Colon Rectum*. 2018;61(11):1297–305. <https://doi.org/10.1097/DCR.0000000000001137>.
207. Robertson JP, Wells CI, Vather R, Bissett IP. Effect of Diversion Ileostomy on the Occurrence and Consequences of Chemotherapy-Induced Diarrhea. *Dis Colon Rectum*. 2016;59(3):194–200. <https://doi.org/10.1097/DCR.0000000000000531>.
208. Lordan JT, Heywood R, Shirol S, Edwards DP. Following anterior resection for rectal cancer, defunctioning ileostomy closure may be significantly delayed by adjuvant chemotherapy: a retrospective study. *Colorectal Dis*. 2007;9(5):420–2. <https://doi.org/10.1111/j.1463-1318.2006.01178.x>.
209. Gustafsson CP, Gunnarsson U, Dahlstrand U, Lindfors U. Loop-ileostomy reversal-patient-related characteristics influencing time to closure. *Int J Colorectal Dis*. 2018;33(5):593–600. <https://doi.org/10.1007/s00384-018-2994-x>.
210. Lasithiotakis K, Aghahoseini A, Alexander D. Is early reversal of defunctioning ileostomy a shorter, easier and less expensive operation? *World J Surg*. 2016;40(7):1737–40. <https://doi.org/10.1007/s00268-016-3448-7>.
211. Danielsen AK, Park J, Jansen JE, Bock D, Skullman S, Wedin A, et al. Early closure of a temporary ileostomy in patients with rectal cancer: a multicenter randomized controlled trial. *Ann Surg*. 2017;265(2):284–90. <https://doi.org/10.1097/SLA.0000000000001829>.
212. Kłęk S, Pisarska M, Milian-Ciesielska K, Cegielnny T, Choruz R, Salówka J, et al. Early closure of the protective ileostomy after rectal resection should become part of the Enhanced Recovery After Surgery (ERAS) protocol: a randomized, prospective, two-center clinical trial. *Wideochir Inne Tech Maloinwazyjne*. 2018;13(4):435–41. <https://doi.org/10.5114/wiitm.2018.79574>.
213. Gallyamov EA, Agapov MA, Lutsevich OE, Kubyskhin VA, Kakotkin WV, Tolstykh MP. Early ileostomy closure in patients with rectal cancer. Primary results of the randomized controlled multicenter trial. *Khirurgiya (Mosk)*. 2019;6(35–40). English, Russian. <https://doi.org/10.17116/hirurgia201906135>.
214. Bausys A, Kuliavas J, Dulskas A, Kryzauskas M, Pauza K, Kilius A, et al. Early versus standard closure of temporary ileostomy in patients with rectal cancer: a randomized controlled trial. *J Surg Oncol*. 2019;120(2):294–9. <https://doi.org/10.1002/jso.25488>.
215. Wang L, Chen X, Liao C, Wu Q, Luo H, Yi F, et al. Early versus late closure of temporary ileostomy after rectal cancer surgery: a meta-analysis. *Surg Today*. 2020. <https://doi.org/10.1007/s00595-020-02115-2>.
216. Cheng Z, Dong S, Bi D, Wang Y, Dai Y, Zhang X. Early versus late preventive ileostomy closure following colorectal surgery: systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. *Dis Colon Rectum*. 2021;64(1):128–37. <https://doi.org/10.1097/DCR.0000000000001839>.
217. Ng ZQ, Levitt M, Platell C. The feasibility and safety of early ileostomy reversal: a systematic review and meta-analysis. *ANZ J Surg*. 2020;90(9):1580–7. <https://doi.org/10.1111/ans.16079>.
218. Hsieh MC, Kuo LT, Chi CC, Huang WS, Chin CC. Pursestring closure versus conventional primary closure following stoma reversal to reduce surgical site infection rate: a meta-analysis of randomized controlled trials. *Dis Colon Rectum*. 2015;58(8):808–15. <https://doi.org/10.1097/DCR.0000000000000401>.
219. Ferrara F, Parini D, Bondurri A, Veltri M, Barbierato M, Pata F, et al. Italian guidelines for the surgical management of enteral stomas in adults. *Tech Coloproctol*. 2019;23(11):1037–56. <https://doi.org/10.1007/s10151-019-02099-3>.
220. Keane C, Park J, Öberg S, Wedin A, Bock D, O'Grady G, et al. Functional outcomes from a randomized trial of early closure of temporary ileostomy after rectal excision for cancer. *Br J Surg*. 2019;106(5):645–52. <https://doi.org/10.1002/bjs.11092>.
221. Park J, Danielsen AK, Angenete E, Bock D, Martinez AC, Haglind E, et al. Quality of life in a randomized trial of early closure of temporary ileostomy after rectal resection for cancer (EASY trial). *Br J Surg*. 2018;105(3):244–51. <https://doi.org/10.1002/bjs.10680>.
222. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. *Ann Surg*. 2004;240(4):711–7; discussion 717–8. <https://doi.org/10.1097/01.sla.0000141194.27992.32>.
223. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. *J Clin Oncol*. 2011;29(35):4633–40. <https://doi.org/10.1200/JCO.2011.37.7176>.
224. Li J, Liu H, Yin J, Liu S, Hu J, Du F, et al. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study. *Oncotarget*. 2015;6(39):42354–61. <https://doi.org/10.18632/oncotarget.6093>.
225. Smith RK, Fry RD, Mahmoud NN, Paulson EC. Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision. *Int J Colorectal Dis*. 2015;30(6):769–74. <https://doi.org/10.1007/s00384-015-2165-2>.
226. Araujo RO, Valadão M, Borges D, Linhares E, de Jesus JP, Ferreira CG, et al. Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. *Eur J Surg Oncol*. 2015;41(11):1456–63. <https://doi.org/10.1016/j.ejso.2015.08.156>.
227. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWW): an international multicentre registry study. *Lancet*. 2018;391(10139):2537–45. [https://doi.org/10.1016/S0140-6736\(18\)31078-X](https://doi.org/10.1016/S0140-6736(18)31078-X).
228. Fernandez LM, São Julião GP, Figueiredo NL, Beets GL, van der Valk MJM, Bahadoer RR, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait

- Database: a retrospective, international, multicentre registry study. *Lancet Oncol.* 2021;22(1):43–50. [https://doi.org/10.1016/S1470-2045\(20\)30557-X](https://doi.org/10.1016/S1470-2045(20)30557-X).
229. Li J, Li L, Yang L, Yuan J, Lv B, Yao Y, et al. Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. *Oncotarget.* 2016;7(28):44857–70. <https://doi.org/10.18632/oncotarget.8622>.
230. Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2017;2(7):501–13. [https://doi.org/10.1016/S2468-1253\(17\)30074-2](https://doi.org/10.1016/S2468-1253(17)30074-2).
231. Haak HE, Maas M, Lambregts DMJ, Beets-Tan RGH, Beets GL, Dutch Watch-and-Wait Consortium. Is watch and wait a safe and effective way to treat rectal cancer in older patients? *Eur J Surg Oncol.* 2020;46(3):358–62. <https://doi.org/10.1016/j.ejso.2020.01.005>.
232. Smith FM, Rao C, Oliva Perez R, Bujko K, Athanasiou T, Habr-Gama A, et al. Avoiding radical surgery improves early survival in elderly patients with rectal cancer, demonstrating complete clinical response after neoadjuvant therapy: results of a decision-analytic model. *Dis Colon Rectum.* 2015;58(2):159–71. <https://doi.org/10.1097/DCR.0000000000000281>.
233. AIOM linee guida Retto e Ano - Edition 2019. <https://www.aiom.it/linee-guida-aiom-neoplasie-del-retto-e-ano-2019/>. Accessed 14 Mar 2021.
234. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Rectal cancer. Version 1.2021-December 22, 2020. <https://www.nccn.org/default.aspx>. Accessed 14 Mar 2021.
235. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. *N Engl J Med.* 1994;331(8):502–7. <https://doi.org/10.1056/NEJM199408253310803>.
236. Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. *J Natl Cancer Inst.* 2000;92(5):388–96. <https://doi.org/10.1093/jnci/92.5.388>.
237. Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. *J Clin Oncol.* 2006;24(22):3542–7. <https://doi.org/10.1200/JCO.2005.04.9544>.
238. Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. *Lancet Oncol.* 2014;15(2):184–90. [https://doi.org/10.1016/S1470-2045\(13\)70599-0](https://doi.org/10.1016/S1470-2045(13)70599-0).
239. Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, Lupattelli M, et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). *Radiother Oncol.* 2014;113(2):223–9. <https://doi.org/10.1016/j.radonc.2014.10.006>.
240. Breugom AJ, van Gijn W, Muller EW, Berglund Å, van den Broek CBM, Fokstuen T, Gelderblom H, Kapiteijn E, Leer JWH, Marijnen CAM, Martijn H, Meershoek-Klein Kranenbarg E, Nagtegaal ID, Pahlman L, Punt CJA, Putter H, Roodvoets AGH, Rutten HJT, Steup WH, Glimelius B, van de Velde CJH. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. *Ann Oncol.* 2015;26(4):696–701. <https://doi.org/10.1093/annonc/mdl560>.
241. Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. *Lancet Oncol.* 2015;16(2):200–7. [https://doi.org/10.1016/S1470-2045\(14\)71199-4](https://doi.org/10.1016/S1470-2045(14)71199-4).
242. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. *Lancet Oncol.* 2014;15(11):1245–53. [https://doi.org/10.1016/S1470-2045\(14\)70377-8](https://doi.org/10.1016/S1470-2045(14)70377-8).
243. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2015;16(8):979–89. [https://doi.org/10.1016/S1470-2045\(15\)00159-X](https://doi.org/10.1016/S1470-2045(15)00159-X).
244. Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. *J Clin Oncol.* 2012;30(17):2036–8. <https://doi.org/10.1200/JCO.2012.41.6727>.
245. Liu SL, O'Brien P, Zhao Y, Hopman WM, Lamond N, Ramjeesingh R. Adjuvant treatment in older patients with rectal cancer: a population-based review. *Curr Oncol.* 2018;25(6):e499–506. <https://doi.org/10.3747/co.25.4102>.
246. Xu Z, Mohile SG, Tejani MA, Becerra AZ, Probst CP, Aquina CT, et al. Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: An NCDB analysis. *Cancer.* 2017;123(1):52–61. <https://doi.org/10.1002/cncr.30261>.
247. Jiang DM, Raissouni S, Mercer J, Kumar A, Goodwin R, Heng DY, et al. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer. *Ann Oncol.* 2015;26(10):2102–6. <https://doi.org/10.1093/annonc/mdv331>.
248. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. *J Clin Oncol.* 1999;17(8):2412–8. <https://doi.org/10.1200/JCO.1999.17.8.2412>.
249. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. *Ann Intern Med.* 2002;136(5):349–57. <https://doi.org/10.7326/0003-4819-136-5-200203050-00007>.
250. Neugut AI, Fleischauer AT, Sundararajan V, Mitra N, Heitjan DF, Jacobson JS, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. *J Clin Oncol.* 2002;20(11):2643–50. <https://doi.org/10.1200/JCO.2002.08.062>.
251. Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results–Medicare. *J Clin Oncol.* 2001;19(17):3712–8. <https://doi.org/10.1200/JCO.2001.19.17.3712>.
252. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol.* 2014;32(24):2595–603. <https://doi.org/10.1200/JCO.2013.54.8347>.
253. Engstrand J, Nilsson H, Strömberg C, Jonas E, Freedman J. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. *BMC Cancer.* 2018;18(1):78. <https://doi.org/10.1186/s12885-017-3925-x>.
254. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. *Clin Epidemiol.* 2012;4:283–301. <https://doi.org/10.2147/CLEP.S34285>.
255. Cook EJ, Welsh FK, Chandrakumar K, John TG, Rees M. Resection of colorectal liver metastases in the elderly: does age matter? *Colorectal Dis.* 2012;14(10):1210–6. <https://doi.org/10.1111/j.1463-1318.2012.02946.x>.
256. van Tuil T, Dhaif AA, Te Riele WW, van Ramshorst B, van Santvoort HC. Systematic review and meta-analysis of liver resection for colorectal metastases in elderly patients. *Dig Surg.* 2019;36(2):111–23. <https://doi.org/10.1159/000487274>.
257. Magouliotis DE, Tzovaras G, Diamantis A, Tasiopoulou VS, Zacharoulis D. A meta-analysis of liver-first versus classical strategy for synchronous colorectal liver metastases. *Int J Colorectal Dis.* 2020;35(3):537–46. <https://doi.org/10.1007/s00384-020-03503-3>.
258. Hajibandeh S, Hajibandeh S, Sultana A, Ferris G, Mwendwa J, Mohamedahmed AYY, et al. Simultaneous versus staged colorectal and hepatic resections for colorectal cancer with synchronous hepatic metastases: a meta-analysis of outcomes and clinical characteristics. *Int J Colorectal Dis.* 2020;35(9):1629–50. <https://doi.org/10.1007/s00384-020-03694-9>.
259. Kelly ME, Spolverato G, Lê GN, Mavros MN, Doyle F, Pawlik TM, et al. Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. *J Surg Oncol.* 2015;111(3):341–51. <https://doi.org/10.1002/jso.23819>.
260. Ghiasloo M, Pavlenko D, Verhaeghe M, Van Langenhove Z, Uytendaele O, Berardi G, et al. Surgical treatment of stage IV colorectal cancer with synchronous liver metastases: A systematic review and network meta-analysis. *Eur J Surg Oncol.* 2020;46(7):1203–13. <https://doi.org/10.1016/j.ejso.2020.02.040>.

261. Martínez-Cecilia D, Cipriani F, Shelat V, Ratti F, Tranchart H, Barkhatov L, et al. Laparoscopic versus open liver resection for colorectal metastases in elderly and octogenarian patients: a multicenter propensity score based analysis of short- and long-term outcomes. *Ann Surg.* 2017;265(6):1192–200. <https://doi.org/10.1097/SLA.0000000000002147>.
262. Syn NL, Kabir T, Koh YX, Tan HL, Wang LZ, Chin BZ, et al. Survival advantage of laparoscopic versus open resection for colorectal liver metastases: a meta-analysis of individual patient data from randomized trials and propensity-score matched studies. *Ann Surg.* 2020;272(2):253–65. <https://doi.org/10.1097/SLA.0000000000003672>.
263. Saida Y. Current status of colonic stent for obstructive colorectal cancer in Japan; a review of the literature. *J Anus Rectum Colon.* 2019;3(3):99–105. <https://doi.org/10.23922/jarc.2019-009>.
264. Matsuzawa T, Ishida H, Yoshida S, Isayama H, Kuwai T, Maetani I, et al. A Japanese prospective multicenter study of self-expandable metal stent placement for malignant colorectal obstruction: short-term safety and efficacy within 7 days of stent procedure in 513 cases. *Gastrointest Endosc.* 2015;82(4):697–707.e1. <https://doi.org/10.1016/j.gie.2015.03.1978>.
265. Gavriilidis P, de'Angelis N, Wheeler J, Askari A, Di Saverio S, Davies JR. Diversion, resection, or stenting as a bridge to surgery for acute neoplastic left-sided colonic obstruction: a systematic review and network meta-analysis of studies with curative intent. *Ann R Coll Surg Engl.* 2021;103(4): 235–44. <https://doi.org/10.1308/rcsann.2020.7137>.
266. Song HY, Kim JH, Kim KR, Shin JH, Kim HC, Yu CS, et al. Malignant rectal obstruction within 5 cm of the anal verge: is there a role for expandable metallic stent placement? *Gastrointest Endosc.* 2008;68(4):713–20. <https://doi.org/10.1016/j.gie.2007.12.051>.
267. Tao K, Kuwai T, Ishaq S, Enomoto T, Saida Y. Newly developed proximal release-type colonic stent placement for malignant lower rectal obstruction. *VideoGIE.* 2020;5(6):250–1. <https://doi.org/10.1016/j.vgie.2020.02.003>.
268. van Hooff JE, van Halsema EE, Vanbiervliet G, Beets-Tan RG, DeWitt JM, Donnellan F, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy.* 2014;46(11):990–1053. <https://doi.org/10.1055/s-0034-1390700>.
269. Arezzo A, Passera R, Lo Secco G, Verra M, Bonino MA, Targarona E, et al. Stent as bridge to surgery for left-sided malignant colonic obstruction reduces adverse events and stoma rate compared with emergency surgery: results of a systematic review and meta-analysis of randomized controlled trials. *Gastrointest Endosc.* 2017;86(3):416–26. <https://doi.org/10.1016/j.gie.2017.03.1542>.
270. Wang X, He J, Chen X, Yang Q. Stenting as a bridge to resection versus emergency surgery for left-sided colorectal cancer with malignant obstruction: A systematic review and meta-analysis. *Int J Surg.* 2017;48:64–8. <https://doi.org/10.1016/j.ijsu.2017.10.004>.
271. Yang P, Lin XF, Lin K, Li W. The role of stents as bridge to surgery for acute left-sided obstructive colorectal cancer: meta-analysis of randomized controlled trials. *Rev Invest Clin.* 2018;70(6):269–78. <https://doi.org/10.24875/RIC.18002516>.
272. Allievi N, Ceresoli M, Fugazzola P, Montori G, Coccolini F, Ansaloni L. Endoscopic stenting as bridge to surgery versus emergency resection for left-sided malignant colorectal obstruction: an updated meta-analysis. *Int J Surg Oncol.* 2017;2017:2863272. <https://doi.org/10.1155/2017/2863272>.
273. Foo CC, Poon SHT, Chiu RHY, Lam WY, Cheung LC, Law WL. Is bridge to surgery stenting a safe alternative to emergency surgery in malignant colonic obstruction: a meta-analysis of randomized control trials. *Surg Endosc.* 2019;33(1):293–302. <https://doi.org/10.1007/s00464-018-6487-3>.
274. Takahashi H, Okabayashi K, Tsuruta M, Hasegawa H, Yahagi M, Kitagawa Y. Self-expanding metallic stents versus surgical intervention as palliative therapy for obstructive colorectal cancer: a meta-analysis. *World J Surg.* 2015;39(8):2037–44. <https://doi.org/10.1007/s00268-015-3068-7>.
275. Cao Y, Gu J, Deng S, Li J, Wu K, Cai K. Long-term tumour outcomes of self-expanding metal stents as 'bridge to surgery' for the treatment of colorectal cancer with malignant obstruction: a systematic review and meta-analysis. *Int J Colorectal Dis.* 2019;34(11):1827–38. <https://doi.org/10.1007/s00384-019-03372-5>.
276. Hu Y, Fan J, Xv Y, Hu Y, Ding Y, Jiang Z, et al. Comparison of safety between self-expanding metal stents as a bridge to surgery and emergency surgery based on pathology: a meta-analysis. *BMC Surg.* 2020;20(1):255. <https://doi.org/10.1186/s12893-020-00908-3>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

